Board

Board Decisions

The Board of the Global Fund meets twice a year on average. At each meeting, the Board takes a number of decisions, which are legally binding on the Board, the Secretariat and in-country partners.

Search for a decision point by title, date, Board meeting or decision point number to read the text in full.

Date
YYYY-MM-DD
Board Meeting DP# Title
2007-02-09 SB01 GF/SB01/DP06 Credit Suisse Account
<ol> <li>The Board has fully considered the Inspector General's report on the Credit Suisse account, the Secretariat's response and the independent review on the performance of the Office of the Inspector General (OIG). <br /><br /></li> <li>The Board instructs the Secretariat to reduce and maintain the funds in the Credit Suisse account at the minimum level necessary to carry out the functions approved by the Board, which are the following: <br /><br /> <ol> <li>holding the foundation's capital, of CHF 50,000, as required by Swiss law; <br /><br /></li> <li>paying for fees to the Fund's external auditors; <br /><br /></li> <li>receiving private-sector contributions that the Trustee is not able to receive directly, such as proceeds from the Project(RED) campaign, and other miscellaneous receipts, which the Secretariat shall remit immediately upon receipt to the Trustee; <br /><br /></li> <li>paying rent and related charges for the Global Fund's premises in Geneva; <br /><br /></li> <li>paying the rental allowance for the current Executive Director, until 31 March 2007; and <br /><br /></li> <li>paying filing fees in certain jurisdictions for the Global Fund to qualify to receive private, charitable contributions. <br /><br /></li> </ol> </li> <li>The Board requests the Director, Internal Oversight Services of the World Health Organization, in his role as the ad-interim Inspector General of the Global Fund to monitor the transactions of the Credit Suisse account on a continual basis. <br /><br /></li> <li>The Board takes note that the Secretariat has voluntarily suspended the use of the credit cards connected with this account since September 2006 and instructs the Secretariat to cancel the credit cards with immediate effect. <br /><br /></li> <li>The Board endorses the recommendations for improvement in controls contained in the report of the Inspector General, notes Secretariat agreement with these recommendations, and directs the Secretariat to complete their implementation as soon as possible. <br /><br /></li> <li>The ad-interim Inspector General and the new Inspector General should follow up on the full implementation of the improvements to the controls and report back to the Board at the Fifteenth Board Meeting (April 2007) and Sixteenth Board Meeting (November 2007), respectively. <br /><br /></li> <li>The Board requests the ad-interim Inspector General, to conduct an independent analysis of the remaining issues raised by the Inspector General's report and the Secretariat response, and advise the Board whether further action is required, not later than the Fifteenth Board Meeting in April 2007.</li> </ol>
2007-02-09 SB01 GF/SB01/DP05 Decision on the Office of the Inspector General
<ol> <li>Bearing in mind its fiduciary responsibilities:<br /><br /> <ol> <li>The Board welcomes and accepts the offer of the World Health Organization (WHO) to assign, with immediate effect, its Director, Office of Internal Oversight Services (lOS) to lead temporarily the Global Fund's Office of the Inspector General (OIG) for a period of four to six months. This arrangement will be reviewed at the Fifteenth Board meeting in April 2007.<br /><br /></li> <li>The Board approves the engagement by the Director, lOS of an external contractor to provide substantive support in accordance with the scope of work outlined in Part 3 of the Joint Report of the Chairs of the Finance and Audit Committee and the Performance Assessment Committee, presented at the Special Board Meeting held on 8-9 February 2007 (GF/SBM1/5), which may be modified by the Chair and Vice Chair based on input from the Director, lOS. <br /><br /></li> <li>The Board is satisfied that these actions will result in the immediate reestablishment of an effective OIG function to fulfill the Global Fund's immediate assurance requirements. <br /><br /></li> </ol> </li> <li>The Board requests the Finance and Audit Committee to submit, at the Fifteenth Board meeting in April 2007, recommendations with respect to clarifying the role, remit and priorities of the OIG, documenting an overall assurance framework for the Global Fund, reviewing and clarifying the reporting lines, relationships and options for resourcing of the OIG and defining an Action Plan, including terms of reference, selection criteria and provision for candidate review by experts in internal audit and other relevant areas, for the recruitment of the next Inspector General.<br /><br /></li> <li>The recruitment process shall be launched upon approval at the Fifteenth Board meeting in April 2007, and shall result in the appointment of a new Inspector General not later than 31 July 2007.</li> </ol>
2007-02-09 SB01 GF/SB01/DP04 Selec.tion of the Executive Director (Compensation)
<p>The Board decides that the compensation of the Executive Director shall correspond to that offered at the appropriate rate of the WHO UG02 grade.</p>
2007-02-09 SB01 GF/SB01/DP03 Selection of the Executive Director
<p>The Board selects Michel Kazatchkine for the position of Executive Director of the Global Fund and requests the Chair and Vice Chair of the Board to make the necessary arrangements with WHO for the negotiation of the contract and the appointment.</p>
2007-02-09 SB01 GF/SB01/DP02 Approval of Agenda
<p>The agenda for the First Special Board Meeting (GF/SB1/1) is approved.</p>
2007-02-09 SB01 GF/SB01/DP01 Appointment of the Rapporteur
<p>Dr Regina Rabinovich from the Private Foundations Constituency is designated as Rapporteur for the First Special Board Meeting.</p>
2017-02-27 36 GF/BR2017/DP05 Amendment to the Board Leadership Terms of Reference
<ol> <li>The Board notes the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as originally approved through GF/B19/DP10, and as last amended through GF/B32/DP05 (the “Board Leadership Terms of Reference”).</li> <li>In connection with the upcoming launch of the call for nominations for the next Chair and Vice-Chair of the Board, the Board decides to amend and restate Section IV of the Board Leadership Terms of Reference and include the following new Section V in the Board Leadership Terms of Reference: <br /> <ol start="4" type="i"> <li>TIME COMMITMENT <ol> <li>Depending on how the Chair and the Vice-Chair divide the responsibilities between them, the Board Chair should be prepared and able to dedicate an average of 40-50% of an individual’s working time to Global Fund matters, while the Vice Chair should anticipate an average of 25-40% to the same. This commitment may not be uniformly distributed throughout the calendar year. For example, Board, Committee and Coordinating Group meetings, as well as periods before and after such meetings, may require the Board Chair and Vice-Chair to commit full capacity to Global Fund matters for several consecutive days.</li> <li>The time commitment for the Board Chair and Vice-Chair is highly dependent on the Replenishment and Strategy cycles of the Global Fund. In years where there will be either a Replenishment or the development of the Strategy for the upcoming period, it is anticipated that the time commitment of the Board Chair and Vice-Chair would be higher. The Board Chair and Vice-Chair should also be prepared and able to commit additional time in exceptional circumstances.</li> <li>The Board Chair and Vice-Chair shall communicate regularly with Committee Chairs and Vice-Chairs, Board Members, the Secretariat, partners and other stakeholders between Board Meetings. Additionally, the Board Chair and Vice-Chair should be prepared and willing to travel as representatives of the Global Fund, in some cases to locations with security, economic and infrastructural challenges.</li> </ol> </li> <li>HONORARIUM <ol> <li>An honorarium may be provided to the Board Chair and/or Vice-Chair for service in accordance with an honorarium framework as may be approved, or as separately approved on an individual basis, by the Board.”</li> </ol> </li> </ol> </li> <li>The Board decides an annual honorarium in the amount of US$ 40,000 and US$ 30,000 will be available for the next Board Chair and Vice-Chair, respectively.</li> </ol>
2017-02-27 36 GF/BR2017/DP04 Interim Executive Director
<p>The Board appoints Marijke Wijnroks to serve as Interim Executive Director of the Global Fund, effective as of 01 June 2017 until the commencement of the term of the new Executive Director of the Global Fund.</p>
2017-02-27 36 GF/BR2017/DP03 Executive Director Selection Process
<ol> <li>The Board notes: <ol type="a"> <li>its gratitude for the work of the 2016 Executive Director Nomination Committee in leading the 2016-2017 selection process of the Executive Director of the Global Fund (“2016-2017 Selection Process”); and</li> <li>its discussions during the February 2017 Board Retreat with respect to the 2016 – 2017 Selection Process, including the importance of refining the process for identifying, and presenting to the Board, the short-listed candidates for Executive Director taking into account the need to balance transparency and confidentiality considerations throughout the recruitment process.</li> </ol> </li> <li>As such, to facilitate the launch of the new recruitment process for the Executive Director of the Global Fund, the Board requests the Board Leadership, in consultation with the Ethics and Governance Committee (the “EGC”) to review, and propose to the Board, by no later than the EGC’s March 2017 meeting, revisions to the terms of reference of the Executive Director Nomination Committee.</li> <li>Upon completion of the steps outlined in paragraph 2 above, the Board shall appoint the members of the 2017 Executive Director Nomination Committee and launch the new recruitment process for the Executive Director.</li> </ol>
2017-02-27 36 GF/BR2017/DP02 Approval of Agenda
<p>The agenda for the February 2017 Board Retreat (GF/BR2017/01- Revision 5) is approved.</p>
2017-02-27 36 GF/BR2017/DP01 Appointment of Rapporteur
<p>Owen Ryan from the Developed Country NGO constituency is designated as Rapporteur for the February 2017 Board Retreat.</p>
2017-05-04 37 GF/B37/DP14 Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Mr. Norbert Hauser for his leadership as Chair of the Board. Over his time working with the Global Fund, he has shown a high degree of personal commitment, willingness to devote his time and energy, and passion for the work of the Global Fund. During his tenure, Norbert has presided over significant and complex deliberations and decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Aida Kurtović for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and continues to show her personal conviction for the mission of the Global Fund by focusing her efforts as the incoming Chair of the Board. During her tenure as Vice-Chair, Aida has been an active driver of relationship building and collaborations that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board delivered the enhanced governance structure, strengthened ties across Global Fund stakeholders, and helped to guide and direct external relations.</p> <p>The Board wishes Norbert every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Aida into her new role, and looks forward to her tenure, as Chair of the Board.</p>
2017-05-04 37 GF/B37/DP13 Recognition of Dr. Mark Dybul
<p>At the end of his term, the Board wishes to sincerely thank Mark Dybul for the exceptional leadership, vision, and passion he displayed throughout his tenure as Executive Director.</p> <p>Through his tireless, humble, far-sighted efforts to expand and maximize the impact of the Global Fund partnership, Dr. Dybul has inspired all partners to go farther than many thought possible: two successful Replenishments; implementation of a new funding model; shifting operations and attitudes to embrace a strong focus on impact; strengthening partnerships to deliver our mission; supporting the Board in devising a new Strategy; and developing forward-looking initiatives to better promote sustainability and innovation.</p> <p>The Board additionally recognizes Dr. Dybul’s role in enhancing the relationship between the Board and the Secretariat. Through strengthening this relationship, he has helped the Global Fund remain targeted on achieving its mission and focused on best serving those affected by the three diseases.</p> <p>The Board wishes Dr. Dybul every success in the future.</p>
2017-05-04 37 GF/B37/DP12 Amended and Restated Global Fund Quality Assurance Policy for Diagnostic Products
<p>Based on the recommendation of the Strategy Committee, the Board approves the amended and restated Global Fund Quality Assurance Policy for Diagnostic Products, as set forth in Annex 1 to GF/B37/06.</p>
2017-05-04 37 GF/B37/DP11 Health Situation in Venezuela
<ol> <li>The Board expresses: <ol type="a"> <li>Continued concern about the resurgence of malaria, shortages of critical commodities for HIV and TB, and broader health crisis in Venezuela and its impact on the region; and</li> <li>Appreciation for the engagement of communities, civil society groups, PAHO, UNAIDS, WHO and others and their efforts to raise awareness and explore solutions for this situation.</li> </ol> </li> <li>The Board discussed the situation at length, noting Venezuela is currently not eligible for Global Fund financing, and calls for a coordinated regional response to the health crisis in Venezuela and that addresses the impact on the region incorporating relevant partners, donors and financers.</li> <li>Under such circumstances, in the context of a regional response, the Global Fund will continue to engage and, if possible, support the regional response</li> <li>The Board directs the Strategy Committee and the Secretariat to discuss exceptional circumstances in non-eligible countries as part of the ongoing review of the Eligibility Policy.</li> </ol>
2017-05-04 37 GF/B37/DP10 Appointment of the 2017 Executive Director Nomination Committee Membership
<ol> <li>The Board acknowledges the nomination of members for the 2017 Executive Director Nomination Committee (the “Nomination Committee”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as members of the Nomination Committee as described below, in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B36/EDP11 and set out in Annex 1 to GF/B36/ER10: <ol type="a"> <li>Michèle Boccoz, Chair of the Nomination Committee;</li> <li>Vinand Nantulya, Vice- Chair of the Nomination Committee;</li> <li>Ala Alwan, Member;</li> <li>Sarah Boulton, Member, EGC Member;</li> <li>Joanne Carter, Member;</li> <li>Julie Essiam, Member;</li> <li>William Steiger, Member;</li> <li>Peter Felix, Independent Member</li> <li>Reinhard Tittel-Gronefeld, Independent Member</li> </ol> </li> <li>The Board requests the Nomination Committee to start the 2017 recruitment process for the next Executive Director.</li> </ol>
2017-05-04 37 GF/B37/DP09 Wambo.org: Progress Update and Steps for Advancement
<ol> <li>The Board acknowledges the progress update on wambo.org presented by the Secretariat and notes the proposal contained in the paper “Wambo.org: Progress Update and Steps for Advancement”, as set forth in GF/B37/07 – Revision 2, to pilot a limited number of transactions by current Principal Recipients (“PRs”) using domestic funding via wambo.org.</li> <li>Based on the recommendation of the Strategy Committee, the Board approves the piloting of a limited number of transactions (at a maximum ten in total) by current PRs using domestic funding via wambo.org.</li> <li>Accordingly, the Board: <ol type="i"> <li>requests that the Secretariat: (i) provide to the Strategy Committee, by its next meeting, clearly defined draft indicators of success for the pilot; and (ii) report regularly to the Strategy Committee on the operationalization of this pilot, including any lessons learned from such transactions in light of the long-term perspective for wambo.org; and</li> <li>delegates to the Strategy Committee the authority to approve further transactions with domestic funding through wambo.org on a pilot basis, with the objective to provide input into further strategic and operational planning for wambo.org.</li> </ol> </li> </ol>
2017-05-03 37 GF/B37/DP08 Approval of Revisions to the Amended and Restated Global Fund Policy for Restricted Financial Contributions
<ol> <li>Based on the recommendations of the Audit and Finance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as revised and set forth in Annex 1 to GF/B37/04 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy as approved by the Board in November 2014 under decision point GF/B32/DP13.</li> </ol>
2017-05-03 37 GF/B37/DP07 Administration Agreement with the World Bank
<ol> <li>The Board: <ol type="a"> <li>Notes the proposed Administration Agreement between the World Bank and the Global Fund for the Performance Based Funding project in the Democratic Republic of Congo, as presented in GF/B37/03- Revision 1 (the “Administration Agreement”);</li> <li>Acknowledges the Administration Agreement does not provide the Global Fund the right of access to books, records, personnel or sites relating to the Performance Based Funding project, including as required under the Board-approved Charter of the Office of the Inspector General; and</li> <li>Acknowledges that, accordingly, the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, on the funds disbursed under the Administration Agreement.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board authorizes the Secretariat to enter into the Administration Agreement with the World Bank for the Performance Based Funding project in the Democratic Republic of Congo in accordance with the financial and programmatic terms presented in GF/B37/03-Revision 1.</li> <li>However, the Board confirms that this decision does not set a precedent for future investments with development partners or for existing relationships with partners and requests the Secretariat develop a framework to guide future consideration of such investments for presentation to and review by the Audit and Finance Committee, in consultation with the Strategy Committee, for recommendation to the Board.</li> </ol>
2017-05-03 37 GF/B37/DP06 2016 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B37/02 Annex 2.</p>
2017-05-03 37 GF/B37/DP05 2016 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Annual Financial Report, which includes the 2016 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B37/02 Annex 1.</p>
2017-05-03 37 GF/B37/DP04: Appointment of the Board Chair and Vice-Chair
<p>The Board appoints Aida Kurtović as Chair of the Board and Ambassador John Simon as ViceChair of the Board to each serve two-year terms, or until the appointment of their respective successors, starting from the adjournment of the 37th Board Meeting.</p>
2017-05-03 37 GF/B37/DP03 Board Chair and Vice-Chair Terms of Reference
<ol> <li>The Board approves the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B37/22- Revision 1 (the “Terms of Reference”), which shall enter into force upon the conclusion of the 37th Board Meeting in May 2017.</li> <li>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</li> </ol>
2017-05-03 37 GF/B37/DP02 Approval of Agenda
<p>The agenda for the 37th Board Meeting (GF/B37/01- Revision 4) is approved.</p>
2017-05-03 37 GF/B37/DP01 Appointment of the Rapporteur
<p>Ambassador Deborah Birx from the United States constituency is designated as Rapporteur for the 37th Board Meeting.</p>
2017-04-21 36 GF/B36/EDP11 Approval of the Terms of Reference for the 2017 Executive Director Nomination Committee
<ol> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee (the “EGC”), the Board: <ol type="a"> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”);</li> <li>Notes the consultations of the Board Leadership and the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, in accordance with Global Fund procurement regulations, to provide support to the nomination committee in carrying out its mandate; and</li> <li>Approves the terms of reference of the 2017 Executive Director Nomination Committee, as set out in Annex 1 to GF/B36/ER10.</li> </ol> </li> <li>The Board requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>
2017-04-04 36 GF/B36/EDP10 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Acknowledges the original grant duration, as expressed by either the implementation or budgeted period, of Nigeria malaria and its constituent grants, as described in GF/B36/ER09, was shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09 when approved by the Board in January 2015 under GF/B32/EDP05;</li> <li>Approves the redistribution of funding available to Nigeria malaria, and its constituent grants, under the Board’s approval of additional funding in January 2015 (GF/B32/EDP05) as well as the additional implementation period recommended for Nigeria malaria, and its constituent grants, as listed in Tables 1a and 1b of GF/B36/ER09 and described in GF/B36/ER09, paragraph 1.4;</li> <li>Acknowledges Nigeria malaria’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding available for Nigeria malaria under GF/B32/EDP05 and this decision (a) remains the upper-ceiling amount that may be available for the relevant implementation period of each constituent grant, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-03-20 36 GF/B36/EDP09 Performance Targets for the 2017-2022 Strategic Key Performance Indicator Framework
<ol> <li>The Board notes the additional analysis to develop performance targets for the 2017 – 2022 Strategic Key Performance Indicator (the “KPI”) Framework approved by the Board in June 2016 under decision point GF/B35/EDP05 and set forth in Annex 1 to GF/B35/ER05 (the “Strategic KPI Framework”).</li> <li>Based on the recommendation of the Audit and Finance Committee and the Strategy Committee, as set forth in GF/B36/ER08A and GF/B36/ER08B, the Board: <ol type="a"> <li>Approves the performance targets where proposals are complete;</li> <li>Approves the proposed interim indicator proposals for KPIs 5 and 9c; and</li> <li>Agrees with postponing its review and approval of performance targets for KPIs 6a, 6b and 6e until the final Board meeting of 2017.</li> </ol> </li> </ol>
2017-02-16 36 GF/B36/EDP08 Appointment of a Member to the Ethics and Governance Committee
<p>The Board approves the appointment of Ana Filipovska as a voting member of the Ethics and Governance Committee (the “EGC”) for a term that will expire in May 2018, or until the appointment of her successor.</p>
2017-02-08 36 GF/B36/EDP07 Approval of the Report of the 36th Board Meeting
<p>(Board meeting report document available below)</p>
2017-01-30 36 GF/B36/EDP06 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B36/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Approves the additional funding for the South Africa TB/HIV program and its resultant total program budget, as listed in Table 1;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-12-21 36 GF/B36/EDP05 Decision on the Secretariat’s Recommendation on Financing Unfunded Quality Demand from the 2014 – 2016 Allocation Period
<p>The Board:<br /><br />1. Notes the Secretariat's review of the items on the 2014 - 2016 allocation period's unfunded quality demand ("UQD") register, as described GF/B36/ER04;<br /><br />2. Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Bangladesh TB, (ii) Central African Republic TB/HIV, (iii) Myanmar TB, (iv) Philippines TB, and (v) Viet Nam TB, as listed in Table 4 of Section IV to GF/B36/ER04, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br /><br />3. Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br /><br />4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>
2016-12-21 36 GF/B36/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:<br /><br />1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a, 1b and 1c of Section IV to GF/B36/ER04 ("Table 1a", "Table 1b" and "Table 1c");<br /><br />2. Notes the incremental funding approved for APN+, as set forth in Table 1c, is conditioned on the fulfilment of certain time-bound requirements, as described in GF/B36/ER04, and that the Secretariat will inform the Board of the final grant outcome following the relevant deadlines outlined in GF/B36/ER04.<br /><br />3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a, 1b and 1c, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br /><br />4. Approves the reinvestment of within-allocation efficiencies for the Solomon Islands TB and South Africa TB/HIV grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B36/ER04;<br /><br />5. Acknowledges the original grant duration, as expressed by either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 3 of Section IV ("Table 3") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br /><br />6. Approves the additional incremental funding and/or implementation period recommended for (a) Iraq TB and (b) Zimbabwe malaria, and each component's constituent grants, as listed in Table 3, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br /><br />7. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 30 June 2017 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br /><br />8. Approves the additional incremental funding and implementation period recommended for disease components (i) EMMIE malaria, (ii) Myanmar malaria, (iii) Myanmar TB/HIV and (iv) RAI malaria, being Early Applicant grants, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br /><br />9. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants,<br />GF/B36/ER04 (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br /><br />10. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p> <p> </p>
2016-12-19 36 GF/B36/EDP03 Review of the Employee Grievance and Dispute Resolution System
<p>1. The Board acknowledges the work carried out by the Secretariat to review the Global Fund's employee grievance and dispute resolution system, as well as the decisions reached by the Management Executive Committee (MEC) to strengthen internal components of this system (GF/B36/ER03).<br /><br />2. Regarding mechanisms for final resolution of employee grievances, the Board notes the review carried out by the Secretariat on the recognition of the jurisdiction of the International Labour Organization Administrative Tribunal (ILOAT), as compared with other available mechanisms.<br /><br />3. Noting the outcome of this review, and upon recommendation from the Audit and Finance Committee (AFC), the Board requests that the Secretariat continue its work in this area, specifically to (i) further explore available mechanisms for final resolution of employee disputes; and (ii) review the feasibility of implementing alternatives to the current system within the Global Fund's context. The Staff Council will be consulted as part of this exercise.<br /><br />4. Provided an alternative model is identified which is both feasible and considered by MEC to present advantages over the current ILOAT model, the Board requests that the Secretariat develop such an alternative model and present it to the AFC for review and decision at its October 2017 meeting. As part of its presentation to the AFC, the Secretariat will include an analysis of the projected costs of any proposed alternative model, as compared with the current ILOAT model.</p>
2016-12-08 36 GF/B36/EDP02 Recommendation on Revisions to the Constituency Funding Policy
<br/> 1. The Board recalls its approval in November 2009 of the Board Constituency Funding Policy (GF/B20/DP7),<br/>as set forth in Annex 3 to GF/B20/4 (the "Existing Policy"), which makes funds available to Board<br/>constituencies of the Implementer Voting Group to facilitate engagement in the Global Fund's governance<br/>processes;<br/><br/>2. Based on the recommendations presented in GF/B36/ER02, the Board approves the revised Board<br/>Constituency Support Policy, as set forth in Annex 1 to GF/B36/ER02 (the "Revised Policy").<br/><br/>3. Accordingly, the Board:<br/>a) Notes this decision point and the Revised Policy, which supersede the Board decision point<br/>GF/B20/DP7 and the Existing Policy, respectively;<br/>b) Delegates oversight of the Revised Policy to the Ethics and Governance Committee (the "EGC");<br/>c) Delegates to the EGC the authority to determine the Overall Funding Ceiling under the Revised<br/>Policy up to a threshold of an annual average of 1.5 million USD over the three-year period of<br/>the Funding Cycle;<br/>d) Notes that under the Revised Policy the estimated annual average of the Overall Funding Ceiling<br/>for the Funding Cycle 2017-2019 is 1.2 million USD; and<br/>e) Requests the Secretariat to provide the EGC with an annual report on the implementation of the<br/>Revised Policy.<br/><br/>Budgetary implications of the decision for Funding Cycle 2017-2019: an estimated annual average of<br/>1,200,000 USD with be included in the OPEX budget for each year of the 2017-2019 Funding Cycle to support<br/>activities covered under the Revised Policy. (This annual average represents an increase of 200,000 USD over<br/>amounts approved in 2015 and 2016 OPEX budgets with respect to constituency funding. For 2017, this<br/>increase will be accommodated within the OPEX approved at the November 2016 Board Meeting).<br/><br/>The Overall Funding Ceiling for future periods (from 2020 forward) will be approved by the EGC in line with<br/>the delegated authority from the Board outlined in clause 3c of this decision point.
2016-12-07 36 GF/B36/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board: <br /><br />1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1A and 1B of Section IV to GF/B36/ER01 ("Table 1A" and "Table 1B"); <br /><br />2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1A and 1B, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies; <br /><br />3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and <br /><br />4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. <br /><br />This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2016-11-16 36 GF/B36/DP10 Location of the 37th Board Meeting
1. The Board welcomes the invitation of the Government of Rwanda to host the Global Fund's<br/>37th Board Meeting on 03-04 May 2017.<br/><br/>2. Accordingly, the Board agrees to convene the 37th Board Meeting in Kigali, Rwanda.
2016-11-16 36 GF/B36/DP09 Performance Targets for the 2017 – 2022 Strategic Key Performance Indicator Framework
1. The Board notes the additional analysis by the Secretariat to develop performance<br/>targets for the 2017-2022 Strategic Key Performance Indicator (the "KPI") Framework<br/>approved by the Board in June 2016 under the decision point GF/B35/EDP05 and set<br/>forth in Annex 1 to GF/B35/ER05 (the "Strategic KPI Framework").<br/><br/>2. To support the efforts of the Global Fund and partners to implement the 2017-2022<br/>Global Fund Strategy and achieve maximum impact, the Board requests:<br/><br/>a. Board constituencies to submit statements, questions, concerns or suggested<br/>revisions regarding the performance targets, including how country-level<br/>information or estimates will be considered, to the Secretariat by 30 November<br/>2016 followed by the Secretariat's response by 9 December 2016 to be<br/>communicated to all constituencies;<br/><br/>b. The Chairs and Vice-Chairs of the Audit and Finance Committee (the "AFC")<br/>and the Strategy Committee (the "SC") to determine, in accordance with the<br/>respective mandates of the AFC and SC, the performance targets to be<br/>addressed by each committee; and<br/><br/>c. The Chairs and Vice-Chairs of the AFC and the SC to establish a joint-committee<br/>advisory group (the "Advisory Group") by 9 December 2016 that will work with<br/>the Secretariat to present revised performance targets for the Strategic KPI<br/>Framework, based on country-level estimates where relevant and available in<br/>alignment with the principle of country ownership, to the AFC and SC for<br/>recommendation to the Board by the first week of March 2017.<br/><br/>3. The Advisory Group will:<br/><br/>a. Be comprised of four individuals selected from implementer constituencies and<br/>four individuals selected from donor constituencies and two representatives of<br/>the Technical Partners, in consultation with the Chairs and Vice-Chairs of the<br/>AFC and SC, to work with the Secretariat to present revised performance targets<br/>for the Strategic KPI Framework;<br/><br/>b. Consult with the Technical Review Panel and Technical Evaluation Reference<br/>Group;<br/><br/>c. Consider statements, questions, concerns or suggested revisions by Board<br/>constituencies, as well as responses provided by the Secretariat, to advise the<br/>Secretariat on presenting the AFC and SC with revised performance targets for<br/>the Strategic KPI Framework; and<br/><br/>d. Be dissolved upon the Board's approval of performance targets for the Strategic<br/>KPI Framework.<br/><br/>
2016-11-16 36 GF/B36/DP08 Corporate Work Plan and Budget Narrative 2017 and the 2017 Operating Expenses Budget
<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves<br />the following:<br /><br />a. Corporate Work Plan and Budget Narrative 2017, as set forth in GF/B36/05B; and<br /><br />b. 2017 Operating Expenses Budget in the amount of USD 300.0 million, as set forth<br />in GF/B36/05A, which includes USD 17.1 million for the Office of the Inspector<br />General's 2017 operating expenses.</p>
2016-11-16 36 GF/B36/DP07 Executive Director Selection Process
1. The Board notes:<br/><br/>a. Its November 2016 approval (GF/B35/EDP19) of the terms of reference of the 2016<br/>Executive Director Nomination Committee (the "Nomination Committee"), as set<br/>forth in Annex 1 to GF/B35/ER15; and<br/><br/>b. Consultations between the Ethics and Governance Committee and the Chair and<br/>Vice-Chair of the Board with respect to the terms of reference of the Executive<br/>Director, voting procedures for the selection of the next Executive Director, and<br/>anticipated timelines for recruiting the next Executive Director, as outlined in<br/>GF/B36/07.<br/><br/>2. Accordingly, the Board approves:<br/><br/>a. The revised terms of reference of the Executive Director, as presented in Annex 1 to<br/>GF/B36/07, which shall supersede the terms of reference approved by the Board<br/>under decision point GF/B26/EDP08 and set forth in Annex 1 to GF/B26/ER05;<br/>and<br/><br/>b. The voting procedure for the selection of the Executive Director, as presented in<br/>Annex 2 to GF/B36/07, which shall supersede any prior versions of voting<br/>procedures adopted for the selection of any direct report of the Board.
2016-11-16 36 GF/B36/DP06 Catalytic Investments for the 2017 – 2019 Allocation Period
<p>1. The Board notes that up to USD 800 million is available for catalytic investments, subject<br />to the amount of sources of funds for allocation, in accordance with the allocation<br />methodology approved in April 2016 under decision point GF/B35/DP10 and set forth in<br />Annex 1 to GF/B35/05 - Revision 1.<br /><br />2. Based on the recommendation of the Strategy Committee (the "SC") and the amount of<br />sources of funds for allocation recommended by the Audit and Finance Committee (the<br />"AFC") in GF/B36/03, the Board decides USD 800 million will be available for catalytic<br />investments over the 2017 - 2019 allocation period for the priorities and associated costs<br />presented in Table 1 of GF/B36/04 - Revision 2, of which no portion will be moved to<br />further balance scale up, impact and paced reductions through country allocations.<br /><br />3. The Board notes the Secretariat will have flexibility to operationalize catalytic investments,<br />update the SC and Board on such operationalization, and present any reallocations of the<br />associated costs among the approved priorities for the SC's approval.<br /><br />4. The Board asks the Secretariat to provide the SC with a scope of effort and expected<br />outcomes at the start of all strategic initiatives and to seek SC approval during<br />implementation if there is a substantial change to the relevant strategic initiative's scope.</p>
2016-11-16 36 GF/B36/DP05 Sources and Uses of Funds for the 2017 – 2019 Allocation Period
<p>1. Based on the recommendation of the Audit and Finance Committee (the "AFC"), as<br />presented in GF/B36/03, the Board decides the amount of sources of funds for allocation<br />for the 2017 - 2019 allocation period is USD 11.1 billion and comprised of the following<br />amounts:<br /><br />a. USD 10.0 billion, derived from the announced replenishment results of the Fifth<br />Replenishment (2017 - 2019) net of certain adjustments and qualifying deductions, in<br />accordance with the Amended and Restated Comprehensive Funding Policy set forth<br />in Annex 1 to GF/B36/02 - Revision 1; and<br /><br />b. USD 1.1 billion, the forecasted unutilized funds from the 2014 - 2016 allocation period<br />presented by the AFC and the Strategy Committee (the "SC") for inclusion in the<br />sources of funds for allocation for the 2017 - 2019 allocation period following<br />deliberations at the committees' October 2016 meetings.<br /><br />2. Based on the recommendation of the SC, as presented in GF/B36/03, the Board approves<br />USD 0.8 billion for the 2017 - 2019 allocation period's catalytic investments.<br /><br />3. Accordingly, the Board decides the amount of sources of funds for country allocations for<br />the 2017 - 2019 allocation period is USD 10.3 billion, of which USD 0.8 billion is to ensure<br />scale up, impact and paced reductions according to the allocation methodology approved<br />by the Board in April 2016 under decision point GF/B35/DP10.</p>
2016-11-16 36 GF/B36/DP04 Approval of the Amended and Restated Comprehensive Funding Policy
<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves<br />the Amended and Restated Comprehensive Funding Policy, as set forth in Annex 1 to<br />GF/B36/02 - Revision 1.</p>
2016-11-16 36 GF/B36/DP03 Continuing Resource Mobilization Efforts Throughout the Replenishment Cycle
<p>The Board:<br /><br />1. Notes the successful launch of the Global Fund Fifth Replenishment (2017-2019) and the<br />importance of continuing to actively engage to mobilize increased resources throughout<br />the Replenishment cycle; and<br /><br />2. Requests that the Secretariat, under the oversight of the Audit and Finance Committee,<br />develop an ambitious action plan for attracting additional resources which may include<br />providing additional pledging opportunities for donors and maintains visibility of both<br />unfunded quality demand and progress in achieving impact, to be shared with the Board<br />at its 37th Meeting, and subsequently reported on by the Audit and Finance Committee<br />to the Board on a regular basis.</p>
2016-11-16 36 GF/B36/DP02 Approval of Agenda
<p>The agenda for the 36th Board Meeting (GF/B36/01) is approved.</p>
2016-11-16 36 GF/B36/DP01 Appointment of Rapporteur
Carsten Staur from the Point Seven constituency is designated as Rapporteur for the 36th Board Meeting.
2016-11-14 35 GF/B35/EDP20 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B35/ER16 (“Tables 1a and 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;</li> <li>Approves the additional incremental funding and implementation period recommended for the EHRN regional grant, being an Early Applicant grant, as listed in Table 2 of Section IV to GF/B35/ER16 based on the available funding that the Finance and Operational Performance Committee (the “FOPC”) validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-11-01 35 GF/B35/EDP19 Approval of the Terms of Reference for the 2016 Executive Director Nomination Committee
<p>Based on the recommendation of the Board Chair and Vice-Chair (“Board Leadership”), in consultation with the Ethics and Governance Committee (“EGC”) and the Governance Focal Points Network, the Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees <span>of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”).</span></li> <li>Notes the consultations of the Board Leadership and the Governance Focal Points Network with the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, Russell Reynolds Associates, to provide support to the said nomination committee in carrying out its mandate.</li> <li>Approves the terms of reference of the 2016 Executive Director Nomination Committee as set out in Annex 1 to GF/B35/ER15.</li> <li>Invites the Board Leadership to submit in due course for Board approval, in accordance with Article 36 of the BCOP, a Chair and the membership of the nomination committee.</li> </ol>
2016-10-07 35 GF/B35/EDP18 Appointment of a Member of the Strategy Committee
<ol start="1" type="1"><li>The Board approves the appointment of Ambassador Michèle Boccoz as a voting member of the Strategy Committee for a term that will expire on 26 May 2018, or until the appointment of her successor.</li></ol><p></p>
2016-10-07 35 GF/B35/EDP17 Appointment of Independent Committee Member
1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Ethics and Governance Committee (the "EGC"), as set forth in GF/B35/ER13". <br/><br/>2. Accordingly, the Board approves the appointment of Joan Elise Dubinsky to serve as a non-voting independent member of the EGC with expertise in the area of ethics for a two-year term starting from the June 2016 initial meeting of the EGC, or until the appointment of her successor<br/><br/>3. In accordance with the EGC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to the individual appointed as an independent committee member under this decision point an annual amount of USD 13,500.
2016-10-06 35 GF/B35/EDP16 Decision on the Secretariat’s Recommendation on Grant Extensions
The Board:<br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B35/ER12.
2016-10-06 35 GF/B35/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1.a. and 1.b. of Section IV to GF/B35/ER12 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/>4. Approves the additional incremental funding and implementation period recommended for the Kenya malaria disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-08-24 35 GF/B35/EDP14 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:<br/>1. Approves extension of the relevant implementation period for each grant listed in Table 4 of Section IV to GF/B35/ER11.</p><p>This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2016-08-24 35 GF/B35/EDP13 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:<br/>1. Approves the incremental funding recommended for each country and regional disease component, and its constituent grants, as listed in Table 1a and 1b, respectively, of Section IV to GF/B35/ER11 (collectively, "Table 1");<br/><br/>2. Acknowledges each country and regional disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Approves the reinvestment of within-allocation efficiencies for the Zambia TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B35/ER11;<br/><br/>4. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for the Philippines TB disease component, being an Early Applicant grant, as listed in Table 3 of Section IV to GF/B35/ER11, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country and regional disease component's constituent grants, (b) is subject to the availability of funding and (c) shall be committed in annual tranches; and<br/><br/>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country and regional disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p><p>This decision does not have material budgetary implications for the 2016 Operating Expenses Budget.</p>
2016-08-03 35 GF/B35/EDP12 Decision on the Secretariat’s Recommendation on Grant Extensions
1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B35/ER10.
2016-08-03 35 GF/B35/EDP11 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER10 ("Table 1);<br/><br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>4. Approves the additional incremental funding and implementation period recommended for the Uganda HIV disease component, and the component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>5. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and
2016-07-19 35 GF/B35/EDP10 Exceptional Extension and Funding for Bosnia and Herzegovina HIV and TB Grants (Decision not approved)
<h3>Decision not approved.</h3>
2016-07-14 35 GF/B35/EDP09 Approval of the Report of the 35th Board Meeting in Abidjan, Côte d’Ivoire
The Board approves the Report of the 35th Board Meeting, as set forth in GF/B35/28 - Revision 1.
2016-07-08 35 GF/B35/EDP08 Decision on the Secretariat’s Recommendation on Grant Extensions
1. Approves extension of the relevant implementation period for each grant listed in Table 4 of Section IV to GF/B35/ER07.
2016-07-08 35 GF/B35/EDP07 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/><br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1a of Section IV to GF/B35/ER07 ("Table 1a");<br/><br/>2. Approves the reinvestment of within-allocation efficiencies for the Iran HIV grant and its resultant total program budget, as listed in Table 1b of Section IV to GF/B35/ER07;<br/><br/>3. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>4. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for (a) Ghana malaria, (b) Mozambique HIV, (c) Tanzania HIV and (d) Uganda malaria disease components, and each component's constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the "Early Applicants") will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;<br/><br/>7. Approves the additional incremental funding and implementation period recommended for Zimbabwe HIV disease component, being an Early Applicant grant, as listed in Table 3, based on the available funding that the FOPC validated pursuant to GF/FOPC17/DP02;<br/><br/>8. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>9. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-06-10 35 GF/B35/EDP06 Appointment of a member of the Audit and Finance Committee
The Board approves the appointment of Sanne Fournier-Wendes to serve as a non-voting member of the Audit and Finance Committee, representing the Partners Constituency, for a two-year term or until the appointment of her successor.
2016-06-15 35 GF/B35/EDP05 2017 – 2022 Strategic Key Performance Indicator Framework
1. The Board acknowledges the 2017 - 2022 Strategic Key Performance Indicator Framework (the "Strategic KPI Framework"), as presented in Annex 1 to GF/B35/ER05, and the additional methodological work required to set performance targets.<br/>2. Accordingly, the Board approves the Strategic KPI Framework and directs the Secretariat to present the Board with the Strategic KPI Framework's performance targets for approval at the final Board meeting in 2016.
2016-06-09 35 GF/B35/EDP04 Appointment of Independent Committee Members
1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Audit and Finance Committee (the "AFC"), as set forth in GF/B35/ER04". 2. Accordingly, the Board approves the appointment of the following individuals to serve as non-voting independent members of the AFC listed below, in the areas of expertise listed by their name: i. Peter Maertens, audit ii. Jean-Michel Ferat, forensic investigation<br/>3. In accordance with the AFC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to each of the individuals serving as independent committee members an annual amount of USD 13,500.<br/>4. The Board notes each independent committee member appointed under this decision point shall begin their term on 9 June 2016 and serve for two years or until the appointment of their respective successor.
2016-06-03 35 GF/B35/EDP03 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER03 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-05-27 35 GF/B35/EDP02 Appointment of Committee Members
<p><b><i>1. The Board acknowledges the nominations for membership of the Board's Audit and Finance Committee (the "AFC"), Ethics and Governance Committee (the "EGC"), and Strategy Committee ("SC"), as set forth in GF/B35/ER02".</i></b> </p> <p><b><i>2. Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the Committees listed below, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>a. Audit and Finance Committee</i></b> </p> <p><b><i>i. Gregoire Lacoin, European Commission Constituency;</i></b> </p> <p><b><i>ii. Sylvie Bourdenet, France Constituency;</i></b> </p> <p><b><i>iii. Erika Satterwhite, Private Sector Constituency;</i></b> </p> <p><b><i>iv. Anthony Richard Garnett, United Kingdom Constituency;</i></b> </p> <p><b><i>v. Michael Ruffner, United States Constituency;</i></b> </p> <p><b><i>vi. Soltan Mammadov, Eastern Europe &amp; Central Asia Constituency;</i></b> </p> <p><b><i>vii. Thamer Al Hilfi, Eastern Mediterranean Constituency;</i></b> </p> <p><b><i>viii. Grace Rwakarema, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Sugata Ghosh Dastidar, South East Asia Constituency; and</i></b> </p> <p><b><i>x. Han Mengjie, Western Pacific Region Constituency.</i></b> </p> <p><b><i>b. Strategy Committee</i></b> </p> <p><b><i>i. Philippe Meunier, France Constituency;</i></b> </p> <p><b><i>ii. Heiko Warnken, Germany Constituency;</i></b> </p> <p><b><i>iii. Eiji Hinoshita, Japan Constituency;</i></b> </p> <p><b><i>iv. Lennarth Hjelmaker, Point Seven Constituency;</i></b> </p> <p><b><i>v. Kieran Daly, Private Foundations Constituency;</i></b> </p> <p><b><i>vi. Rico Gustav, Communities Constituency;</i></b> </p> <p><b><i>vii. Jorge Saavedra, Developing Country NGOs Constituency;</i></b> </p> <p><b><i>viii. Vinand Nantulya, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Joel Mayowa, West and Central Africa Constituency; and</i></b> </p> <p><b><i>x. LV Fan, Western Pacific Region Constituency.</i></b> </p> <p><b><i>c. Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>i. Sheikh Mubashar, WHO Constituency; and</i></b> </p> <p><b><i>ii. Melanie Renshaw, Partners Constituency.</i></b> </p> <p><b><i>d. Furthermore, the Board appoints Alexandru Cebotari to serve as a non-voting member of the Audit and Finance Committee</i></b> , <b><i>representing the World Bank, and notes that the remaining non-voting member of the Audit and Finance Committee that will represent one of the non-voting, ex-officio members of the Board will be subsequently appointed.</i></b></p> <p><b><i>3. Additionally, the Board approves the appointment of the following individuals, with their nominating Board constituency listed by their name, to serve in their personal capacity as voting members of the Ethics and Governance Committee:</i></b> </p> <p><b><i>a. Jacques Mader, Canada Switzerland Australia Constituency;</i></b> </p> <p><b><i>b. Sarah Boulton, United Kingdom Constituency;</i></b> </p> <p><b><i>c. Sandy Thurman, United States Constituency;</i></b> </p> <p><b><i>d. Jason Wright, Developed Country NGOs Constituency;</i></b> </p> <p><b><i>e. Archil Talakvadze, Eastern Europe &amp; Central Asia Constituency; and</i></b> </p> <p><b><i>f. Mirta Roses Periago, Latin America and Caribbean Constituency.</i></b> </p><p> <b><i>4. The Board notes each Committee Member appointed under this decision point shall begin their term upon approval of this decision point and serve for two years or until the appointment of their respective successor.</i></b></p>
2016-05-24 35 GF/B35/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B35/ER01 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B35/ER01 ("Table 2") isshortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09.</li> <li>Approves the reinvestment of within-allocation efficiencies as well as the additional incremental funding and implementation period recommended for Sudan malaria disease component and its constituent grant, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;</li> <li>Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2016-04-27 35 GF/B35/DP11 Change to the Composition of the Partners Constituency
<p>1. The Board notes that under its previous decision in May 2009 (GF/B19/DP11) to create a non-voting seat on the Board to represent the constituency of key partners whose mission is directly related to the Global Fund and who are not currently represented on the Board (the "Partners Constituency"), any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board for their inclusion in the Partners constituency.</p> <p>2. The Board also notes that the Partnership for Maternal, Newborn &amp; Child Health ("PMNCH") have fully responded to the criteria for accepting new constituency members, developed by the Partners Constituency, and have received unanimous support from the current Partners Constituency Members to be incorporated into the Constituency.</p> <p>3. Based on the request submitted by the Partners Constituency, as outlined in GF/B35/27, the Board decides to invite the PMNCH to be a member of the Partners Constituency.</p>
2016-04-27 35 GF/B35/DP10 Allocation Methodology 2017 - 2019
<p>1.The Board notes:</p><p>a.Its decisions in September 2012 (GF/B27/DP07) and November 2012 (GF/B28/DP04) that established the principles and framework for the allocation-based funding model (the "Funding Model Principles");</p><p>b.Its decisions in October 2013 (GF/B29/EDP10 and GF/B29/EDP11) and March 2014 (GF/B31/DP06, GF/B31/DP07, GF/B31/DP08, GF/B31/DP09 and GF/B31/DP10) to define certain elements for the 2014 - 2016 allocation period that would be reviewed and refined, as appropriate, prior to the 2017 - 2019 allocation period (the "2014 - 2016 Elements"); and</p><p>c.Decisions by the Strategy, Investment and Impact Committee (the "SIIC") in October 2013, under authority delegated by the Board, to establish technical parameters for the 2014 - 2016 allocation period (GF/SIIC09/DP01) and the process for managing and awarding incentive funding and unfunded quality demand (GF/SIIC09/DP02) (the "Prior SIIC Decisions").</p> <p>2. Accordingly, based on the recommendations of the SIIC, as presented in GF/B35/05 - Revision 1, the Board:</p><p>a. Approves the allocation methodology presented in Annex 1 to GF/B35/05 - Revision 1 (the "Allocation Methodology");</p> <p>b. Acknowledges the technical parameters for the 2017 - 2019 allocation period, as presented in Annex 2 to GF/B35/05 - Revision 1 and approved by the SIIC at its 17<sup>th</sup>meeting in March 2016 (the "Technical Aspects"); and</p> <p>c. Affirms the restatement of core parts of the Funding Model Principles, as presented in Annex 3 to GF/B35/05 - Revision 1 (the "Affirmed Principles").</p> <p>3. Accordingly, the Board:</p><p>a. Requests the Strategy Committee to review and approve, at its June 2016 meeting, the method by which the Secretariat will apply and report on the qualitative-factor adjustment process;</p> <p>b. Requests the Secretariat to present the priorities, activities or initiatives, including associated costs, that could be funded as catalytic investments, for the Strategy Committee to review at its June 2016 meeting and recommend to the Board; and</p> <p>c. Acknowledges that the Allocation Methodology, Technical Aspects and Affirmed Principles shall apply for the 2017 - 2019 allocation period and supersede the Funding Model Principles, 2014 - 2016 Elements and Prior SIIC Decision.</p><p><br/></p>
2016-04-27 35 GF/B35/DP09 Challenging Operating Environments Policy
<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Challenging Operating Environments Policy, as set forth in Annex 1 to GF/B35/03.</p>
2016-04-27 35 GF/B35/DP08 Sustainability, Transition and Co-financing Policy
<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Sustainability, Transition and Co- Financing Policy, as set forth in Annex 1 to GF/B35/04 - Revision 1 (the "STC Policy").</p><p>2.Accordingly, the Board:</p><p>a.Acknowledges this decision point and the new co-financing policy set forth in the STC Policy supersede Board decision point GF/B30/DP05 and the previous Counterpart Financing Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Counterpart Financing Policy"); and</p><p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Counterpart Financing Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period.</p>
2016-04-27 35 GF/B35/DP07 Revised Eligibility Policy
<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 2 to GF/B35/06 - Revision 1 (the "Revised Eligibility Policy").</p><p>2.Accordingly, the Board: </p><p>a.Acknowledges this decision point and the Revised Eligibility Policy supersede Board decision point GF/B30/DP05 and the previous Eligibility Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Previous Eligibility Policy"); and</p><p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period. </p>
2016-04-27 35 GF/B35/DP06 2015 Statutory Financial Statements
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 2.</p>
2016-04-27 35 GF/B35/DP05 2015 Annual Financial Report
<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Annual Financial Report, which includes the 2015 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 1. </p>
2016-04-27 35 GF/B35/DP04 The Global Fund Strategy 2017 – 2022: Investing to End Epidemics
<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Global Fund Strategy 2017 - 2022: Investing to End Epidemics, as presented in Annex 1 to GF/B35/02- Revision 1. </p>
2016-04-27 35 GF/B35/DP03 Response to Office of the Inspector General 2015 Annual Opinion and Risk Management Report and Assurance Statement
<p>1.The Board notes its review and discussion of the: </p><p>a.Office of the Inspector General 2015 Annual Opinion on Governance, Risk Management and Internal Controls of the Global Fund, as set forth in GF/B35/11 (the "OIG Annual Opinion"); and</p><p>b.Risk Management Report and Assurance Statement, as set forth in GF/B35/23.</p><p>2.Accordingly, the Board acknowledges that while in-country partnerships are in place and significant initiatives and measures have been implemented to improve programmatic, fiduciary and risk-management processes, immediate and heightened efforts are needed to accelerate progress and advance risk management systems and processes. </p><p>3.The Board requests the Secretariat to:</p><p>a. Present a detailed action plan to advance risk management and internal controls, with measurable and time-bound targets, and a report on progress to the Board in June 2016 through the standing committees that were established under Board decision point GF/B34/EDP07 (the "Standing Committees"); and</p><p>b. In the context of the differentiation initiative, review the business model in high-risk countries and present possible options to the Board after review by the Standing Committees at their second meetings in 2016.</p>
2016-04-27 35 GF/B35/DP02 Approval of Agenda
The agenda for the 35th Board Meeting (GF/B35/01 - Revision 3) is approved.
2016-04-27 35 GF/B35/DP01 Appointment of Rapporteur
<p>Siula Bulu from the Western Pacific Region constituency is designated as Rapporteur for the 35th Board Meeting.</p>
2016-04-21 34 GF/B34/EDP21 Operating Procedures of the Board and Committees
1. The Board notes its January 2016 approval (GF/B34/EDP07) of the amended and restated Operating Procedures of the Board and Committees, which become effective upon the conclusion of the 35th Board Meeting in April 2016.<br/><br/>2. Based on the recommendation of the Transitional Governance Committee, the Board approves the amendments to Articles 15, 16, 20, 22 and 36 of the Operating Procedures of the Board and Committees, as set forth in Annex 1 to GF/B34/ER15 (the "Amended Provisions"), which become effective upon the date of this decision and will be incorporated into the amended and restated Operating Procedures of the Board and Committees.
2016-03-14 34 GF/B34/EDP20 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p><p><br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER14.</p>
2016-03-14 34 GF/B34/EDP19 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/><br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER14 ("Table 1");<br/><br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/><br/>3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B34/ER14 ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DP09.<br/><br/>4. Approves the reinvestment of within-allocation efficiencies for the Congo (Democratic Republic) malaria grant and its resultant total program budget, as listed in Table 2;<br/><br/>5. Approves the additional incremental funding and implementation period recommended for Mozambique malaria disease component and its constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DP02;<br/><br/>6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/><br/>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-04-07 34 GF/B34/EDP18 Appointment of External Auditor
<p>Based on the Audit and Ethics Committee recommendation, set forth in GF/B34/ER13, the Board authorizes the appointment of KPMG SA as the Global Fund's external auditor for an initial three year term beginning with the 2016 fiscal year.</p>
2016-03-24 34 GF/B34/EDP17 Decision on the Secretariat’s Recommendation on Grant Extensions
The Board:<br/>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B34/ER12.
2016-03-24 34 GF/B34/EDP16 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER12 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-03-04 34 GF/B34/EDP15 Appointment of a member of the Finance and Operational Performance Committee
<p>The Board approves the appointment of Dr. HAN Mengjie as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor.</p>
2016-03-04 34 GF/B34/EDP14 Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board
<p>1. The Board approves the appointment of:</p> <p>a. Greg J. Ferrante as Chair of the Audit and Finance Committee;</p> <p>b. Beatrijs Stikkers as Vice-Chair of the Audit and Finance Committee;</p> <p>c. Mohamed Salah Ben Ammar as Chair of the Ethics and Governance Committee;</p> <p>d. Jan Paehler as Vice-Chair of the Ethics and Governance Committee;</p> <p>e. Dorothée Kinde-Gazard as Chair of the Strategy Committee; and</p> <p>f. Julia Martin as Vice-Chair of the Strategy Committee.</p> <p>2. The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 1 May 2016 and serve for two years or until the appointment of their successor.</p>
2016-02-22 34 GF/B34/EDP13 Decision on the Secretariat’s Recommendation on Grant Extensions
The Board: <br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER09.
2016-02-22 34 GF/B34/EDP12 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER09 ("Table 1");<br/>2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the reinvestment of within-allocation efficiencies for the South Sudan TB grant and the resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER09;<br/>4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-02-11 34 GF/B34/EDP11 Location of the 36th Board Meeting
<p>1. The Board acknowledges that the meeting facilities needed to accommodate the 36th Board Meeting on the scheduled dates of 16-17 November 2016 will not be available in Geneva, Switzerland.</p><p>2. Accordingly, the Board agrees to convene the 36th Board Meeting in Montreux, Switzerland, as an exception to article B.6.1. of the Operating Procedures of the Board and Committees.</p>
2016-02-11 34 GF/B34/EDP10 Location of the 35th Board Meeting
<p>1. The Board:</p> <p>a. Welcomes the invitation of the government of Côte d'Ivoire to host the Global Fund's 35th Board Meeting on 26-27 April 2016; and</p> <p>b. Acknowledges the recommendation of the Secretariat set forth in GF/B34/ER08.</p> <p>2. Accordingly, the Board agrees to convene the 35th Board Meeting in Côte d'Ivoire.</p><p><b><i></i></b> </p>
2016-02-10 34 GF/B34/EDP09 Approval of the Report of the 34th Board Meeting
<p>The Board approves the Report of the 34th Board Meeting, as set forth in GF/B34/25.</p>
2016-01-27 34 GF/B34/EDP08 Appointment of the Ethics Officer
<p>1. The Board: <br /> a. Notes its approval of the Terms of Reference of the Ethics Officer (the "Terms of Reference") (GF/B33/EDP14); <br /> b. Notes the requirement set forth in the Terms of Reference whereby the Audit and Ethics Committee ("AEC") and the Executive Director are to jointly select the Ethics Officer, for appointment by the Board on a no-objection basis; <br /> c. Notes the AEC's delegation of authority to Claude Rubinowicz and Wendy Harrison to jointly select, with the Executive Director, the Ethics Officer for recommendation to the Board (GF/AEC12/EDP02); <br /> d. Recognizes the work of the AEC, the Executive Director and the Secretariat to select a suitable candidate for this position; and <br /> e. Accepts the joint recommendation of the AEC and the Executive Director, as set forth in document GF/B34/ER07.</p> <p>2. Accordingly, the Board: <br /> a. Approves the appointment of Nick Jackson to the position of Global Fund Ethics Officer for a three-year term which can be renewed no more than once; and <br /> b. Authorizes the Secretariat to enter into a contract of employment with Nick Jackson for an annual salary subject to the Amended and Restated Global Fund Human Resources Policy Framework, and requests the Secretariat to proceed with that process pursuant to standard Human Resources procedures. <br /><br /></p>
2016-01-28 34 GF/B34/EDP07 Enhanced Governance Structure
<p>1. Based on the recommendations of the Transitional Governance Committee (the "TGC"), as presented in GF/B34/ER06, the Board approves:</p> <p>a. The establishment of the following three standing committees (the "Standing Committees"):</p> <p>i. Audit and Finance Committee</p> <p>ii. Ethics and Governance Committee;</p> <p>iii. Strategy Committee; </p><p>b. The following core governance documents, which shall each become effective upon the conclusion of the first Board meeting in 2016:</p> <p>i. Charter of the Audit and Finance Committee, as set forth in Annex 1 to GF/B34/ER06;</p> <p>ii. Charter of the Ethics and Governance Committee, as set forth in Annex 2 to GF/B34/ER06;</p> <p>iii. Charter of the Strategy Committee, as set forth in Annex 3 to GF/B34/ER06;</p> <p>iv. Terms of Reference of the Coordinating Group, as amended and restated in Annex 4 to GF/B34/ER06;</p> <p>v. Bylaws, as amended and restated in Annex 5 to GF/B34/ER06; and</p> <p>vi. Operating Procedures of the Board and Committees, as amended and restated in Annex 6 to GF/B34/ER06.</p><p>2. The Board acknowledges the Standing Committees shall replace the Audit and Ethics Committee, Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee upon the conclusion of the first Board meeting in 2016.</p> <p>3. Accordingly, the Board requests the:</p> <p>a. Chair and Vice-Chair of the Board to launch the process for the Board to appoint the Chairs and Vice-Chairs, as well as membership, of the Standing Committees, by no later than the first Board meeting in 2016; and</p> <p>b. Secretariat, under the oversight of the Coordinating Group, to update any policies or prior decisions needed to align with the core governance documents approved under paragraph 1 of this decision point</p>
2016-01-18 34 GF/B34/EDP06 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER03 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the reinvestment of within-allocation efficiencies for the Bangladesh TB and Thailand TB/HIV grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER03;<br/>4. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>5. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.
2016-01-13 34 GF/B34/EDP04 Approval of 2016 Targets for the 2014 – 2016 Corporate Key Performance Indicator Framework
<p>1. The Board:</p> <p>a. Acknowledges the Secretariat's presentation of the mid-2015 performance assessments for the 2014-2016 Corporate Key Performance Indicator Framework, as set forth in GF/B34/08; and</p> <p>b. Notes the Secretariat's response to requests by the Board at its November 2015 meeting for additional analysis on certain indicators, including proposed management actions to improve performance, as set forth in GF/B34/ER03 - Annex 1.</p> <p>2. Accordingly, the Board:</p> <p>a. Approves the 2016 performance targets presented in GF/B34/ER03 - Annex 1; noting the revisions to the 2016 performance targets for KPI 7 (Access to Funding) and KPI 10 (Value for Money); and</p> <p>b. Directs the Secretariat to implement its proposed management actions, continue to identify lessons that can inform the next Corporate Key Performance Indicator Framework, and update the committees and the Board at their first meetings in 2016.</p>
2015-12-23 34 GF/B34/EDP03 Decision on the Secretariat’s Recommendation on Grant Extensions
The Board: <br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER02.
2015-12-23 34 GF/B34/EDP02 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p><ol><li><i></i> Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER02 (collectively, "Table 1");</li><li><i></i> Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li><li><i></i> Approves the reinvestment of within-allocation efficiencies for the Zanzibar TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER02;</li><li><i></i> Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li><li><i></i> Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li></ol>
2015-12-07 34 GF/B34/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p> The Board:</p><p>1. Acknowledges that there are ongoing audit and investigation by the Office of the Inspector General ("OIG") on existing Nigeria grants, which, as of the date of this decision point, has revealed evidence pointing to: (1) serious weakness in financial, supply-chain, non-health product procurement and programmatic management in individual grants at both Principal Recipient and sub-recipient levels and, despite the uncompromising efforts of the Secretariat, such weakness in certain instances has manifested in fraud and misappropriation of grant funds, and (2) country risks across the Nigeria portfolio of the Global Fund;</p><p>2. Considers that Nigeria is the most populous country in Africa and its high disease burden of HIV and TB has important impact on the global epidemics and that disengaging Nigeria or halting the launch of the new grants to Nigeria to deliver the proposed targets in the TB/HIV concept note is not a preferred option at this stage if the Global Fund is to fulfil its mission;</p><p>3. Approves the incremental funding recommended for each disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B34/ER01 ("Table 1"), provided that the Secretariat (1) pursues a full recovery, as it has done for other Nigeria recoveries and as supported by evidence, of the amounts derived from the confirmed findings and recommendations of the OIG in accordance with the Global Fund policies, (2) continues its efforts to enforce risk-mitigating mechanisms currently in place and other enhanced measures planned for new grants, and (3) duly implements all additional risk-mitigating actions agreed between the Secretariat and the OIG for the Nigeria portfolio;</p><p>4. Acknowledges that each grant approved under this decision will be implemented by the proposed Principal Recipients listed in Table 1 or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with this decision point and other Global Fund policies;</p><p>5. Affirms that the incremental funding approved under this decision (1) increases the upper-ceiling amount that may be available for the relevant implementation period of each grant listed in Table 1, (2) is subject to the availability of funding, and (3) shall be committed in annual tranches;</p><p>6. Acknowledges that while Nigeria, through the TB/HIV concept note, has requested to access its 2014 Allocation fully, the funding recommended in Table 1 does not exhaust such allocation so as to preserve flexibility to address uncertainties and potential needs associated with a differentiated approach and OIG findings for implementing the TB and HIV programs, and accordingly that the Secretariat through a separate report to the Board may recommend further funding for Nigeria's TB and HIV programs from the country's remaining allocation; and</p><p>7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and related funding request initially reviewed and recommended by the TRP.</p>
2015-11-17 34 GF/B34/DP08 Approval of the amended and restated Market Shaping Strategy
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the amended and restated Market Shaping Strategy, as set forth in Annex 1 to GF/B34/17 - Revision 1 (the "Amended and Restated Market Shaping Strategy"). </p><p>2. This decision point and the Amended and Restated Market Shaping Strategy supersede Board decision point GF/B23/DP21 and the previous Market Shaping Strategy set forth in Annex 1 to GF/B23/09 - Revision 1.</p>
2015-11-17 34 GF/B34/DP07 Enhanced Governance Structure
<ol><li><p>Based on the recommendations of the Transitional Governance Committee (the "TGC"), presented in GF/B34/18 - Revision 1, the Board:</p> a. Approves, in principle, the establishment of the following three standing committees (the "Standing Committees") and each Standing Committee's respective purpose, functions, and composition: <br/> i. Audit and Finance Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 1 to GF/B34/18 - Revision 1; <br/> ii. Ethics and Governance Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 2 to GF/B34/18 - Revision 1; <br/> iii. Strategy Committee to exercise the powers and perform the functions set forth in the draft charter presented in Annex 3 to GF/B34/18 - Revision 1; <br/><br/> b. Endorses, in principle, the draft: <br/> i. Amended and restated Terms of Reference of the Coordinating Group, as set forth in Annex 4 to GF/B34/18 - Revision 1; <br/> ii. Amended and restated Bylaws, as set forth in Annex 5 to GF/B34/18 - Revision 1; and <br/> iii. Amended and restated Operating Procedures of the Board and Committees, as set forth in Annex 6, revision 1, to GF/B34/18 - Revision 1; and <br/><br/> c. Notes that the Standing Committees shall replace the Audit and Ethics Committee, Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee upon the conclusion of the first Board meeting in 2016. <br/><br/></li><li><p>Accordingly, the Board requests the TGC (i) consider all potential refinements, suggested by the Board, to the charters and other core governance documents referenced in paragraph 1 above and (ii) propose final versions to the Board for approval as soon as possible to enable the Chair and Vice-Chair of the Board to launch the process for the Board to appoint the Chairs and Vice-Chairs, as well as membership, of the Standing Committees, by no later than the first Board meeting in 2016.</p></li></ol> <ol></ol>
2015-11-17 34 GF/B34/DP06 Global Fund Board’s commitment on Replenishment
<ol><li><p>The Board:</p><p>a. Expresses its strong commitment to the Global Fund Fifth Replenishment (2017-2019) aimed at raising the appropriate levels of funding for implementation of the "Investing to End Epidemics" Strategy; </p><p>b. Recognizes the importance of the preparatory meeting that will take place in Tokyo in December 2015; and</p> c. Acknowledges the challenging environment for mobilizing resources, the need to continue maximizing the Global Fund's results and impact, and the initiative to maximize absorption capacity. <br/><br/></li><li>Accordingly the Board will: <br/><br/> a. Explore options to enhance its active engagement in contributing towards a successful outcome of the Replenishment, including the broadening of the donor base; and <br/><br/> b. Seek the support of high-level individual(s) who, in collaboration with the Board leadership and Secretariat, will advocate on its behalf for a successful Global Fund Replenishment.</li></ol>
2015-11-17 34 GF/B34/DP05 2016 Corporate Work Plan and Operating Expenses Budget
<p>1. Based on the recommendation of the Finance and Operational Performance Committee (the "FOPC"), the Board approves the following: </p><p>a. Corporate Work Plan and Budget Narrative 2016, as set forth in GF/B34/13; and</p><p>b. 2016 Operating Expenses Budget up to the amount of USD 305.0 million, as set forth in GF/B34/14 (the "2016 OPEX Budget"), which includes USD 16.3 million for the Office of the Inspector General's 2016 operating expenses based on the recommendation of the Audit and Ethics Committee</p><p>2. The Board requests the Secretariat to include in its periodic reporting to the FOPC on budget matters:</p><p>a. The foreign-exchange impact on the 2016 OPEX Budget, as requested by the Board in 2010 (GF/B22/DP18), tracked against budget rate;</p><p>b. Budgetary variations by type of expenses; and</p><p>c. Progress updates on the priority projects and activities outlined in the 2016 OPEX Budget. </p><p>3. The Board notes operating expenses over the 2014 - 2016 period, including the 2016 OPEX Budget, remain within the USD 900 million reserved for operating expenses at the time the Board approved the resources available for allocation over the 2014 - 2016 period</p><p> <br/><br/></p>
2015-11-16 34 GF/B34/DP04 Strategic Framework 2017 - 2022
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee (the "SIIC"), the Board approves the Strategic Framework 2017 - 2022, as set forth in Annex 1 to GF/B34/11, and notes the next steps of presenting further details in a final strategy narrative and on implementation planning.</p><p>2. As such, the Board requests the Secretariat to submit the final strategy narrative through the SIIC for Board approval at the first Board meeting in 2016, taking into consideration lessons from implementing the current strategy, recommendations from the Strategic Review 2015, and additional input collected throughout the strategy development process.</p>
2015-11-16 34 GF/B34/DP03 Strategic Review 2015
<p>1. Based on the recommendation of the Strategy, Investment and Impact Committee (the "SIIC"), the Board:</p><p>a. Acknowledges the results and recommendations of the Strategic Review 2015 commissioned by the Technical Evaluation Reference Group (the "TERG"), as presented in GF/B34/10;</p><p>b. Requests the Secretariat to consider the TERG's recommendations as it prepares the final strategy narrative that will be presented for the SIIC to review and recommend to the Board for approval by the first Board meeting in 2016; and</p><p>c. Requests the Secretariat to provide the SIIC with its response to the TERG's recommendations in relation to the current strategic period.</p><p>2. The Board also notes its appreciation for the TERG and its evaluation team for their work to commission and produce the Strategic Review 2015.</p> <ol></ol>
2015-11-16 34 GF/B34/DP02 Approval of Agenda
<p>The agenda for the 34 <sup>th</sup> Board Meeting (GF/B34/01 - Revision 1) is approved.</p>
2015-11-16 34 GF/B34/DP01 Appointment of Rapporteur
Mr Kieran Daly from the Private Foundations constituency is designated as Rapporteur for the 34th Board Meeting.
2015-11-12 33 GF/B33/EDP30 Appointment of Member of the Strategy, Investment and Impact Committee
<p>The Board approves the appointment of Ambassador Lennarth Hjelmaker as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor. </p>
2015-11-13 33 GF/B33/EDP29 Decision on the Secretariat’s Recommendation on Policy Exceptions for Processing HIV and TB Funding Applications from Certain Countries in the Middle East Region
1. Acknowledges the current political context and challenging implementation environment in Iraq, Palestine, Syria and Yemen due to ongoing conflicts; and<br/><br/>2. Accordingly, approves the following policy exceptions for processing HIV and TB funding applications from these countries to access relevant 2014-2016 funding allocations:<br/><br/>• Waiver of the CCM eligibility requirements;<br/>• Waiver of the counterpart financing requirement; and<br/>• Waiver of the "willingness-to-pay" requirement<br/><br/><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b>
2015-11-13 33 GF/B33/EDP28 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:<br/><br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER18.</p><p><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b> <br/></p>
2015-11-27 33 GF/B33/EDP27 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;<br/>4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;<br/>5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.<br/>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.
2015-11-10 33 GF/B33/EDP26 Global Fund Strategy Cycle
<ol><li>Based on the recommendations of the Strategy, Investment and Impact Committee (the "SIIC"), as set forth in GF/B33/ER17, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022 (the "2017 - 2022 Strategy"), with a mid-point review of progress and implementation. </li><li>The Board notes the importance of coherence between the strategy, allocation and replenishment, as well as the need to provide advanced articulation of the Global Fund's strategy and objectives to guide implementation planning, facilitate advocacy efforts and support mobilization of resources.</li><li>Accordingly, the Board directs the SIIC, or its successor committee, to develop a timeline for developing and finalizing the strategy that will commence immediately after the 2017 - 2022 Strategy as part of the mid-point review of the 2017 - 2022 Strategy. </li></ol><p><br/></p>
2015-10-29 33 GF/B33/EDP25 Appointment of Member of the Strategy, Investment and Impact Committee
The Board approves the appointment of Dr Suriya Wongkongkathep as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor.
2015-10-19 33 GF/B33/EDP24 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER15.</li> </ol> <p>Annex: Kyrgyzstan (KGZ-H-UNDP)</p>
2015-10-19 33 GF/B33/EDP23 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV of GF/B33/ER15 ("Table 1");</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Dominican Republic (DOM-H-CONAVIH, DOM-H-IDCP0, Lao (People's Democratic Republic) (LAO-S-GFMOH), Malawi (MWI-M-MOH, MWI-M-WVM, MWI-C-MOH)<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /></p>
2015-10-12 33 GF/B33/EDP22 Decision on the Secretariat’s Recommendation on waiver of the Board condition for Congo HIV grant
<p>The Board:</p> <ol> <li>Approves waiver of the Board condition imposed in the Congo HIV grant (COG-911-G06-H) restricting the “use of funds to finance activities other than (i) the procurement of Health Products and Pharmaceuticals and (ii) other activities deemed essential in the framework of the program,” and</li> <li>Approves disbursement of grant funds to the principal recipient the Secretariat Executif Permanent/Comité National de Lutte contre le SIDA (SEP /CNLS) to conduct activities essential to the implementation of the HIV program.</li> </ol>
2015-10-12 33 GF/B33/EDP21 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B33/ER14.</li> </ol> <p>Annex:</p> <p>Angola (AGO-M-MOH), Sri Lanka (SRL-607-G07-T, SRL-809-G10-M)</p>
2015-10-12 33 GF/B33/EDP20 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex:</p> <p>Azerbaijan (AZE-T-MOH), Bangladesh (BGD-H-NASP, BGD-H-SC, BGD-H-ICDDRB), Cape Verde (CPV-C-CCSSIDA), Comoros (COM-M-PNLP), Haiti (HTI-C-PSI), Lao (People's Democratic Republic) (LAO-H-GFMOH), Panama (PAN-C-UNDP), Sri Lanka (LKA-M-MOH), Zanzibar (QNB-C-MOH).<br /><br />Regional grants: Abidjan-Lagos Corridor Organization (OCAL) (QPF-H-ALCO), African Network for the Care of Children Affected by HIV/AIDS (ANECCA) (QPA-H-ANECCA), ECSA-HC Uganda Supranational National Reference Laboratory (QPA-T-ECSA), Humanist Institute for Cooperation with Developing Countries, Southern Africa (HIVOS) (QPA-H-HIVOS), Removal of Legal Barriers (RLB) (QPA-H-UNDP).</p>
2015-10-08 33 GF/B33/EDP19 Appointment of Member of the Finance and Operational Performance Committee
The Board approves the appointment of Eiji Hinoshita as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor. 
2015-09-21 33 GF/B33/EDP18 Approval of the Governance Performance Assessment Framework
<ol><li>Based on the recommendation of the Transitional Governance Committee, the Board approves the Governance Performance Assessment Framework, as set forth in Annex 1 to GF/B33/ER11 (the “Framework”).</li><li>The Board agrees with the approach for partially implementing the Framework in 2015, as described in GF/B33/ER11, and acknowledges that full implementation of the Framework will start in 2016. </li></ol>
2015-09-14 33 GF/B33/EDP17 Strategy Development Process — Alignment of Strategy Cycle (Decision not approved)
<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, as set forth in GF/B33/ER10, the Board decides the Global Fund’s strategy should cover a period that aligns the start of each strategy cycle to the start of a replenishment and allocation period.</li> <li>Accordingly, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022, with a mid-point review of progress and implementation alongside replenishment.</li> </ol>
2015-09-11 33 GF/B33/EDP16 Decision on the Secretariat’s Recommendation on Grant Extension
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER09.</li> </ol> <p>Annex: Liberia (LBR-T-MOH), Madagascar (MDG-809-G11-H, MDG-809-G12-H), Syria (SYR-011-G02-H).</p>
2015-09-11 33 GF/B33/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B33/ER09 (“Table 1”);</li> <li>Approves the reinvestment of newly identified existing funds for the Burkina Faso TB/HIV grant (BFA-H-SPCNLS) and its resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER09;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Belize (BLZ-C-UNDP), Burkina Faso (BFA-S-PADS, BFA-M-PADS), Cambodia (KHM-H-NCHADS, KHM-S-PRMOH), Center for Health and Policy Studies (QMZ-T-PAS), Elimination 8 - SADC (QPA-M-E8S), Guinea (GIN-H-CNLS, GIN-H-PSI), India (IDA-M-NVBDCP, IDA-M-CARITAS, IDA-H-NACO, IDA-H-IHAA, IDA-H-PLAN, IDA-H-SAATHII, IDA-T-CTD, IDA-T-IUATLD, IDA-T-WV), Kenya AIDS NGOs Consortium Regional (QPB-H-KANCO), Kenya (KEN-M-TNT, KEN-M-AMREF, KEN-H-KRCS, KEN-H-TNT, KEN-T-AMREF, KEN-T-TNT), Korea (Democratic People’s Republic) (PRK-T-UNICEF), Lao (People’s Democratic Republic) (LAO-M-GFMOH), South Sudan (SSD-H-UNDP), Sri Lanka (LKA-T-MOH), Sudan (SDN-S-FMOH), Suriname (SUR-C-MOH), Tajikistan (TJK-H-UNDP), Togo (TGO-H-PMT, TGO-T-PMT), Zanzibar (QNB-M-MOH).</p>
2015-07-30 33 GF/B33/EDP14 Terms of Reference of the Ethics Officer
<ul><li>Based on the recommendation of the Board Leadership, the Board: <ol type="a"><li> Approves the Terms of Reference of the Ethics Officer, as set forth in Annex 1 to document GF/B33/ER08; and</li><li>Notes that the Terms of Reference of the Ethics Officer supersede the Board’s earlier decisions regarding the reporting arrangement for the Ethics Officer (GF/B33/DP09)</li></ol></li><li>Accordingly, the Board instructs the Secretariat to launch the recruitment process for the Ethics Officer, who will be jointly selected by the Audit and Ethics Committee (AEC) and the Executive Director, and appointed by the Board on a no-objection basis for a three-year term that may be renewed no more than once.</li><li>The Board requests the AEC and Finance and Operational Performance Committee to determine the future budgetary implications of this function as part of the standard Operating Expenses budget approval process, with particular consideration given to methods for maximizing value for money.</li></ul>
2015-07-24 33 GF/B33/EDP13 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER07.</li> </ol> <p>Annex: Abidjan-Lagos Corridor Organization (MAW-607-G01-H), Djibouti (DJB-613-G05-H), Guinea-Bissau (GNB-M-UNDP), Kosovo (KOS-711-G04-H), Nigeria (NGA-T-IHVN), Pakistan (PKS-M-DOMC PKS-T-NTP).</p>
2015-07-24 33 GF/B33/EDP12 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Afghanistan (AFG-M-UNDP), Botswana (BWA-M-BMOH), Comoros (COM-T-ASCOBEF), Congo (Democratic Republic) (COD-H-CORDAID, COD-H-SANRU, COD-H-MOH, COD-T-CARITAS, COD-H-MCOD-T-MOH), Somalia (SOM-T-WV) and Swaziland (SWZ-H-CANGO, SWZ-H-NERCHA).</p>
2015-07-17 33 GF/B33/EDP11 Location of the Thirty-Fourth Board Meeting, 16-17 November 2015
The Board decides to convene the Thirty-Fourth Board Meeting in Geneva, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.
2015-07-07 33 GF/B33/EDP10 Approval of the Report of the Thirty-Third Board Meeting
<p>The Board approves the Report of the Thirty-Third Board Meeting, as set forth in GF/B33/24.</p>
2015-06-29 33 GF/B33/EDP09 Terms of Reference of the Ethics Officer (Decision not approved)
<p>#</p>
2015-06-30 33 GF/B33/EDP08 #
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER05 – Revision 1.</li> </ol> <p>Annex: Guatemala (GUA-610-G04-T), Haiti (HTI-102-G09-H), India (IDA-T-CTD), Lao (PDR) (LAO-708-G09-M), Nepal (NEP-H-SCF, NEP-M-SCF), Syria (SYR-607-G01-T), Zanzibar (ZAN-T-MOHSW).</p>
2015-06-30 33 GF/B33/EDP07 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER05 – Revision 1 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-H-MOH), Bulgaria (BGR-T-MOH), Burkina Faso (BFA-T-PADS, BFA-H-SPCNLS, BFA-C-IPC), Cambodia (KHM-M-UNOPS), Cape Verde (CPV-M-CCSSIDA), Côte d'Ivoire (CIV-M-PNLP), Eritrea (ERI-T-MOH, ERI-H-MOH), Ethiopia (ETH-H-HAPCO, ETH-T-FMOH), Fiji (FJI-T-MHMS), Ghana (GHA-H-ADRA, GHA-H-PPAG, GHA-H-MOH, GHA-H-GAC, GHA-T-MOH), Mauritius (MUS-H-NAS, MUS-H-PILS), Multicountry Western Pacific (QMJ-C-UNDP, QMJ-M-UNDP), Nicaragua (NIC-H-INSS), Niger (NER-H-CISLS), Pakistan (PAK-T-NTP, PAK-T-MC), Russian Federation (RUS-H-OHI), Rwanda (RWA-T-MOH, RWA-H-MOH), Solomon Islands (SLB-M-MHMS, SLB-T-MHMS), Sudan (SDN-H-UNDP), Swaziland (SWZ-T-NERCHA) and Tanzania (TZA-C-STC).</p>
2015-06-11 33 GF/B33/EDP06 Appointment of a new Vice-Chair of the Finance and Operational Performance Committee
The Board approves the appointment of Mr. Michael Ruffner as the non-voting, neutral Vice-Chair of the Finance and Operational Performance Committee (the "FOPC") for the remainder of his predecessor's term.
2015-06-05 33 GF/B33/EDP05 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER03.</li> </ol> <p>Annex: Malawi (MLW-H-NAC), Multi Country Americas REDCA+ HIV Grant (MAR-H-SICSA).</p>
2015-06-05 33 GF/B33/EDP04 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER03 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-M-MOH), Ethiopia (ETH-S-FMOH, ETH-M-FMOH), Gambia (GMB-H-NAS, GMB-H-ActionAid), Guinea (GIN-M-CRS), Lao (People Democratic Republic) (LAO-T-GFMOH), Mozambique (MOZ-M-MOH, MOZ-M-WV, MOZ-H-MOH, MOZ-T-MOH, MOZ-C-FDC), Papua New Guinea (PNG-H-OSHF), Philippines (PHL-H-SC), Sao Tome &amp; Principe (STP-T-UNDP), Senegal (SEN-H-ANCS, SEN-H-CNLS), Somalia (SOM-H-UNICEF, SOM-M-UNICEF), South Sudan (SSD-T-UNDP), Tanzania (TZA-H-MOF, TZA-T-MOF), Uganda (UGA-S-MoFPED, UGA-S-TASO, UGA-C-TASO, UGA-H-MoFPED, UGA-T-MoFPED), Viet Nam (VNM-H-VAAC, VNM-H-VUSTA, VNM-T-NTP) and Yemen (YEM-M-NMCP).</p>
2015-06-04 33 GF/B33/EDP03 Appointment of Member of the Strategy, Investment and Impact Committee
The Board approves the appointment of Ms. Sandra Roelofs as a voting member of the Strategy, Investment and Impact Committee (the “SIIC)”) for a term that will expire on 9 March 2016, or until the appointment of her successor.
2015-05-15 33 GF/B33/EDP02 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 3 of Annex 1 to GF/B33/ER01.</li> </ol> <p>This decision does not have material budgetary implications for the 2014 Operating Expenses Budget.</p> <p>Annex: Cameroon (CMR-011-G10-H), Cameroon (CMR-011-G11-H), Indonesia (IND-M-MOH), Sudan (SUD-011-G15-H), Thailand (THA-H-DDC).</p>
2015-05-15 33 GF/B33/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER01;</li> <li>Approves the reinvestment of newly identified existing funds for the Ukraine TB/HIV program and its constituent grants and its resultant total program budget, as listed in Table 2 of Annex 1 to GF/B33/ER01;</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</p> <p>Annex: Armenia TB - Ministry of Health of the Republic of Armenia (ARM-T-MOH), Bhutan - TB - Ministry of Health of Bhutan (BTN-T-MOH), Costa Rica - HIV - Humanist Institute for Cooperation (HIVOS) (CRI-H-HIVOS), Eritrea - Malaria - Ministry of Health of Eritrea (ERI-M-MOH), Iraq - TB - UNDP (IRQ-T-UNDP), UKR-C-AUA, UKR-C-AUN, UKR-C-UCDC.</p>
2015-04-01 33 GF/B33/DP11 Appreciation of Outgoing Chair and Vice-Chair of the Board
<ol><li>The Board expresses its deep appreciation to Dr Nafsiah Mboi for her leadership as Chair of the Board. She has served the Global Fund with a high degree of personal commitment and passion. During her tenure, Ibu Naf has presided over significant deliberations and decisions that will continue to shape the future of the Global Fund. </li><li>The Board also expresses sincere gratitude to Ambassador Mireille Guigaz for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mireille has been an active driver of discussions and initiatives that will have a lasting impact on the Global Fund. </li><li>Their stewardship of the Board through the launch of a new funding model, an ethics and integrity initiative, and the approval of a governance plan for impact have pointed the Global Fund towards continued success and efficiency in achieving its mission. </li><li>The Board wishes Ibu Naf and Mireille every success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively. </li></ol>
2015-04-01 33 GF/B33/DP10 Ethics and Integrity: Second Stage Policy Proposals
<ol><li>The Board acknowledges the Audit and Ethics Committee's second stage policy proposals as set forth in document GF/B33/15 - Revision.</li><li>Accordingly, the Board: <ol type="a"><li>Approves the Code of Ethical Conduct for Governance Officials contained in Annex A to GF/B33/15 - Revision 2; and</li><li>Notes that the Code of Ethical Conduct for Governance Officials will be reviewed following appointment of the Ethics Officer. This review will be conducted by the Board Leadership in collaboration with the Committee responsible for ethics matters (the "Committee"). The findings of the review will be presented to the Board for discussion and potential revisions to the Code of Ethical Conduct as applicable.</li></ol></li><li>In addition, the Board: <ol type="a"><li>Notes the Board's decision to approve the reporting arrangements for the Ethics Officer described in GF/B33/DP09;</li><li>Endorses, in principle, the Terms of Reference of the Ethics Officer contained in Annex B to GF/B33/15 - Revision 2; and</li><li>Requests that the Terms of Reference of the Ethics Officer be further developed by the Board Leadership in collaboration with the Committee, with the support of the Office of the Inspector General, through a comprehensive consultation process and submitted to the Board through the Committee for approval by June 2015.</li></ol></li><li>Following approval by the Board of the Terms of Reference of the Ethics Officer in June 2015, the recruitment process will be launched.</li></ol>
2015-04-01 33 GF/B33/DP09 Ethics and Integrity: Reporting and Location Arrangements for the Ethics Officer
<ol><li>The Board approves a reporting arrangement for the Ethics Officer as follows: <ol type="a"><li> The Ethics Officer will report on its activities directly to the Board through the Committee responsible for ethics matters (the "Committee").</li><li>The Ethics Officer will provide regular advice and support: <ol type="i"><li>To the Executive Director on ethical matters pertaining to the Secretariat's activities, including issues related to grant recipients, CCMs, third-party providers (e.g., LFAs and suppliers) and staff. Based on the Ethics Officer's advice, the Executive Director will determine and implement appropriate remedial actions.</li><li>To the Committee on all other ethical matters not included in paragraph 1(b)(i) above. Based on the Ethics Officer's advice, the Committee will determine appropriate remedial actions.</li></ol></li><li>The Ethics Officer will be located within the Office of the Inspector General for administrative purposes only. </li></ol></li></ol>
2015-04-01 33 GF/B33/DP08 Policy on Co-infections and Co-morbidities
<ol><li>The Board acknowledges its approval of an interim measure for the financing of Hepatitis C virus treatment until the approval of a broader policy on co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria (GF/B32/DP07).</li><li>Based on the recommendations of the Strategy, Investment and Impact Committee, the Board approves the framework for financing co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, as set forth in GF/B33/11.</li><li>Accordingly, the Board notes this decision point supersedes GF/B32/DP07.</li></ol>
2015-03-31 33 GF/B33/DP07 Remaining Targets for the 2014 - 2016 Corporate Key Performance Indicator Framework
<ol><li>The Board: <ol type="a"><li>Notes additional analysis was required to finalize the performance targets for the updated 2014 - 2016 Global Fund Corporate Key Performance Indicator Framework (the "KPI Framework") that was approved in November 2014 (GF/B32/DP10); and</li><li>Acknowledges the Secretariat's presentation of 2014 performance assessments and updates, as well as updated performance targets, for the KPI Framework, as set forth in GF/B33/04B.</li></ol></li><li>Accordingly, the Board approves the updated performance targets for Key Performance Indicators 6, 12 and 16, as presented in GF/B33/04B.</li></ol>
2015-03-31 33 GF/B33/DP06 Appointment of External Auditor
The Board appoints Ernst &amp; Young SA as the Global Fund's external auditor for the 2015 fiscal year.
2015-03-31 33 GF/B33/DP05 2014 Statutory Financial Statements
The Board authorizes the issuance of, and therefore approves, the Global Fund's 2014 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in Annex 2 to GF/B33/03 - Revision 1. 
2015-03-31 33 GF/B33/DP04 Annual Financial Report 2014
The Board authorizes the issuance of, and therefore approves, the Global Fund's Annual Financial Report 2014, which includes the 2014 Consolidated Financial Statements that have been audited by Ernst &amp; Young SA, as set forth in Annex 1 to GF/B33/03 - Revision 1.
2015-03-31 33 GF/B33/DP03 Appointment of the Chair and Vice-Chair of the Board
The Board appoints Norbert Hauser as Chair of the Board and Aida Kurtovic as Vice -Chair of the Board to each serve a term starting from the adjournment of the Thirty-Third Board Meeting on 1 April 2015 and until the adjournment of the first in person Board Meeting in 2017.
2015-03-31 33 GF/B33/DP02 Approval of Agenda
<p>The agenda for the Thirty-Third Board Meeting (GF/B33/01 - Revision 2) is approved.</p>
2015-03-31 33 GF/B33/DP01 Appointment of Rapporteur
Professor Christian Otu Onyebuchi Chukwu from the West and Central Africa constituency is designated as Rapporteur for the Thirty-Third Board Meeting.
2015-03-28 32 GF/B32/EDP15 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex to GF/B32/ER14 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>See Details: Annex including table of recommendation on Additional Funding from the 2014 Allocation- Afghanistan (HSS and Tuberculosis - AFG-T-UNDP, AFG-T-MOPH), Ghana (Malaria - GHN-M-MOH, GHN-M-AGAMal), Multi-country Africa - SADC (HIV/AIDS - QML-H-SADC), Pakistan (Malaria - PAK-M-SC, PAK-M-DOMC), Paraguay (HIV/AIDS - PRY-H-CIRD), South Sudan (Malaria - SSD-M-PSI), Sudan (Malaria - SUD-M-UNDP).</p>
2015-03-18 32 GF/B32/EDP14 Decision on the Secretariat’s recommendation on grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B32/ER13.</li> </ol> <p>See Details: Annex including table of recommendation on grant extensions- Bolivia (BOL-809-G08-M), Kyrgyzstan (KGZ-S10-G08-T)).</p>
2015-03-18 32 GF/B32/EDP13 Decision on the Secretariat’s recommendations on additional funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B32/ER13 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>See Details: Annex including table of recommendations on additional funding from the 2014 Allocation- Democratic People’s Republic of Korea (Malaria), Islamic Republic of Iran (HIV/AIDS), Republic of Honduras (Malaria), Republic of Moldova (Tuberculosis), Romania (Tuberculosis), Suriname (Malaria).</p>
2015-03-06 32 GF/B32/EDP12 Terms of Reference of the Privileges and Immunities Advisory Group
<ol><li> The Board notes its decision to establish a dedicated group of donor and implementer representatives to identify strategies and advocate for the acquisition of privileges and immunities for the Global Fund (GF/B32/DP06).</li><li> Accordingly, the Board approves the terms of reference of the Privileges and Immunities Advisory Group as set forth in Annex 1 to GF/B32/ER12.</li></ol>
2015-02-27 32 GF/B32/EDP11 Appointment of Member of the Finance and Operational Performance Committee
The Board approves the appointment of Ms. Beatrijs Stikkers as a voting member of the Finance and Operational Performance Committee (the "FOPC") for a term that will expire on 1 May 2016, or until the appointment of her successor.
2015-02-13 32 GF/B32/EDP10 Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER07 - Revision 1.</li> </ul> <p>.Annex Table 2: Papua New Guinea (PNG-012-G09-H)</p>
2015-02-13 32 GF/B32/EDP09 Reference not in use
<p>The EDP number (GF/B32/EDP09) is not in use.</p>
2015-02-13 32 GF/B32/EDP08 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER07 - Revision 1;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex Table 1: Guyana (GYA-304-G01-H), Papua New Guinea (PNG-M-PSI, PNG-M-RAM, PNG-T-WVI)</p>
2015-02-09 32 GF/B32/EDP07 Approval of the Report of the Thirty-Second Board Meeting
<p>The Board approves the Report of the Thirty-Second Board Meeting (GF/B32/29 - Revision 1).</p>
2015-01-16 32 GF/B32/EDP06 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER06.</li> </ul> <p>Annex: Congo (Democratic Republic) (ZAR-911-G13-T, ZAR-911-G14-T, ZAR-H-SANRU, ZAR-H-CORDAID), Sudan (SUD-011-G16-M, SUD-011-G15-H), Tanzania (TNZ-809-G13-H)</p>
2015-01-16 32 GF/B32/EDP05 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER06 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bangladesh (BGD-M-BRAC, BGD-M-NMCP, BGD-T-BRAC, BGD-T-NTP), Cameroon (CMR-M-MOH), Nigeria (NGA-M-NMEP, NGA-M-SFH), Philippines (PHL-T-PBSP), Rwanda (RWA-M-MOH), Zimbabwe (ZWE-M-MOHCC, ZWE-TB-MOHCC)</p>
2014-12-22 32 GF/B32/EDP04 Membership of the Transitional Governance Committee
<ol><li>The Board notes its decision to establish the Transitional Governance Committee (GF/B32/DP05) under terms of reference set forth in Annex 1 to GF/B32/ER05 (the “Terms of Reference”) and acknowledges the recommendations on membership of the Transitional Governance Committee presented in GF/B32/ER05.</li><li>Accordingly, the Board approves the appointment of the following individuals to serve on the Transitional Governance Committee for a term that will expire upon the conclusion of the Transitional Governance Committee’s mandate, as outlined in the Terms of Reference: <ol type="a"><li>Ton Coenen;</li><li>Marina Hue;</li><li>Jimmy Kolker;</li><li>Jorge Saavedra;</li><li> Viorel Soltan; and</li><li> Carsten Staur.</li></ol></li><li>The Board acknowledges that members of the Transitional Governance Committee shall serve in their independent, personal capacity. As such, membership on the Transitional Governance Committee shall not apply towards the rule that each Board constituency may participate in a maximum of two committees. </li></ol>
2014-12-18 32 GF/B32/EDP03 Appointment of Inspector General
<ol><li>The Board appoints Mr. Mouhamadou Diagne to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 30 June 2015.</li><li>The Board authorizes the Global Fund to enter into a contract of employment with Mouhamadou Diagne for an annual salary that is above CHF 245,000 and does not exceed CHF 310,000, and requests the Board Chair to facilitate that process.</li></ol>
2014-12-08 32 GF/B32/EDP02 Decision on the Secretariat’s Recommendation on Grant Extensions
<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER01.</li> </ul>
2014-12-08 32 GF/B32/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2014-11-21 32 GF/B32/DP13 Approval of the Amended and Restated Global Fund Policy for Restricted Financial Contributions
<ol><li>Based on the recommendations of the Finance and Operational Performance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as set forth in Annex 1 to GF/B32/20 (the “Amended and Restated Policy”). </li><li>The Amended and Restated Policy shall supersede the prior version of the Policy for Restricted Financial Contributions (GF/B15/DP29) and be effective as of 22 November 2014, and shall not alter the characterization of any sources of funds that have been factored into the 2014 allocation of resources. </li></ol>
2014-11-21 32 GF/B32/DP12 Applying Risk Differentiation
<ol><li>Based on the recommendation of the Finance and Operational Performance Committee, the Board adopts the risk differentiation framework presented in paragraphs 34 through 37 of GF/B32/14. </li><li>The Board directs the Secretariat to operationalize this risk differentiation framework and report on its implementation at each Board Meeting. Furthermore, the Secretariat shall conduct annual reviews to update the risk differentiation framework as appropriate, and report to the Board once a year on the outcome of such reviews. </li></ol>
2014-11-21 32 GF/B32/DP11 Approval of the Risk Management Policy
<ol><li>The Board acknowledges multiple operational tools are utilized and updated by the Secretariat to execute the Global Fund's approach to risk management, as outlined in the Enterprise Risk Management Framework set forth in Annex 1 to GF/B32/13. </li><li>Accordingly, based on the recommendation of the Finance and Operational Performance Committee, the Board approves the Risk Management Policy, as set forth in Annex 3 to GF/B32/13 (the "Policy"). </li><li>The Policy shall supersede the Risk Management Framework adopted by the Board in November 2009 at its Twentieth Meeting (GF/B20/DP15) and become effective as of the date of this decision. </li></ol>
2014-11-21 32 GF/B32/DP10 Approval of the Global Fund Corporate KPI Framework 2014-2016
<ol> <li>The Board :</li> <ol type="a"> <li>Notes the Global Fund Corporate Key Performance Indicator Framework for 2014-2016 (the “KPI Framework”), which was approved in November 2013 (GF/B30/DP07), required additional methodological work during 2014 to finalize certain indicators; and</li> <li>Recognizes the work by the Secretariat to complete the methodology of the KPI Framework in consultation with the relevant committees of the Board.</li> </ol> <li>Accordingly, the Board approves the updated KPI Framework, currently available performance targets for 2015, and the plan to present the remaining 2015 performance targets for approval at the Thirty-Third Board Meeting, as set forth in GF/B32/24.a – Revision 2.</li> </ol>
2014-11-21 32 GF/B32/DP09 Ethics and Integrity Initiative: First Stage Policy Proposals
<ol><li>The Board acknowledges the Audit and Ethics Committee’s recommendation of policy principles arising from the First Stage of the Ethics and Integrity Initiative, as set forth in GF/B32/18 – Revision 1.</li><li>Accordingly, the Board approves:</li><ol type="a"><li>The Ethics and Integrity Framework contained in Annex A to GF/B32/18 – Revision 1; and</li><li>The proposal for creation of a dedicated and independent ethics function led by an Ethics Officer, as described in Annex B to GF/B32/18 – Revision 1.</li></ol><li>The Board furthermore requests the Audit and Ethics Committee to develop the following for the Board’s approval at its Thirty-Third Meeting:</li><ol type="a"><li>A Terms of Reference, reporting line and resourcing for the Global Fund ethics function, developed in consultation with the Finance and Operational Performance Committee; and</li><li>A Code of Ethical Conduct for Governance Officials, developed in consultation with all Board constituencies, and based on the Global Fund’s core ethical values and the principles contained in Annex C to GF/B32/18 – Revision 1.</li></ol></ol>
2014-11-21 32 GF/B32/DP08 Market Dynamics Oversight
<ol><li>Based on the joint recommendation of the Strategy, Investment and Impact Committee (the “SIIC”) and the Finance and Operational Performance Committee (the “FOPC”), as outlined in GF/B32/23, the Board:</li><ol type="a"><li>Affirms its commitment to optimizing the performance and impact of investments in health products and devices, through the review and updating of the Market Shaping Strategy (Annex 1 to GF/B23/09 - Revision 1) as well as oversight of its implementation and operationalization; </li><li>Decides the Market Dynamics Advisory Group (the “MDAG”) will cease as of the date of this decision, and that no advisory body shall be created or utilized to support the Board and its Committees in their responsibilities over market-dynamics matters; </li><li>Acknowledges the Secretariat’s responsibility to develop, update and implement strategic policies and initiatives on market-dynamics matters in collaboration with partners with relevant expertise;</li><li>Decides that the overall responsibilities for oversight and monitoring of market-dynamics matters, which include strategic and operational components, shall rest with the FOPC and SIIC as follows: <ol type="i"><li>The SIIC shall be responsible for guiding and overseeing the development and updating of strategic policies related to market-dynamics matters, such as the Market Shaping Strategy for recommendation to the Board by its November 2015 meeting; and</li><li>The FOPC shall be responsible for oversight of the implementation of strategic policies, including the financial and operational aspects of related sourcing and procurement initiatives.</li></ol></li></ol><li>Accordingly, the Board approves the amendments and restatements of the following governance documents, which shall become effective as of the date of this decision: <ol type="a"><li>Bylaws, as set forth in Annex 1 to GF/B32/23;</li><li>Charter of the Finance and Operational Performance Committee, as set forth in Annex 2 to GF/B32/23; and</li><li>Charter of the Strategy, Investment and Impact Committee, as set forth in Annex 3 to GF/B32/23.</li></ol></li><li>The Board directs the FOPC and SIIC, in collaboration with the Secretariat, to develop procedures and mechanisms on reporting and engagement to facilitate the FOPC and SIIC in the discharge of their responsibilities, including establishment of methods for how the committees will communicate, as a whole and through focal points, and ways to enlist experts that can provide technical support when appropriate. Such procedures and mechanisms will be in place and communicated among the members of the FOPC and SIIC by the end of the 2014 calendar year.</li></ol>
2014-11-21 32 GF/B32/DP07 Global Fund Financing of Hepatitis C Treatment
<ol><li>The Board acknowledges the Strategy, Investment and Impact Committee’s (the “SIIC”) plan to develop recommendations for Board consideration at its March 2015 meeting on the Global Fund’s role in funding treatment of co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, and directs the Secretariat to engage and collaborate with partners to support the SIIC’s development of such recommendations. </li><li>As an interim measure until there is an outcome to those deliberations, where there is a currently approved budget for Hepatitis C virus (“HCV”) treatment within an existing Global Fund grant, the Global Fund may continue to fund such treatment up to the approved budget amount, as set forth in GF/B32/22, and may otherwise permit continuation of Global Fund funded HCV treatment programs during this interim period with new grants in these countries up to previously approved budgeted levels.</li><li>The Board encourages partners to finance broader and additional HCV treatment needs, including those identified within Global Fund grant programs. </li><li>The Board acknowledges the close working relationship and collaboration among the Global Fund, UNITAID and other partners on market-shaping activities, including the expansion of access to HCV treatments. </li></ol>
2014-11-21 32 GF/B32/DP06 Privileges and Immunities
<ol><li>The Board acknowledges: <ol type="a"><li>The absence of privileges and immunities exposes the Global Fund’s resources, staff and mission to serious risks and challenges;</li><li>The importance of States, particularly implementing country governments, to accord privileges and immunities to the Global Fund through either applying domestic legislation or executing the Board-endorsed multilateral Agreement on Privileges and Immunities; and </li><li>The Secretariat’s efforts to require host-country grantees to take all appropriate and necessary actions to ensure the Global Fund is accorded privileges and immunities within three years from the effective date of a Framework Agreement signed between the Global Fund and host-country grantees.</li></ol></li><li>To further ensure progress in protecting the Global Fund through privileges and immunities, the Board requests: <ol type="a"><li>The Secretariat to dedicate required resources for the acquisition of privileges and immunities for the Global Fund;</li><li>The Finance and Operational Performance Committee and the Audit and Ethics Committee to oversee jointly the acquisition of privileges and immunities for the Global Fund, and report to the Board on an annual basis on implementing and donor countries that have and have not provided such protection to the Global Fund; and </li><li>The Board Leadership to constitute a dedicated group of donor and implementer representatives to identify strategies and advocate for the acquisition of privileges and immunities for the Global Fund. </li></ol></li></ol>
2014-11-20 32 GF/B32/DP05 Approving the Governance Plan for Impact
<ol><li>The Board acknowledges the: </li><ol type="a"><li>Observations, options and survey results presented in the advisory report issued by the Office of the Inspector General (the “OIG”) on the effectiveness and efficiency of Global Fund governance, as set forth in GF-OIG-14-008 (the “OIG Advisory Report, Governance Review”);</li><li>Analysis and recommendations presented in the Governance Plan for Impact prepared by the 2014 Ad-Hoc Working Group on Governance, as set forth in GF/B32/08 – Revision 2 (the “Governance Plan”); and</li><li>Related discussions and deliberations during the Board Retreat held in Montreux, Switzerland on 16 – 18 November 2014.</li></ol><li>Accordingly, the Board notes the recommendations on governance function contained in the Governance Plan and approves: </li><ol type="a"><li>The finalization of an enhanced governance structure, to be presented at the November 2015 Board meeting, comprised of the Board, Coordinating Group and the following re-configured standing committees:</li><ol type="i"><li>Audit and Finance;</li><li>Ethics and Governance; and</li><li>Strategy and Operations.</li></ol><li>Measures to transition the current governance structure to the enhanced governance structure, by the beginning of April 2016, which consists of:</li><ol type="i"><li>Establishment of the Transitional Governance Committee, under the terms of reference set forth in Annex 2 to the Governance Plan; </li><li>Modified responsibilities for the Coordinating Group, as reflected in its amended terms of reference, as set forth in Annex 4 to the Governance Plan; and</li><li>Maintaining the current allocation of responsibilities among the three standing committees (i.e., Audit and Ethics, Finance and Operational Performance, Strategy, Investment and Impact) until the enhanced governance structure is in place.</li></ol><li>Amended terms of reference for the Chair and Vice-Chair of the Board, as set forth in Annex 5 to the Governance Plan, to reflect the allocation of their shared and individual responsibilities. </li></ol><li>With respect to cross-cutting activities, the Board approves the recommendations set forth in the Governance Plan regarding the following:</li><ol type="a"><li>The Model for managing cross-cutting activities, as depicted in Figure 5 of the Governance Plan;</li><li>Responsibilities for risk management;</li><li>Assessment of organizational performance; and</li><li>Reaffirmation of the Partnership Forum with a refocused scope, as outlined in the proposed amendments to the By-laws set forth in Annex 6 to the Governance Plan.</li></ol><li>Furthermore, the Board approves the recommendations set forth in the Governance Plan for the following areas:</li><ol type="a"><li>Transparency of Board and committee votes, including revisions to the Operating Procedures of the Board and Committees set forth in Annex 7 to the Governance Plan;</li><li>Institutional memory management; </li><li>Elevating the implementer voice; and</li><li>Lifecycle management practices as well as constituency management, which shall be overseen by the Transitional Governance Committee described in paragraph 2.b.i of this decision point.</li></ol><li>In relation to the topic of legal status, the Board decides, noting the unique legal status of the Global Fund, to utilize the transition measures to, and eventual implementation of, the enhanced governance structure outlined in the Governance Plan to facilitate the Board’s understanding and determination of the set of norms and standards the Global Fund strives to comply with in its governance and operations.</li><li>The Board authorizes the Secretariat, in coordination with the Transitional Governance Committee, to amend, restate or develop the relevant governance documents to reflect the implications of this decision point. Such amended, restated or developed governance documents shall be presented to the Board for approval. In doing so, the Secretariat will also propose additional modifications to rules, procedures or structures established under this decision point, which may be required for its implementation, for further approval by the Board.</li><li>This decision point and its related modifications to governance documents shall take immediate effect upon the date the Board approves this decision point.</li></ol><p>Finally, the Board notes this decision point marks the conclusion of the work and mandate of the 2014 Ad-Hoc Working Group on Governance, and extends its gratitude and appreciation to the 2014 Ad-Hoc Working Group on Governance, as well as the Office of the Inspector General, for their efforts to produce analysis, observations, options and recommendations to guide the Board in furthering the effectiveness and efficiency of governance matters. </p>
2014-11-20 32 GF/B32/DP04 Communication on Status of Recoveries
<ol><li>As outlined in GF/B23/DP24 and reiterated in GF/B23/DP28, the Board continues to work with a full commitment to transparency and to endeavor to uphold the independence of the Office of the Inspector General (the “OIG”) within the Global Fund. In order to further promote this independence, the Board decides to supersede GF/B23/DP28 in its entirety with this decision point (GF/B32/DP04). </li><li>The Board recognizes the need to have clear, consistent and contextualized information regarding the status of recoveries related to non-compliant expenditures identified within grant programs financed by Global Fund resources. </li><li>With respect to non-compliant expenditures identified from OIG audits and investigations, the Board requests the Global Fund Secretariat to prepare a Recoveries Report (the “Report”) for the periods ending 30 June and 31 December of each year. The Report will detail, among other items: <ol type="a"><li>the amounts reported by the OIG as being non-compliant and/or as constituting financial loss; </li><li>the amounts deemed recoverable by the Secretariat based on the OIG’s findings, including an explanation of the method and process employed for the determination of such amounts; and </li><li>progress on outstanding recovery actions, including a description of the context within which recovery-related processes are being handled by the Secretariat and any lessons learned. </li></ol></li><li>The Board requests the AEC to: <ol type="a"><li>review the Report; </li><li>engage with the Finance and Operational Performance Committee (the “FOPC”) on matters within the FOPC’s mandate that relate to the process of developing and updating the Report; and </li><li>present any recommended amendments to this decision point to the Board for approval. </li></ol></li><li>Following the review of the Report by the AEC, the Secretariat shall submit the Report to the Board. </li><li>Furthermore, the Board directs the Secretariat to develop, for AEC approval, a methodology and format for future reporting within the Report, which describes measures taken with respect to recoverable amounts identified in the due course of grant management operations. </li></ol><p>The Board requests the OIG to report independently on the Secretariat’s progress on matters related to recoveries as part of the OIG’s Report to the Board or as otherwise determined by the AEC.</p>
2014-11-20 32 GF/B32/DP03 2015 Corporate Work Plan, Budget Narrative and Operating Expenses Budget
<ol><li>Based on the recommendation of the Finance and Operational Performance Committee (the “FOPC”), the Board approves the following: <ol type="a"><li>Corporate Work Plan and Budget Narrative 2015, as set forth in GF/B32/04; and</li><li>2015 Operating Expenses Budget in the amount of USD 299.8 million, as set forth in GF/B32/03 (the “2015 OPEX Budget”), which includes USD 16.4 million for the Office of the Inspector General’s 2015 operating expenses based on the recommendation of the Audit and Ethics Committee.</li></ol></li><li> As previously decided by the Board (GF/B22/DP18), the Secretariat will manage the 2015 OPEX Budget’s exposure to foreign-exchange rate volatility and include in its periodic reporting to the FOPC on budget matters any measures taken to minimize such exposure.</li></ol>
2014-11-20 32 GF/B32/DP02 Approval of Agenda
<p>The agenda for the Thirty-Second Board Meeting (GF/B32/01) is approved.</p>
2014-11-20 32 GF/B32/DP01 Appointment of Rapporteur
Mr. Paul Schaper from the Private Sector constituency is designated as Rapporteur for the Thirty-Second Board Meeting.
2014-11-07 31 GF/B31/EDP28 Location of the Thirty-Second Board Meeting
Based on the need to accommodate both the Board retreat and meeting, the Board agrees to convene the Thirty-Second Board Meeting in Montreux, Switzerland as an exception to article B.6.1 of the Operating Procedures of the Board and Committees.
2014-11-03 31 GF/B31/EDP27 Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER30.</p> <p>Table 2: Secretariat’s Recommendations on Grant Extension (see Annex for details)</p> <p>Tanzania (TNZ-607-G09-T)</p>
2014-11-03 31 GF/B31/EDP26 Decision on the Secretariat’s Recommendation on Additional Funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER30 ( “Table 1”); provided, however, that the disbursement of any and all funding for the grant “KAZ-T-NCTP” is subject to satisfactory resolution in line with the Global Fund policies by the Republic of Kazakhstan of all recoveries and other OIG matters now pending in draft or final forms;</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>GF/B32/EDP26 - Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation (see Annex for details)</p> <p>Indonesia (IDN-M-PERDHAK and IDN-M-MOH), Kazakhstan (KAZ-T-HOPE and KAZ-T-NCTP), Timor Leste (TLS-M-MOH), Philippines (PHL-M-PSFI), Swaziland (SWZ-M-NERCHA), Zambia (ZMB-C-CHAZ, ZMB-C-MOH, ZMB-M-CHAZ and ZMB-M-MOH)</p>
2014-10-13 31 GF/B31/EDP25 Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <p>Approves extension of the relevant implementation period for the grant listed in Table 3 of Attachment 1 to GF/B31/ER26.</p> <p>Table 3: Secretariat’s Recommendations on Grant Extension (see attached: Burundi, BRN-202-G05-M (BRN-M-SEPCNLS))</p>
2014-10-13 31 GF/B31/EDP24 Decision on the Secretariat’s Funding Recommendation for a Grant Renewal
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2 of Attachment 1 to GF/B31/ER26 (“Table 2”) in the amount indicated, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for the listed grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for the renewal of such existing grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the grant shall be the sum of the amount set out in Table 2 for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for a Grant Renewal (see attached: Macedonia, MKD-H-MOH)</p>
2014-10-13 31 GF/B31/EDP23 Decision on the Secretariat’s recommendation on additional funding from the 2014 Allocation
<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER26 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation. (see attached: Moldova, HIV/AIDS, MDA-H-PAS, MDA-H-PCIMU).</p>
2014-09-05 31 GF/B31/EDP22 Launch of the selection process for the next Inspector General
<p>The Board:</p><ol><li>Approves the establishment of a seven-member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (the “IG AHNC”) according to the Terms of Reference set out in Annex 1 of the Electronic Report to the Board that is numbered GF/B31/ER22.</li><li>Appoints the following five individuals, based on nominations by the voting constituencies of the Board as well as the World Bank, to serve as members of the IG AHNC, each serving in his or her personal capacity: <ul><li>Jan PAEHLER, who will also serve as Chair of the IG AHNC</li><li>Pavel AKSENOV</li><li>Galina MIKHLIN-OLIVER</li><li>Navin RUGHOONUNUN</li><li>Timothy ZIEMER</li></ul></li><li>Delegates authority to the Board Chair, in consultation with the Board Vice Chair, and Chair and Vice Chair of the Audit and Ethics Committee, to appoint by 5 September 2014, the two remaining members of the IG AHNC that are not affiliated with a Board constituency, as stipulated in the Terms of Reference of the IG AHNC.</li></ol>
2014-09-25 31 GF/B31/EDP21 Decision on the Secretariat’s Recommendations on Policy Exceptions for Processing Iraq TB Grant (IRQ-T-UNDP) Related Transition Funding Application
<ol> <li>The Board acknowledges the current political context and challenging implementation environment in Iraq due to ongoing conflicts. and</li> <li>Accordingly, the Board approves the following policy exceptions for processing IRQ-T-UNDP related transition funding application: <ol type="a"> <li>Maintaining the counterpart financing threshold at the level of 40%;</li> <li>Waiver of the “willingness to pay” requirement; and</li> <li>Waiver of the CCM eligibility requirements to access transition funding.</li> </ol> </li> </ol>
2014-08-25 31 GF/B31/EDP20 Decision on the Secretariat’s recommendations on grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 69,353,613 for UGD-708-G07-H and US$ 1,200,000 for UGD-708-G13-H (Uganda).</p>
2014-08-01 31 GF/B31/EDP19 Decision on the Secretariat’s recommendation for discontinuation of funding for a renewal
<p>The Board:</p><ol><li>Declines approval of additional funding for the next implementation period for the Round 10 Jordan TB grant (JOR-011-G04-T).</li></ol><p>Table 1: Secretariat’s Recommendation for Discontinuation of Funding for a Renewal </p><p><i>See attached table.</i></p>
2014-08-01 31 GF/B31/EDP18 Decision on the Secretariat’s funding recommendation for grant extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 1.</li> </ol> <p>Table 1: Secretariat’s Recommendations on Grant Extensions</p> <p>See attached table detailing total recommended funding amount of US$ 3,561,367 for US$ 3,561,367 (Ethiopia) and US$ 3,561,367 for US$ 3,561,367 (Syrian Arab Republic).</p>
2014-07-21 31 GF/B31/EDP17 Interim Condensed Consolidated Financial Statements
The Board notes the Audit and Ethics Committee’s (the “AEC”) responsibility to oversee financial accounting and reporting matters and requests that, following a limited review by the Global Fund’s external auditor, the AEC reviews and authorizes the publication of interim condensed consolidated financial statements which have been prepared by the Secretariat.
2014-07-21 31 GF/B31/EDP16 Appointment of the External Auditor
The Board authorizes the appointment of Ernst &amp; Young Ltd as the Global Fund’s external auditor for the 2014 fiscal year. 
2014-06-23 31 GF/B31/EDP15 Decision on the Secretariat’s funding recommendation for a grant renewal
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation for a Grant Renewal</p> <p>See attached table detailing total recommended funding amount of EUR 981,882 for KOS-911-G05-T (Kosovo).</p>
2014-06-06 31 GF/B31/EDP14 Decision on the Secretariat’s Recommendations on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation periods and, where applicable, the additional funding requested for the relevant grant listed in Table 3.</li> </ol> <p>See attached table detailing total recommended funding amount of EUR 12,794,690 for BUR-H-SPCNLS (Burkina Faso) and US$ 1,277,361 for NEP-M-EDCD (Nepal).</p>
2014-06-06 31 GF/B31/EDP13 Decision on the Secretariat’s Funding Recommendation for an Interim Applicant
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 2, based on the understanding that the amount approved is upper ceilings rather than final funding amount for that period and that on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 2 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 2: Secretariat’s Funding Recommendation for an Interim Applicant.</p> <p>See attached table detailing total recommended funding amount of EUR 21,336,770 for NGR-708-G07-M (Niger).</p>
2014-06-06 31 GF/B31/EDP12 Decision on the Secretariat’s Funding Recommendation for the Continuation of a Global Fund TB Program in the Central African Republic
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation</p> <p>See attached table detailing total recommended funding amount of EUR 971,313 for CAF-911-G09-T (Central African Republic).</p>
2014-06-06 31 GF/B31/EDP11 Appointment of Independent Member of the Audit and Ethics Committee
The Board approves the appointment of Ms. Jeya Wilson as an independent member of the Audit and Ethics Committee (the “AEC”) for a term that will expire on 9 March 2016, or until the appointment of her successor.
2014-05-23 31 GF/B31/EDP10 Approval of the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance
<p>The Board approves the Terms of Reference for the 2014 Ad-Hoc Working Group on Governance, as set forth in Annex 1 to GF/B31/ER06.</p>
2014-05-26 31 GF/B31/EDP09 Decision on the Secretariat’s Recommendation on a Grant Extension
<p>The Board:</p> <ol> <li>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 11,300,472 for the following grant: ZAR-911-G14-T for Democratic Republic of Congo (DRC).</p>
2014-05-09 31 GF/B31/EDP08 Approval of the Report of the Thirty-First Board Meeting
<p>The Board approves the Report of the Thirty-First Board Meeting (GF/B31/19).</p>
2014-04-25 31 GF/B31/EDP07 Decision on the Secretariat’s Recommendation on a Grant Extension
<p>TheBoard:</p> <p>Approvesextension of the relevant implementation period and, where applicable, theadditional funding requested for the grant listed in Table 3.</p> <p>See attached table detailing total recommended funding amount of US$ 12,973,121 for the following grant: SUD-011-G15-H for Sudan.</p>
2014-04-25 31 GF/B31/EDP06 Decision on the Secretariat’s Funding Recommendation for an Interim Applicant
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grant’s total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches.</p> <p>See attached table detailing total recommended funding amount of EUR 731,918 for the following grant: MOL-H-PCIMU for Moldova.</p>
2014-04-25 31 GF/B31/EDP05 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ US$ 309,646,766 for the following grants: ETH-T-FMOH for Ethiopia, KEN-H-KRC and KEN-H-MOF for Kenya, MOR-011-G04-H and MOR-011-G05-T for Morocco, UGD-T-MoFPED for Uganda.</p> <p>NOTES:</p> <ol type="a"> <li>Discrepancies between the CCM Request figures and the Program Scorecard result from the clarifications process with the CCM after the Request for Renewal was submitted and/or from corrections and adjustments made by the Global Fund Secretariat at the time of grant renewal review. Based on Board Decision GF/B26/DP7 on the Modification of Rules Governing Grant Renewals dated 11 May 2012, a modified ceiling of 90% of the TRP adjusted Phase 2 amount is applied to the Grant Renewals. This also takes into account discrepancies between the CCM Request figures and the Secretariat’s recommendation.</li> </ol>
2014-04-28 31 GF/B31/EDP04 Appointment of Board Constituency representatives to the Finance and Operational Performance Committee
<ol><li> The Board acknowledges the nominations for membership of the Board’s Finance and Operational Performance Committee (the “FOPC”), as set forth in GF/B31/ER03 Revision 1”.</li><li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016 or until the appointment of their respective successors: <ul><li>Hristijan Jankuloski, Developing Country NGO;</li><li>Ren Minghui, Western Pacific Region;</li><li>Nilaya Mitash, South East Asia;</li><li>Rachel Ong, Communities;</li><li>Safiatou Thiam, West and Central Africa;</li><li>Kieran Daly, Private Foundations;</li><li>Arun Thangaraj, Canada and Switzerland;</li><li>Reinhard Tittel-Gronefeld, Germany;</li><li>Nazzereno Todini, Private Sector; and</li><li>Takeshi Osuga, Japan.</li></ul></li><li>The Board appoints the following individuals to serve as non-voting members of the FOPC, representing the Board constituencies listed by their name, for a term that will expire on 1 May 2016, or until the appointment of their respective successors: <ul><li>Alexandru Cebotari, World Bank; and</li><li>Martins Pavelsons, Partners.</li></ul></li></ol>
2014-04-25 31 GF/B31/EDP03 Approval of the 2013 Statutory Financial Statements
The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Statutory Financial Statements, which have been audited by Ernst &amp; Young Ltd, as set forth in GF/B31/ER02 Annex 2. 
2014-04-25 31 GF/B31/EDP02 Approval of the 2013 Annual Financial Report
The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Annual Financial Report, which includes the 2013 Consolidated Financial Statements that have been audited by Ernst &amp;amp; Young Ltd, as set forth in GF/B31/ER02 Annex 1.
2014-03-28 31 GF/B31/EDP01 Decision on the Secretariat’s Recommendations on Grant Extensions
<p>The Board:</p> <ol> <li>Approves extension of the relevantimplementation periods and, where applicable, the additional funding requested forthe grants listed in Table 1.</li> </ol> <p>See attached table detailing total recommended funding amount of US$ 35,730,528 for the following Ukraine grants: UKR-011-G08-H, UKR-011-G09-H and UKR-011-G10-H.</p>
2014-03-07 31 GF/B31/DP14 Appointment of Strategy, Investment and Impact Committee Members and Launch of New Call for Nominations of Members of the Finance and Operational Performance Committee
<ol><li>The Board acknowledges the nominations for membership of the Board’s Strategy, Investment and Impact Committee (the “SIIC”), as set forth in GF/B31/10”.</li><li> Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"><li> Aida Kurtovic, Eastern Europe and Central Asia;</li><li>Vinand Nantulya, Eastern and Southern Africa;</li><li>Abdalla Osman, Eastern Mediterranean Region;</li><li>Mirta Roses, Latin America and the Caribbean;</li><li>Asia Russell, Developed Country NGO;</li><li>Helga Fogstad, Point 7;</li><li>Jason Lane, UK-Australia;</li><li>Julia Martin, USA;</li><li>Philippe Meunier, France; and</li><li>Jan Paehler, European Commission.</li></ol></li><li> Noting that the Chair of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the SIIC, the Board appoints the following individuals to serve as additional non-voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"><li> Lucica Ditiu, Partners; and</li><li>Mbulawa Mugabe, UNAIDS.</li></ol></li><li> The Board decides to launch a new call for nominations for the Finance and Operational Performance Committee (the “FOPC”) with a due date for nominations by 26 March 2014. The Chair and Vice-Chair of the Board will present its recommendation of candidates to the Board for approval by 15 April 2014.</li><li> The Board notes that qualified candidates that have already been nominated, but not appointed, for a Committee role will remain in consideration for FOPC membership.</li><li>The Board urges constituencies to nominate additional candidates that clearly demonstrate the competencies and skills that are required to perform the responsibilities of FOPC members. </li></ol>
2014-03-07 31 GF/B31/DP13 Appointment of Audit and Ethics Committee Members
<ol><li>The Board acknowledges the recommendations set forth in GF/B31/10 outlining the membership appointment recommendations for the Board’s Audit and Ethics Committee (the “AEC”).</li><li> Accordingly, the Board approves the appointment of the following individuals to the AEC for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"><li> Graham Jocelyne as independent Chair of the AEC;</li><li>Mohammed Abdellatif as independent member of the AEC;</li><li>Gabor Amon as independent member of the AEC;</li><li>Wendy Harrison as independent member of the AEC; and</li><li>Christopher Kassami as a constituency-nominated member from the Eastern and Southern Africa Constituency.</li></ol></li></ol>
2014-03-07 31 GF/B31/DP12 Extension Policy Under The New Funding Model
<ol><li>The Board decides: <ol type="a"><li>The Secretariat is authorized to extend a grant’s implementation period by a maximum of 12 months beyond the end date set forth in the relevant grant agreement: <ol type="i"><li>When the extension does not require funding in addition to the amounts approved by the Board for such implementation period ; or</li><li>When any portion of the extension requires funding in addition to the amounts approved by the Board for such implementation period, provided the period of additional funding does not exceed six months and the amount of additional funding does not exceed USD 10 million.</li></ol></li><li>Any other circumstances warranting an extension will be recommended by the Secretariat to the Board for approval. </li><li>The Secretariat will develop a framework for exercising the authority delegated under this decision, and report to the Board the extensions approved by the Secretariat under such authority through the monthly Grant Approvals Committee Report on funding recommendations.</li><li>The Secretariat will review the implementation of this decision and present any recommended modifications to the Strategy, Investment and Impact Committee for approval.</li></ol></li><li>The Board also decides that as of the date of this decision, the extension framework adoptedunder this decision supersedes all prior policies and decisions concerningextensions whether in whole or with respect to relevant parts, including thefollowing Board Decision Points:</li><li>B24/EDP/5: Procedure forRolling Continuation Channel Mid-Term Performance Reviews and Extensions;</li><li>GF/B20/DP31: ArchitectureReview – Transition Provisions;</li><li>GF/B16/DP7, GF/B14/DP27 and GF/B13/DP2: Phase 2Decision-Making Policies and Procedures; and</li><li>GF/B26/DP5: Delegation of Authority to Secretariat forGrant Operations. </li></ol>
2014-03-07 31 GF/B31/DP11 Revision to the OIG Disclosure Policy and the OIG Charter
<ol><li>Based on the recommendation of the Audit and Ethics Committee, the Board approves the Policy for Disclosure of Reports Issued by the Inspector General, as revised and set forth in Annex 1 to GF/B31/12, which supersedes and replaces the disclosure policy adopted by the Board under GF/B20/DP23.</li><li>Accordingly, the Board approves the following revision to Section 15 of the Charter of the Office of the Inspector General <a>[1]</a>(the “OIG Charter”) to align the OIG Charter with the revised Policy for Disclosure of Reports Issued by the Inspector General: </li></ol><blockquote><p>“15. Reporting: Final reports of Office of the Inspector General regarding its <strike>external</strike> assurance and investigations work will be posted on the Global Fund’s public internet site in accordance with the Board-approved ‘Policy for Disclosure of Reports Issued by the Inspector General’<strike>. Internal assurance findings will be promptly reported to the Executive Director and the AEC for internal action.</strike>”</p></blockquote>
2014-03-07 31 GF/B31/DP10 Composition of and Allocation to Country Bands
<ol><li>Based on the recommendations of the Strategy, Investment and Impact Committee (the “SIIC”), the Board approves the composition of Country Bands for the 2014 – 2016 allocation period, as defined and set forth in Annex 1 to GF/B31/09 – Revision 1.</li><li>In accordance with its decision to approve the transition framework recommended by the Finance and Operational Performance Committee and the SIIC (GF/B31/DP09), the Board acknowledges USD 15.8 billion is available for allocation to Country Bands for the 2014 – 2016 allocation period, consisting of the following: <ol type="a"><li> USD 14.8 billion for indicative funding; and</li><li> USD 950 million for incentive funding.</li></ol></li><li>The Board approves the following allocation of indicative funding for the 2014 – 2016 allocation period: <ol type="a"><li> Country Band 1: USD 11,250 million;</li><li> Country Band 2: USD 915 million;</li><li> Country Band 3: USD 1,530 million; and</li><li> Country Band 4: USD 1,105 million.</li></ol></li><li>The Board also decides incentive funding, in the amount of USD 950 million, will be apportioned across and within Country Bands 1, 2 and 3 in accordance with the methodology approved by the SIIC under authority delegated by the Board (GF/SIIC09/DP2). </li></ol>
2014-03-07 31 GF/B31/DP09 Transition from the Third to the Fourth Replenishment Period
<ol><li>The Board notes its prior decision to approve the Amended and Restated Comprehensive Funding Policy (GF/B31/DP05) (the “CFP”) as a standard financial management framework, and acknowledges unique measures are required to facilitate the 2014 allocation of resources to Country Bands, the first under the allocation-based funding model, to manage the transition from the rounds-based system. </li><li>Accordingly, based on the joint recommendation of the Finance and Operational Performance Committee (the “FOPC”) and the Strategy, Investment and Impact Committee (the “SIIC”), the Board adopts the following transition framework: <ol type="a"><li>The total amount that will be allocated to Country Bands (the “Total Allocation”) using the allocation methodology will be comprised of the following amounts: <ol type="i"><li>The Initial Allocation, in the amount of USD 10.22 billion, as approved under decision point GF/B31/DP08, which will determine the amount of incentive funding; and</li><li>The amount of Sources of Funds, as defined in the CFP, originating from the Third Replenishment Period (2011 – 2013), or earlier, which have not been disbursed as at 31 December 2013 (the “Existing Funds”), in the amount of USD 5.55 billion, as recommended by the FOPC.</li></ol></li><li>While each grant applicant’s portion of the Total Allocation must be requested by the applicant and approved by the Board prior to 31 December 2016, it may be utilized beyond such date in accordance with the terms of the relevant grant agreement;</li><li> The Total Allocation will address the remaining pipeline of grant funding due to Board-approved proposals or other Board decisions originating from the Third Replenishment Period, or earlier, as at 31 December 2013, (the “Existing Grants Pipeline”) while taking a comprehensive approach such that performance and strategic impact are reflected in the investment of the entirety of funds;</li><li> While each disease component’s portion of the Total Allocation will typically cover a period of four years starting from 1 January 2014, the Secretariat, working together with countries and/or regions, has the operational flexibility to structure longer or shorter grant implementation periods while applying the principles of the allocation model (GF/B28/DP4) to guide funding levels towards the amounts derived from the allocation formula;</li><li>Accordingly, a 25-percent target minimum reduction compared to the most recent available four-year disbursement levels (the “Graduated Reduction”) will be applied across the portfolio of disease components that have funding levels above their notional shares under the allocation methodology; and</li><li> If a disease component’s Existing Grants Pipeline exceeds the amount that would result from applying the Graduated Reduction described in paragraph 2.e. above, then instead of applying the Graduated Reduction, the disease component’s Existing Grants Pipeline will serve as a basis to determine its total allocation starting from 1 January 2014.</li></ol></li><li>The Board notes the transition framework established under this decision represents measures tailored to address the unique circumstances and challenges of transitioning from the rounds-based system to the allocation-based funding model and shall not apply to subsequent allocations and Replenishment Periods.</li></ol>
2014-03-07 31 GF/B31/DP08 2014 – 2016 Initial Allocation
<ol><li>The Board acknowledges: <ol type="a"><li>The Finance and Operational Performance Committee’s recommendation on the amount of announced replenishment results for the 2014 – 2016 Replenishment Period, net of certain adjustments and qualifying deductions, that will be allocated to Country Bands at the start of the Allocation Period (the “Initial Allocation”), as set forth in GF/B31/06, in accordance with the Comprehensive Funding Policy, as amended and restated under decision point GF/B31/DP05; and</li><li>The Board’s approval of the Strategy, Investment and Impact Committee’s recommendation to apportion USD 100 million to finance Special Initiatives and USD 200 million to finance Regional Programs over the 2014 – 2016 period (GF/B31/DP06 and GF/B31/DP07 respectively).</li></ol></li><li>Accordingly, the Board decides the Initial Allocation for the 2014 – 2016 Replenishment Period is USD 10.22 billion.</li></ol>
2014-03-07 31 GF/B31/DP07 Regional Programs
<ol><li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards investments that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7). </li><li> Based on the recommendation of the Strategy, Investment and Impact Committee, as set forth in GF/B31/08B, the Board: <ol type="a"><li>Decides that USD 200 million will be available for new Regional Programs over the 2014 – 2016 allocation period;</li><li>Recognizes that Regional Programs will be presented to the Board for funding approval throughout the 2014 – 2016 allocation period; and</li><li>Acknowledges funding applications that are submitted by a group of small island economies or other small countries that typically would not apply as individual countries due to inherent administrative inefficiencies (the “Multi-Country Applications”) will be funded from amounts allocated to the individual disease components participating in each Multi-Country Application. </li></ol></li></ol>
2014-03-07 31 GF/B31/DP06 Special Initiatives
<ol><li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards initiatives that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7) (the “Special Initiatives”). </li><li> Based on the recommendation of the Strategy, Investment and Impact Committee (the “SIIC”), the Board decides that up to USD 100 million will be available over the 2014 – 2016 allocation period for the following Special Initiatives, as described in GF/B31/08A – Revision 1, in the amounts listed below: <ol type="a"><li> USD 30 million for the Humanitarian Emergency Fund;</li><li>USD 17 million for Country Data Systems; </li><li>USD 29 million for Technical Assistance for Strong Concept Notes and PR Grant-making Capacity Building; </li><li>USD 15 million for Technical Assistance on Community, Rights and Gender; and</li><li>USD 9 million for Enhancing Value for Money and Financial Sustainability of Global Fund Supported Programs.</li></ol></li><li>The funds available for Special Initiatives may be reallocated by the Secretariat among the Special Initiatives set forth under paragraph 2 above, upon the SIIC’s approval, in consultation with the Finance and Operational Performance Committee (the “FOPC”), of an updated budget and plan to implement such initiatives.</li><li>The Secretariat shall recover investments towards Special Initiatives from funding provided through grant programs whenever possible. </li><li>With respect to the use of funds available for the Special Initiatives, the Board requests the Secretariat to report to the FOPC on the financial implications and to the SIIC on the operational and strategic implications. </li></ol>
2014-03-07 31 GF/B31/DP05 Amended and Restated Comprehensive Funding Policy
<ol><li>Based on the recommendation of the Finance andOperational Performance Committee, the Board approves the amended and restatedComprehensive Funding Policy, as set forth in GF/B31/04 – Annex 1 (the “Amendedand Restated CFP”). </li><li> The Amended and Restated CFP supersedes all priorversions of the Comprehensive Funding Policy, and any related decisionspreviously adopted by the Board or its Committees that are inconsistent withthe Amended and Restated CFP. </li></ol>
2014-03-07 31 GF/B31/DP04 2014 Operating Expenses Budget
<ol><li>Based on the recommendation of the Finance and Operational PerformanceCommittee (the “FOPC”), the Board approves the 2014 operating expenses budgetin the amount of USD 298.8 million, as set forth in GF/B31/03 Part A (the “2014Operating Expenses Budget”), which includes USD 20.5 million for the Office ofthe Inspector General’s 2014 operating expenses.</li><li>As previously decided by the Board (GF/B22/DP18), the Secretariat willmanage the 2014 Operating Expenses Budget’s exposure to foreign-exchange ratevolatility and include in its periodic reporting to the FOPC on budget mattersany measures taken to minimize such exposure. </li></ol>
2014-03-07 31 GF/B31/DP03 Approval of Report of the Thirtieth Board Meeting
<p>The report of the Thirtieth Board Meeting (GF/B31/02) is approved.</p>
2014-03-07 31 GF/B31/DP02 Approval of Agenda
<p>The agenda for the Thirty-First Board Meeting (GF/B31/01) is approved.</p>
2014-03-07 31 GF/B31/DP01 Appointment of Rapporteur
Minister Benedict Xaba from the Eastern and Southern Africa constituency is designated as Rapporteur for the Thirty-First Board Meeting.
2014-02-28 30 GF/B30/EDP09 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board: </p><ol><li>Approves, in accordance with its decision to launchthe transition to the New Funding Model (GF/B28/DP5), incremental funding inthe amount listed for the interim-applicant grants in Table 3 (the “RecommendedIncremental Funding under the New Funding Model”), which will be in addition tothe relevant grants’ total budget amounts that the Board has already approvedfor the implementation period. The Recommended Incremental Funding under theNew Funding Model increases the upper-ceiling amount available for commitmentrather than representing the final funding amount for the relevantimplementation period, and is subject to the availability of funding and to theprovision that the approved funding for the relevant grants shall be committedin annual tranches. </li></ol><p>See attached tabledetailing total recommended funding amount of US$ 3,000,000 for the followinggrants: CAM-708-G12-T (Cambodia) and MLW-708-G05-M (Malawi).</p>
2014-02-28 30 GF/B30/EDP08 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for thegrants listed in Table 2 in the amounts indicated for each grant, based on theunderstanding that the amounts approved are upper ceilings rather than finalfunding amounts for that period and that on-going implementation arrangementsfor each grant shall be pursued by the Secretariat consistent with theprinciples of the recommendations set forth in the related documentation submittedto the Board and in accordance with Global Fund policies. Approval is alsosubject to the availability of funding and to the provision that funding forrenewals of existing grants shall be committed in annual tranches (GF/B25/DP16,paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the nextimplementation period of each grant shall be the sum of the amount set out inTable 1 below for each listed grant and the amount of any funds approved forthe prior implementation period which have not been utilized during thatperiod, either as undisbursed funds or cash balances held by recipients underthe grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 89,129,143 for the followinggrants: COG-911-G06-H, COG-911-G05-H (Congo), LSO-H-MoFDP, LSO-813-G09-H (Lesotho), MOZ-708-G07-T (Mozambique)and MAT-011-G01-H (Multicountry Americas - REDTRASEX).</p>
2014-02-28 30 GF/B30/EDP07 Decision on the Secretariat’s Funding Recommendations for Early Applicants
<p>The Board:</p><p>Approves,in accordance with its decision to launch the transition to the New FundingModel (GF/B28/DP5), funding in the amount listed for the early-applicant grantsin Table 1 (the “Total Incremental Funding Recommendation”). The TotalIncremental Funding Recommendation increases the upper-ceiling amount availablefor commitment for the relevant implementation period and is subject to theavailability of funding and to the provision that the approved funding for eachgrant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 55,629,879. for thefollowing: Eurasian Harm Reduction Network (EHRN) (HIV/ AIDS), The RegionalMalaria Elimination Initiative in Mesoamerica and Hispaniola - EMMIE (Malaria)and Philippines (TB).</p>
2014-01-14 30 GF/B30/EDP06 Appointment of Board Constituency representative to the Audit and Ethics Committee
<ol><li>In accordance with paragraph 15.2 of the Global Fund’s Board and Committee Operating Procedures (‘Operating Procedures’) and after the approval of the Coordinating Group on 13 January 2014, the Board leadership decides to appoint Marc de Santis from the Canada/Switzerland constituency to serve as a member of the Audit and Ethics Committee (‘AEC’) to fill a current vacancy.<br/><br/></li><li>Mr de Santis shall serve on the AEC for a two year term or until the appointment of his successor. This appointment is effective on 14 January 2014.</li></ol>
2013-12-20 30 GF/B30/EDP05 Decision on the Secretariat’s Early Applicant Funding Recommendation
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model(GF/B28/DP5), funding in the amount listed for the early-applicant grants in Table 1 (the “Total Incremental Funding Recommendation”). The Total Incremental Funding<br/>Recommendation increases the upper-ceiling amount available for commitment for the relevant implementation period and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 100,000,000 for the following grant: Malaria - Regional Artemisinin Resistance Initiative (Cambodia, Lao PDR, Myanmar, Thailand and Viet Nam)</p>
2013-12-20 30 GF/B30/EDP04 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches</p><p>See attached tabledetailing total recommended funding amount of US$ 2,248,918 for the following grants: EGY-607-G02-T ; SUR-708-G04-M</p>
2013-12-20 30 GF/B30/EDP03 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 300,584,953 for the following grants: COL-011-G05-T ; COL-011-G06-T ; GUA-M-MSPAS ; KAZ-H-RAC ; KEN-011-G13-M ; KEN-011-G14-M ; MMM-011-G01-H ; PER-011-G08-H ; STP-011-G05-H ; SLE-M-CRSSL ; SLE-M-MOHS ; SOM-T-WV ; TNZ-405-G06-H ; TNZ-809-G13-H ; VTN-011-G10-S ; YEM-911-G07-T ; ZIM-M-UNDP</p>
2013-11-22 30 GF/B30/EDP02 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 30,831,682 for the following grants: BEN-T-PNTUB ; DMR-309-G07-T ; MON-H-MOH ; MWP-708-G06-H ; NIC-202-G05-T ; TGO-809-G08-H ; TGO-809-G09-H ; VTN-910-G08-T</p>
2013-11-22 30 GF/B30/EDP01 Decision on the Secretariat’s Funding Recommendations for Grant Renewals
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 46,371,589 for the following grants: <span>ERT-H-MOH ; </span>ERT-T-MOH ; IRN-M-UNDP ; TLS-H-MOH</p>
2013-11-08 30 GF/B30/DP08 Appointment of Committee Leadership
<ol><li>The Board approves theappointment of:<br/><br/><ol type="a"><li>Claude Rubinowicz as Vice-Chair of the Audit and Ethics Committee;<br/><br/></li><li>Soltan Mammadov and Jason Lawrence as Chair and Vice-Chair,respectively, of the Finance and Operational Performance Committee; and<br/><br/></li><li>David Stevenson and Anita Asiimwe as Chair and Vice-Chair, respectively,of the Strategy, Investment and Impact Committee.<br/><br/></li></ol></li><li>The Board notes each Committee Chair andVice-Chair appointed under this decision shall begin their term on 1 March 2014and serve for two years or until the appointment of their successor.</li></ol>
2013-11-08 30 GF/B30/DP07 The Global Fund Corporate Key Performance Indicator Framework for 2014-2016
<ol><li>The Board:<br/><br/><ol type="a"><li>Notes and approves theGlobal Fund Key Performance Indicator Framework for 2014-2016 (the “KPIFramework”), as set forth in GF/B30/7 – Revision 1;<br/><br/></li><li>Directs the Secretariat toreport annual key-performance-indicator results to the Board Committees and tothe Board, and where available, interim results will be made available throughthe routine information dashboard;<br/><br/></li><li>Acknowledges that furthermethodological work is required to extend the scope of specified indicators, asdescribed in GF/B30/7 – Revision 1, and requests the Secretariat to submitindicator revisions to the Board for approval, with a complete KPI framework,including baselines for each measure, finalized by June 2014 (subject to agreedexceptions set forth in Annex 2 to GF/B30/7 – Revision 1);<br/><br/></li><li>Directs the Secretariat tocomplement indicator results with sex and age dis-aggregated data wherefeasible; and<br/><br/></li><li>Requests the Secretariat toregularly review performance targets to drive effectiveness and efficiency andsubmit any proposed changes to the Board for approval.<br/><br/></li></ol></li><li>Budgetary implications of this decision will beincluded in the operating expenses budget of the Secretariat.</li></ol>
2013-11-08 30 GF/B30/DP06 2014 Operating Expenses Budget Approval Process
<ol><li>The Board delegates to theFinance and Operational Performance Committee (the “FOPC”) authority to approvean interim operating expenses budget for the first quarter of the 2014 fiscalyear (the “Q1 2014 Budget”), subject to the following:<br/><br/><ol type="a"><li>The Q1 2014 Budget will notexceed the first-quarter amount of the 2013 operating expenses budget; and<br/><br/></li><li>The full 2014 operatingexpenses budget will be presented to the Board for approval at the Thirty-FirstBoard Meeting in February 2014.<br/><br/></li></ol></li><li>This decision’s impact onthe 2014 operating expenses budget will not exceed USD 77.4 million.</li></ol>
2013-11-08 30 GF/B30/DP05 Revision of the Policy on Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund
<ol><li>The Board approves the amended policy on “Eligibility Criteria,Counterpart Financing Requirements and Prioritization of Proposals for Fundingfrom the Global Fund”<sup>[1]</sup>as set out in GF/B30/6 – Revision 1, Attachment 1 (the “Amended Policy”). TheAmended Policy, “The Global Fund Eligibility and Counterpart Financing Policy,”is effective upon the date of this decision and applies to all subsequenteligibility determinations.<br/><br/></li><li>The Board requests the Strategy, Investment and Impact Committee and the Secretariat to initiate a process that by the end of 2014 will provide options and recommendations to the Board to refine the Global Fund’s approach to transitioning countries. This approach shall include consideration of appropriate public health indicators to measure progress in sustaining and enhancing gains against the three diseases.</li></ol><p><span style="font-size: 12px; line-height: 1.5;"></span></p>
2013-11-07 30 GF/B30/DP04 Revision to the Whistle-blower Policy
The Board decides to replace the Whistle-blowing Policy and Procedures for the Global Fund to Fight AIDS, Tuberculosis and Malaria (approved at the Twenty-Third Board Meeting) with the revised Whistle-blowing Policy and Procedures, as set forth in Annex 1 of the Report of the Audit and Ethics Committee (GF/B30/12 Revision 1).
2013-11-07 30 GF/B30/DP03 Approval of Report of the Twenty-Ninth Board Meeting
<p>The report of the Twenty-Ninth Board Meeting (GF/B30/2) is approved.</p>
2013-11-08 30 GF/B30/DP02 Approval of Agenda
<p>The agenda for the Thirtieth Board Meeting (GF/B30/1) is approved.</p>
2013-11-07 30 GF/B30/DP01 Appointment of Rapporteur
Mr. David Stevenson from the Canada and Switzerland constituency is designated as Rapporteur for the Thirtieth Board Meeting.
2013-11-01 29 GF/B29/EDP14 Decision on the Secretariat’s Funding Recommendations for Interim Applicant
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 285,226 for the following grant: SWZ-809-G06-M</p>
2013-11-01 29 GF/B29/EDP13 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 401,799,230 for the following grants: AGO-911-G05-T ; CIV-910-G12-H ; CIV-910-G13-H ; ZAR-M-MOH ; ZAR-M-SANRU ; ZAR-M-PSI ; GHN-809-G11-H ; GUA-311-G05-H ; GUA-311-G06-H ; MLW-H-NAC ; MSA-910-G01-H ; NMB-T-MoHSS ; THA-M-DDC</p>
2013-10-04 29 GF/B29/EDP12 Appointment of Independent Member of the Audit and Ethics Committee
<ol><li>The Board approves the appointment of Mr. Mohamed Abdellatif as an independent member of the Audit and Ethics Committee (the “AEC”) to fill one current vacancy.</li><li>Mr. Mohamed Abdellatif shall serve on the AEC until the end of his predecessor’s term.</li></ol>
2013-10-01 29 GF/B29/EDP11 Revising the distribution of funding by disease in the new funding model allocation methodology
<p>The Board decides:</p><ol><li>Prior to the initial allocation of available resources to Country Bands for the 2014 – 2016 allocation period, the Secretariat will apportion such resources among the three diseases based on the following distribution: 50% for HIV/AIDS, 32% for malaria, and 18% for tuberculosis.</li><li>In accordance with Board Decision GF/B27/DP7, applicants will have flexibility in deciding how to allocate financing between the three diseases for their individual country programs.</li><li>The Board reaffirms its prior decision to recognize the importance of core TB-HIV collaboration services to achieve successful outcomes in TB and HIV grants (GF/B18/DP12). Taking note of the insufficient progress in implementing this prior decision on TB-HIV collaboration services, the Board requests the Secretariat to ensure integrated TB-HIV services are addressed in the country-dialogue and concept-note development process for countries with high TB-HIV co-infection rates, as set forth in the WHO policy on collaborative TB/HIV activities: “Guidelines for National Programs and Other Stakeholder” (2012).</li><li>The Strategy, Investment and Impact Committee will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li></ol>
2013-10-01 29 GF/B29/EDP10 Division between Indicative and Incentive Funding
<p>The Board</p><ol><li>The Board affirms its goal of raising US$ 15 billion so that it can effectively support countries in their fight against HIV/AIDS, tuberculosis and malaria in the 2014 – 2016 period. The available resources will be awarded to indicative and incentive funding to invest strategically in areas where there is high potential to achieve impact and value for money while rewarding ambitious, high-quality expressions of full demand, based on robust National Strategic Plans or investment cases. The 2014 – 2016 allocation period is the first where principles adopted under the new funding model (GF/B28/DP4) will be applied. The Board notes that the current replenishment cycle will result in unique actions in order to adjust investments in notionally over- and under-allocated countries. Accordingly, the Board acknowledges implementation methodology developed for the 2014 – 2016 allocation period will be reviewed and modified, as appropriate, for future allocation periods. <br/><br/></li><li>The Board decides: <br/><br/><ol><li type="a">For each allocation period, a fixed percentage of the amount of resources approved by the Board for initial allocation (the “Initial Allocation”), after deduction of the amount allocated to the Country Band corresponding to higher income (GNI per capita) and lower disease burden (“Band 4”), will be used for allocating Incentive Funding to Country Bands 1, 2 and 3. For the 2014 – 2016 allocation period, the Incentive Funding fixed percentage will be set, based on the following Initial Allocation scenarios: 10% for up to US$ 11 billion, 15% for over US$ 11 billion and up to US$ 13.5 billion, or 20% for over US$ 13.5 billion. The balance of the Initial Allocation will be used for Indicative Funding. <br/><br/></li><li type="a">No Incentive Funding will be allocated to the countries within Band 4 since Band 4 is subject to a separate allocation methodology approved by the Strategy, Investment and Impact Committee (the “SIIC”), which recognizes the particular needs of countries / disease components in Band 4. <br/><br/></li><li type="a">A graduated reduction will be applied to the funding levels of disease components that have received funding at levels above their notional shares under the allocation methodology. For 2014 – 2016, this graduated reduction will seek to reflect a target minimum reduction of 20% across the portfolio of impacted disease components relative to the most recent available three-year disbursement levels. The Secretariat shall have discretion to apply appropriate reductions for such disease components to reach the target reduction across the portfolio. <br/><br/></li><li type="a">Disease components that will, after the reduction referred to above, receive funding at levels that exceed their notional shares under the allocation methodology by more than 50% over the 2014 – 2016 allocation period will not be eligible for Incentive Funding during the 2014 – 2016 allocation period. <br/><br/></li><li type="a">Additional resources that become available after the initial allocation of available resources, including accelerations in the graduated reductions described in paragraph 3 of this decision and additional contributions from donors, will be apportioned to fund Unfunded Quality Demand in accordance with the methodology approved by the SIIC for which countries in all four Country Bands will be eligible. <br/><br/></li><li type="a">The SIIC will review this decision and propose appropriate modifications to the Board for approval prior to the 2017 – 2019 allocation period.</li></ol></li></ol>
2013-09-06 29 GF/B29/EDP09 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 27,934,678 for the following grants: CMR-011-G11-H ; NGR-708-G08-H ; RUS-304-G01-H ; YEM-708-G06-M</p>
2013-09-06 29 GF/B29/EDP08 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 842,017,272 for the following grants: CIV-809-G09-M ; GEO-H-GPIC ; GEO-T-GPIC ; GYA-304-G01-H ; LBR-M-PII ; LBR-M-MOH ; MKD-011-G04-T ; MEA-011-G01-H ; MEI-011-G01-H ; NGA-H-NACA ; NGA-H-ARFH ; NGA-H-SFHNG ; SAF-H-RTC ; SAF-910-G09-H ; SAF-304-G04-H ; SAF-H-NDOH ; SAF-H-NACOSA ; South Africa Grant TBD ; TNZ-M-MOFEA ; TNZ-809-G11-M ; TNZ-102-G01-M ; ZAM-811-G28-H ; ZAM-011-G29-H</p>
2013-08-23 29 GF/B29/EDP07 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (as indicated in the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of US$ 8,941,930 for the following grants: PHL-607-G08-H ; SLB-810-G01-T ;ZAM-708-G19-M ; ZAM-711-G26-T</p>
2013-08-23 29 GF/B29/EDP06 Decision on the Secretariat’s Funding Recommendations for Grant Renewals
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grant listed in Table 1 in the amount indicated for such grant, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for such grant shall be pursued by the Secretariat consistent with the principles of the recommendation set forth in the related Memo submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that the funding for the renewal of such grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li><li>Reaffirms that the maximum funding amount available for the next implementation period of such grant shall be the sum of the amount set out in Table 1 below for such grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 6,026,955 for the following grant: MYS-H-MAC</p>
2013-08-23 29 GF/B29/EDP05 Appointment to Replace Out-Going SIIC Member
<p>The Board:</p> <ol> <li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee (‘SIIC’), to replace one out-going member:<br />a. Ambassador Philippe Meunier, representing France.</li> <li>Notes that Ambassador Philippe Meunier shall serve on the SIIC until the end of his predecessor’s term.</li> </ol>
2013-08-16 29 GF/B29/EDP04 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,526,508 for the following grants: BAN-T-NTP ; BAN-T-BRAC ; IDA-708-G14-H ; IDA-708-G15-H ; IND-M-MOH ; JAM-708-G02-H ; RUS-506-G05-H ; SUD-708-G10-M ; ZIM-809-G12-T</p>
2013-08-16 29 GF/B29/EDP03 Decision on the Secretariat’s Funding Recommendations for Grant Renewals (including Interim Applicants)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Program Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 602,905,795 for the following grants: BLR-S10-G04-T ; CAM-H-NCHADS ; CAF-810-G08-M ; ECU-910-G06-H ; ECU-910-G07-H ; GIN-T-MSHP ; GYA-M-MOH ; HND-H-CHF ; HND-T-UECFSS ; IND-T-MOH ; IND-809-G10-T ; LAO-T-GFMOH ; MAL-809-G07-H ; MON-T-MOH ; MOZ-911-G09-H ; MOZ-911-G10-H ; NGA-809-G11-M ; NGA-809-G14-M ; STP-M-UNDP ; SNG-T-PLAN ; SNG-T-PNT ; SRL-911-G15-S</p>
2013-08-02 29 GF/B29/EDP02 Revision to the Declaration of Interest Form for Assessing Conflicts of Interest
<p>The Board approves the revised Declaration of Interest Form attached as Annex 1 of GF/B29/ER1.</p>
2013-08-02 29 GF/B29/EDP01 Appointment of the External Auditor
Based on the recommendation of the Audit and Ethics Committee, the Board approves the appointment of Ernst &amp; Young as the Global Fund’s external auditor for the 2013 fiscal year.
2013-06-19 29 GF/B29/DP06 Appreciation of Outgoing Chair and Vice-Chair of the Board
<p>The Board expresses its deep appreciation to Simon Bland for his leadership as Chair of the Board. He has served the Global Fund with a high degree of personal commitment and passion. During his tenure, Simon has successfully guided the Board through significant challenges and important decisions that will continue to shape the future of the Global Fund.</p><p>The Board also expresses sincere gratitude to Mphu Ramatlapeng for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mphu has been instrumental in driving governance reform, coordinating important deliberations, and facilitating decisions of the Board that will have a lasting impact on the Global Fund.</p><p>Their stewardship of the Board through the Consolidated Transformation Plan, the development of a new funding model, and the appointments of the Executive Director and the Inspector General have pointed the Global Fund towards continued success and efficiency in achieving its mission.</p><p>The Board wishes Simon and Mphu all the success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively.</p>
2013-06-19 29 GF/B29/DP05 Approval of the 2012 Annual Report
The Board approves the 2012 Annual Report of the Global Fund, as set forth in GF/B29/11.
2013-06-18 29 GF/B29/DP04 Appointment of Inspector General
<p>The Board:</p> <ol> <li>Selects Martin O'Malley to serve as the next Inspector General of the Global Fund for a six-year term beginning on or around September 2013</li> <li>Requests the Board Chair and Vice-Chair to facilitate the appointment of Martin O'Malley to the position of Inspector General.</li> </ol>
2013-06-18 29 GF/B29/DP03 Approval of Report of the Twenty-Eighth Board Meeting
<p>The report of the Twenty-Eighth Board Meeting (GF/B29/2) is approved.</p>
2013-06-18 29 GF/B29/DP02 Approval of Agenda
<p>The agenda for the Twenty-Ninth Board Meeting (GF/B29/1) is approved.</p>
2013-06-18 29 GF/B29/DP01 Appointment of Rapporteur
Dr. Aziza Bennani from the Eastern Mediterranean Region constituency is designated as Rapporteur for the Twenty-Ninth Board Meeting.
2013-06-14 28 GF/B28/EDP28 Discontinuation of funding for the Congo malaria grants (COG-810-G03-M and COG-810-G04-M)
<p>The Board:</p><p>Declines approval of additional funding for the next implementation period for the Round 8 Congo malaria grants (COG-810-G03-M and COG-810-G04-M).</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table.</span></p>
2013-06-14 28 GF/B28/EDP27 Decision on additional funding for the Rwanda SSF HIV grant (RWN-HMOH)
<p>The Board:</p><p>Approves additional funding for the Phase 2 period of the Rwanda SSF HIV grant (RWN-H-MOH) in the amount listed in Table 4, subject to relevant clarifications and conditions stipulated by the TRP. The amount approved represents the upper ceiling rather than the final funding amount for the Phase 2 period and on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that continued funding for the grant shall be committed in annual tranches (GF/B25/DP16, para 7 of Annex 1).</p><p>See attached tabledetailing total recommended funding amount of USD 150,684,607 for the following grant: RWN-H-MOH</p>
2013-06-14 28 GF/B28/EDP26 Decision on the Secretariat’s Funding Recommendations for grant renewals
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 3 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Program Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li><li> Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 3 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 125,959,401 for the following grants: MOZ-911-G11-M ; MOZ-911-G12-M ; TNZ-911-G14-S ; ECU-910-G08-T ; ECU-910-G09-T</p>
2013-06-14 28 GF/B28/EDP25 Decision on the Secretariat’s Funding Recommendations for Interim Applicants
<p>The Board:</p><p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p><p>See attached tabledetailing total recommended funding amount of USD 27,531,616 for the following grants: Chad newly approved but as yet unsigned malaria grant under the Transitional Funding Mechanism ; PNG-612-G07-T ; KEN-S11-G11-T ; KEN-S11-G12-T</p>
2013-06-14 28 GF/B28/EDP24 Decision on the Secretariat’s Funding Recommendations for Early Applicants
<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the early-applicant grants in Table 1 (the “Total Incremental Funding Recommendation”). The Total Incremental Funding Recommendation increases the upper-ceiling amount available for commitment for the relevant implementation period and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of USD 622,110,305 for the following grants: Myanmar/HIV/AIDS ; Myanmar/Tuberculosis ; Myanmar/Malaria ; El Salvador/HIV/AIDS ; Zimbabwe/HIV/AIDS</p>
2013-05-31 28 GF/B28/EDP23 Discontinuation of Funding for the Guinea-Bissau HSS Grant (GNB-809-G09-S)
<p>The Board:</p><p>The Board declines approval of additional funding for the next implementation period for the Round 8 Guinea-Bissau HSS Grant (GNB-809-G09-S).</p><p>Table 3: Secretariat’s Recommendations for Discontinuation of Funding for Renewals</p><p>See attached table.</p>
2013-05-31 28 GF/B28/EDP22 Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li> Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.<br/>Table 1: The Secretariat’s Funding Recommendations for Renewals</li></ol><p>See attached tabledetailing total recommended funding amount of USD 262,191,837 for the following grants: NMB-202-G01-H ; NMB-202-G07-H ; IDA-T-CTD ; IDA-T-IUALTD ; IDA-T-WVI</p>
2013-05-24 28 GF/B28/EDP21 Approval of the Global Fund’s 2012 Consolidated Financial Statements
<p>The Board:</p><p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2012 Consolidated Financial Statements, which have been audited by Ernst &amp; Young, as set forth in Annex 1 to B28/ER/16.</p>
2013-05-03 28 GF/B28/EDP20 Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Notes the consolidation of Pakistan’s Round 8 (PKS-809-G09-T) and Round 9 (PKS-910-G11-T) tuberculosis grants (the “Constituent Grants”) into one Single Stream of Funding (“SSF”) grant with the National Tuberculosis Control Program as Principal Recipient and a total budget amount for the implementation period comprised of the sum of the Board-approved budgets of the Constituent Grants, as set forth in Table 2; and</li><li>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the interim-applicant SSF grant in Table 2 (the “Additional Amount”), which will be in addition to the total budget amount of the Constituent Grants for the implementation period. The Additional Funding increases the upper-ceiling amount available for commitment rather than the final funding amount for the implementation period and is subject to the provision that continued funding for the SSF grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li></ol><p>See attached tabledetailing total recommended funding amount of USD 8,000,000 for the following grant: PKS-T-NTP</p>
2013-05-03 28 GF/B28/EDP19 Decision on the Secretariat’s Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 319,497,728 for the following grants: COL-911-G04-H ; ETH-911-G11-S ; GNB-910-G11-T ; TNZ-M-MOFEA ; GHN-809-G08-M ; GHN-M-MOH ; UKR-911-G07-T ; MCP-911-G01-H</p>
2013-04-26 28 GF/B28/EDP18 Appointment to Replace Out-Going SIIC Member.
<p>The Board:</p><ol><li>Approves the appointment of the following individual to the SIIC, to replace one out-going member:<br/>a. Koichi Aiboshi, representing Japan.</li><li>Notes that Mr. Koichi Aiboshi shall serve on the SIIC until the end of his predecessor’s term.</li></ol>
2013-04-02 28 GF/B28/EDP17 Decision on the Secretariat’s Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 26,899,613 for the following grants: NEP-T-NTC ; HTI-911-G08-T ; COG-810-G02-T</p>
2013-03-19 28 GF/B28/EDP16 Revised Charter of the Office of the Inspector General and Terms of Reference for the Inspector General
<p>Based on the recommendations of the Audit and Ethics Committee and information presented in the Electronic Report to the Board dated 12 March 2013 and titled “Revised Charter of the Office and the Inspector General and Terms of Reference for the Inspector General” (“B28/ER/12”), the Board:</p><ol><li>Approves the revised Charter of the Office of the Inspector General, as set forth in Annex 1 to B28/ER/12 (the “Charter”);</li><li>Approves the Terms of Reference for the Inspector General (the “TOR”), as set forth in Annex 2 B28/ER/12 (the “TOR”); and</li><li>Notes the Charter and TOR shall be effective as of the date of this decision.</li></ol>
2013-03-15 28 GF/B28/EDP15 Decision on additional funding for the Rwanda SSF Tuberculosis grant (RWN-T-MOH).
<p>The Board:</p><ol><li>Approves additional funding for the Phase 2 period of the Rwanda SSF Tuberculosis grant (RWN-T-MOH) in the amount listed in Table 2, subject to relevant clarifications and conditions imposed by TRP. Approval is granted based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for the Phase 2 period and that on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li></ol><p>See attached tabledetailing total recommended funding amount of USD 22,054,804 for the following grant: RWN-T-MOH</p>
2013-03-15 28 GF/B28/EDP14 Decision on the Secretariat’s Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 39,383,839 for the following grants: BIH-910-G03-H ; PKS-911-G13-H ; PKS-911-G14-H ; NMB-202-G03-M-00</p>
2013-03-15 28 GF/B28/EDP13 Finance and Operational Performance Committee, and Strategy, Investment and Impact Committee Member Appointments
<p>The Board:</p><ol><li>Approves the appointment of the following individuals to the Finance and Operational Performance Committee, to replace two out-going members:<br/><br/>a. Matthew Flomo, representing West and Central Africa; and<br/><br/>b. Reinhard Tittel-Gronefeld, representing Germany.<br/><br/></li><li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee, to replace one out-going member:<br/><br/>a. Marat Turkeyev, representing Eastern Europe and Central Asia<br/><br/></li><li>Notes that each of the members appointed by this decision shall serve until the end of their predecessor’s term.</li></ol>
2013-03-15 28 GF/B28/EDP13 2013 Inspector General Ad-Hoc Nominations Committee
<p>The Board:</p><ol><li>Establishes a seven member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (“IG AHNC”) according to the Terms of Reference set out at Annex 1 to this Decision Point with the following membership:<br/><br/>• Gabor AMON<br/>• Wendy HARRISON<br/>• Aida KURTOVIC<br/>• Galina MIKHLIN-OLIVER<br/>• Jan PAEHLER<br/>• Navin RUGHOONUNUN<br/>• Timothy ZIEMER<br/><br/></li><li>Requests the Audit and Ethics Committee, working in collaboration with Legal Counsel of the Global Fund, and the Interim Inspector General, to present for Board approval by not later than 5 March 2013:<br/><br/>a. revised Terms of Reference for the role of Inspector General; and<br/><br/>b. a revised Charter for the Office of the Inspector General.<br/><br/></li><li>Requests the Audit and Ethics Committee to develop, and apply to candidates shortlisted by the AHNC, an appropriate conflict of interest assessment process to ensure that the Board will receive from the AHNC only the names of candidates who are without any conflict of interest for the role.<br/><br/></li><li>Requests the AHNC to incorporate the AEC’s final recommendations into the AHNC’s decision making and present to the Board the AHNC’s recommendation on the strongest candidate(s) for the role of Inspector General, and the reasons for its recommendation, by 10 June 2013.</li></ol>
2013-03-15 28 GF/B28/EDP11 Appointment of Global Fund Board Chair and Vice-Chair
The Board appoints Dr Nafsiah Mboi as Chair of the Board and Madame Mireille Guigaz as Vice-Chair of the Board for a two-year mandate from the adjournment of the Twenty-Ninth Board Meeting and until the adjournment of the first Board Meeting in 2015
2013-02-25 28 GF/B28/EDP10 Reference not in use
<p>The EDP number (GF/B28/EDP10) is not in use.</p>
2013-02-04 28 GF/B28/EDP09 Decision on 3-month Extensions to Phase 1 for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G07-H, ECU-910-G08-T, ECU-910-G09-T)
<p>The Board:</p><ol><li>Approves additional 3-month extensions to Phase 1 ending dates for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G08-T) following the “Resubmission Request” recommendation2. Additional funding is not provided for these grant extensions while the CCM submits a revised Request for Renewal.</li><li>Approves 3-month extensions to Phase 1 ending dates with funding for the grants listed in Table 2 in the amounts indicated for each grant, following the “Resubmission Request” recommendation. Additional Funding will be provided to the grants implemented by Civil Society Principal Recipients in order to prevent disruption of programmatic activities while the CCM submits a revised Request for Renewal.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 482,472 for the following grants: ECU-910-G07-H ; ECU-910-G09-T</p>
2013-02-04 28 GF/B28/EDP08 Decision on January 2013 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat in consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 187,471,224 for the following grants: VTN-S10-G09-H ; HTI-811-G07-M ; MLW-911-G08-M ; TGO-910-G10-M ; TGO-910-G11-M ; KEN-S11-G11-T ; KEN-S11-G12-T ; MON-S-MOH</p>
2012-12-14 28 GF/B28/EDP07 Decision on additional funding for the Madagascar Round 9 Malaria grants (MDG-910-G16-M; MDG-910-G17-M; MDG-910-G18-M; MDG-910-G19-M)
<p>The Board:</p><p>Approves additional funding for the Phase 2 period of the Madagascar Round 9 Malaria grants (MDG-910-G16-M; MDG-910-G17-M; MDG-910-G18-M; MDG-910-G19-M) in the amount listed in Table 2 subject to TRP clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</p><p>See attached tabledetailing total recommended funding amount of USD 61,957,049 for the following grants: MDG-910-G16-M ; MDG-910-G17-M ; MDG-910-G18-M ; MDG-910-G19-M</p>
2012-12-14 28 GF/B28/EDP06 Decision on December 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 269,567,949 for the following grants: BEL-910-G02-H ; BEN-H-SEIBsa ; BEN-H-PlanBen ; BEN-H-PNLS ; CAM-S-PRMOH ; CMR-910-G07-M ; CMR-910-G08-M ; CMR-910-G09-T ; COM-910-G04-H ; GNB-M-MOH ; MAC-910-G02-H ; MEX-910-G01-H ; PKS-910-G11-T ; PKS-910-G12-T ; SRL-911-G13-H ; SRL-911-G14-H ; SUR-910-G05-T ; VTN-910-G08-T</p>
2012-12-06 28 GF/B28/EDP05 Decision on November 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 339,631,976 for the following grants: IDA-910-H ; IDA-910-G21-H ; IDA-910-G24-H ; IDA-405-G05-H ; IDA-405-G06-H ; IND-910-G15-H ; IND-H-NAC ; IND-H-MOH ; IND-809-G09-H ; LSO-810-G08-T</p>
2012-12-13 28 GF/B28/EDP04 Terms of Reference of Chair and Vice-Chair of Global Fund Board
<p>The Board approves the revised Terms of Reference for the Chair and Vice-Chair of the Board of the Global Fund, as set forth in B28/ER/04 (the "Revised Terms of Reference"), which supersede the existing Terms of Reference for the Chair and Vice Chair of the Board, as last amended in December 2010 (GF/B22/DP6).</p><p>The Board shall utilize the Revised Terms of Reference in the nomination and election of the next Chair and Vice-Chair of the Board.</p>
2012-12-13 28 GF/B28/EDP03 2013 Operating Expenses Budget
<p>The Board approves the 2013 Operating Expenses Budget, as set forth in GF/B28/ER03-Annex 1, in the amount of USD 301.2 million (USD 297.2 million recurring plus USD 4.0 million non-recurring costs), which includes USD 21.1 million budgeted for the Office of the Inspector General.</p><p>Following approval of this decision, the Secretariat may enter into a forward contract to manage the 2013 Operating Expenses Budget's exposure to currency risk in accordance with GF/B22/DP18. If the exchange rate determined on the date of signature of the forward contract results in a foreign-exchange adjustment to the budget amount approved by the Board, the adjusted amount shall be communicated to the Board and deemed the approved 2013 Operating Expenses Budget. In the absence of hedging, monitoring of the 2013 Operating Expenses Budget will be measured at the exchange rate used to prepare the budget.</p>
2012-12-13 28 GF/B28/EDP02 Strategic Investment in Monitoring and Evaluation
<p>The Board notes:</p><ol><li>the importance of strengthened national data systems to ensure effective program implementation; demonstrate impact; and guide the optimal use of limited resources;</li><li>the High-Level Independent Review Panel's recommendation to focus on outcomes rather than inputs and to improve in-country data quality; and</li><li>the concerns cited in the Five-Year Evaluation and by the Technical Review Panel regarding the need to strengthen in-country data systems and capacity.</li></ol><p>The Board approves a strategic investment of up to US$ 10 million of incremental Grant funds to strengthen national data systems to measure impact in 20 priority countries established by the Global Fund. The amount of the additional Grant funds committed to each country shall be determined on the basis of joint country and partner data quality assessments.</p>
2012-11-30 28 GF/B28/EDP01 Extensions for South Africa HIV/AIDS Grants
<p>The Board:</p><ol><li>Approves extension of the current implementation periods of SAF-910-G09-H, SAF-H-NACOSA, SAF-304-G04-H, and SAF-H-NDOH to 30 September 2013; and</li><li>Approves the commitment of up to USD 26,831,949 in additional funding from the indicative amounts of grant funds available, but not yet approved or committed, for the next implementation periods to fund extensions for SAF-910-G09-H, SAF-H-NACOSA and SAF-H-NDOH, as set forth in Table 1.</li></ol>
2012-11-15 28 GF/B28/DP08 Recognition of Debrework Zewdie
<p>The Board notes that this meeting will be the last involving participation by Debrework Zewdie as Deputy General Manager.</p><p>The Board therefore thanks Debrework for her wonderful service to the Global Fund. In her work as Deputy General Manager and Head of the Strategy, Investment and Impact Division, she has demonstrated enormous commitment and passion for the mission of the Global Fund. The Board acknowledges the numerous contributions Debrework has made to the organization and, in particular, the Board praises her leadership in reforming the grant renewals process.</p><p>The Board wishes Debrework every success in the future as she continues to work towards improving global health.</p>
2012-11-15 28 GF/B28/DP07 Appointment of Executive Director
<p>The Board:</p><ol><li>Selects Mark Dybul to serve as the next Executive Director of the Global Fund for a four-year term beginning on or around 4 February 2013.<br/> </li><li>Requests the Board Chair and Vice-Chair to facilitate the appointment of Mark Dybul to the position of Executive Director.</li></ol>
2012-11-15 28 GF/B28/DP06 Integration of the Lessons from the Affordable Medicines Facility - malaria
<p>The Board refers to its decision (GF/B20/DP24) to review the findings of the Independent Evaluation of the Affordable Medicines Facility - malaria (AMFm) Phase 1 and make a recommendation on whether to "expand, accelerate, modify, terminate or suspend the AMFm business line" in pilot countries.</p><p>The Board:</p><ol><li>notes the findings of the Independent Evaluation ("IE"), as detailed in the Strategy, Investment and Impact Committee ("SIIC") Report to the Board (GF/B28/04), on the effectiveness of the AMFm in the eight pilot programs and, in particular, notes the results regarding the "upstream" success parameters recommended in 2010 by the Technical Evaluation Reference Group ("TERG").<br/><br/></li><li>recognizes that the successes of the AMFm are due to the co-payment system, consisting of price negotiations with manufacturers and direct co-payments from the Global Fund to manufacturers on behalf of approved first-line buyers, and the use of supporting interventions.<br/><br/> </li><li>notes that the results of the IE and the TERG's interpretation of those findings indicate there is sufficient evidence to approve a modified approach to support countries in achieving the Roll Back Malaria targets of universal coverage of malaria treatment if coupled with efforts to improve access to diagnostic testing.<br/><br/></li><li>recognizes the importance of ensuring access to affordable diagnostic testing and treatment for malaria and the role of the private sector in delivering this access.<br/><br/></li><li>notes the role of the Global Fund in helping to ensure sustainable affordable pricing for health commodities through innovative strategies and initiatives, including through engagement of the private sector.<br/><br/></li><li>thanks countries, partners, donors and manufacturers for their participation and support in AMFm.</li></ol><p>The Board decides to modify the existing AMFm business line by integrating the lessons learned from the operations and resourcing of Phase 1 of the AMFm into Global Fund grant management and financial processes by:</p><ol><li>requesting the Secretariat to establish and operationalize a co-payment system through which the Global Fund will make direct payments to manufacturers on behalf of in-country buyers and at negotiated prices for countries which request the use of approved grant funds for a private sector subsidy to achieve their malaria case management targets and utilize supporting interventions; and<br/><br/></li><li>Acknowledging the need for an assessment by technical partners of the feasibility to include diagnostic testing into the co-payment system, which would inform the operationalization of the co-payment system.</li></ol><p><u>2013 Transition by AMFm Pilot Countries to Full Integration</u>:</p><p>The Board:</p><ol><li>notes that the integration of a co-payment system into Global Fund grant management and financial processes will mean that, following a responsible Transition, co-payments for anti-malarial drugs will no longer be available through a separate funding mechanism hosted by the Global Fund.<br/><br/></li><li>decides that, during the Transition in 2013 to operationalizing the integration of a co-payment system, the pilot countries will have a defined funding allocation to support private sector co-payments, subject to availability of dedicated resources for such payments, and that each country will determine the parameters, such as the use of demand levers, under which that funding is utilized.<br/><br/></li><li>requests the Secretariat to report to the FOPC and SIIC prior to the end of 2012 on the outcome of resource mobilization efforts undertaken to finance the co-payments for the Transition.<br/><br/></li><li>authorizes the Secretariat to deploy remaining resources from malaria grants in Phase 1 for supporting interventions, which is separate from co-payment funds.</li></ol>
2012-11-15 28 GF/B28/DP05 Evolving the Funding Model (Part Three)
<p>Referring to its previous decision <i>Evolving the Funding Model</i> (GF/B27/DP7) and GF/B28/DP4, the Board decides to launch the transition to the new funding model immediately by taking the following steps:</p><ol><li><u>Transition to the Full Implementation of the New Funding Model</u>: The Board decides to invest a portion of currently available uncommitted assets, to be determined by the Finance and Operational Performance Committee (FOPC) before the end of 2012, in a transition phase to test elements of the new funding model.<br/> </li><li><u>Participation</u>:<a id="_ftnref1" name="_ftnref1" href="#_ftn1"><sup>1</sup></a> The Secretariat would invite countries to participate in the Transition Phase, considering those that are:<br/><br/><ol type="a"><li>Significantly "underfunded" over the 2013-2014 period;<br/><br/></li><li>At risk of service interruptions;<br/> </li><li>Positioned to achieve rapid impact; and<br/><br/></li><li>Diverse in areas including, but not limited to size, geography, capacity and proposal modalities (including non-CCM and regional applicants), such that lessons learned can be derived from all aspects of the funding model, including funding for underserved and most-at-risk populations (MARPs).<a id="_ftnref2" name="_ftnref2" href="#_ftn2" target="_self"><sup>2<br/><br/></sup></a>The Secretariat will report quarterly to the Strategy, Investment and Impact Committee (SIIC) on the identity of countries participating in the Transition Phase. Countries, including those not invited to participate in the Transition Phase, are nonetheless encouraged to work on developing strong national strategies, reflecting full expressions of demand, and beginning Country Dialogues and iterative processes to encourage Concept Notes to be ready to allow for funding, based on the replenishment, to begin in early 2014.<br/> </li></ol></li><li><u>Disease Split</u>: As previously agreed by the Board (GF/B27/DP7), to apportion resources to the Country Bands for this transition period, the Board will first split the total projected resources between the three diseases based on the historical distribution of the Global Fund's portfolio: 52% for HIV, 32% for malaria, and 16% for tuberculosis.<br/> </li><li><u>Allocating Funding to Eligible Countries in the Transition Phase</u>: The Secretariat will determine an indicative funding range for each participating country based on the principles approved by the Board for indicative funding ranges in GF/B28/DP4 as adjusted by qualitative criteria<a id="_ftnref3" name="_ftnref3" href="#_ftn3"></a> and informed by the extent to which each country is "underfunded". The SIIC will assess the indicators used in the allocation formula prior to the commencement of the Transition Phase.<br/><br/></li><li><u>Channeling Funding During the Transition Phase</u>: The primary vehicle for investing the additional funding during the transition phase will be existing grants. <br/> </li><li><u>Use of Concept Note and Incentive Funding in the Transition Phase</u>: A subset of participating countries will receive an invitation to participate in the Concept Note process outlined in GF/B27/DP7, and as such will have an opportunity to access incentive funding in addition to the indicative range amounts per country. The incentive funding available to these countries will be limited to a ceiling established by the Secretariat at the time the transition is launched. <br/><br/></li><li><u>Strategic Investment Frameworks, Minimum Standards and Investment Guidance</u>: The guidance package the Secretariat will make available to Country Coordinating Mechanisms (CCMs) in the transition phase will include Strategic Investment Frameworks and Minimum Standards. <br/> </li><li><u>Independent Technical Review of Funding Requests</u>: To optimize learning, during this transition, the Secretariat and the Technical Review Panel (TRP) will jointly identify entry points for the TRP to review and provide feedback and recommendations on funding requests. As part of the transition to the full implementation of the new funding model, the composition and modalities of the TRP may change from current practice during the transition phase.<br/><br/></li><li><u>Board Approval of Investments during the Transition Phase</u>: During the transition phase, the Board will approve electronically the investments negotiated by the Secretariat and recommended by the TRP, on the basis of the Board's "no-objection" process for approving funding decisions for renewals and continuations of existing grants.<br/><br/></li><li><u>Existing Policies and Procedures</u>: The Board authorizes the Secretariat, under the oversight of the FOPC and SIIC, to make temporary exceptions to, or apply restrictions contained in, existing policies and procedures to the extent necessary to implement the transition phase of the new funding model. <br/><br/></li><li><u>Assessing the Effectiveness of the Transition:</u> The SIIC will have responsibility for assessing the effectiveness of the Transition, based on a monitoring and evaluation plan presented by the Secretariat, in consultation with the Technical Evaluation Reference Group. The SIIC will report to the Board regarding the effectiveness and lessons learned from the Transition.</li></ol><div style="text-align: center;">***</div><p><u>Notes:</u></p><p><a id="_ftn1" name="_ftn1" href="#_ftnref1"></a>1) Participation in the transition phase will not preclude access to new financing when the new funding model is implemented in full.</p><p><a id="_ftn2" name="_ftn2" href="#_ftnref2"></a>2) For the purposes of the transition to the new funding model, "MARPs" will be defined as subpopulations, applying to HIV/AIDS, malaria and tuberculosis, within a defined and recognized epidemiological context:</p><p>2.1) That have significantly higher levels of risk, mortality and/or morbidity;</p><p>2.2) Whose access to or uptake of relevant services is significantly lower than the rest of the population; and</p><p>2.3) Who are culturally and/or politically disenfranchised and therefore face barriers to gaining access to services.</p><p>2.4) The qualitative criteria will include external financing, "willingness to pay", absorptive capacity, performance of current and previous Global Fund grants and risk.</p>
2012-11-15 28 GF/B28/DP04 Evolving the Funding Model (Part Two)
<p>Building on its previous decision Evolving the Funding Model (GF/B27/DP7), the Board decides the following:</p> <ol> <li>Allocation Period: Every three years,aligned with the replenishment cycle, the Secretariat shall (i) identify the amount of resources available for allocation to the Country Bands, and (ii) update the country-specific information required to use the allocation formula described below.<br /><br /></li> <li>Implementation of Grants: While the allocation period will be aligned with the replenishment cycle, the planning and implementation of grants will be aligned with country planning cycles. The standard period of Global Fund financing for an applicant will be three years, subject to flexibility where deemed appropriate by the Secretariat<a id="_ftnref1" name="_ftnref1" href="#_ftn1"><sup>1</sup></a>.<br /><br /></li> <li>Establishment of Country Bands: The Board approves the following approach to determine the composition and structure of Country Bands (groups of countries) for the purposes of allocating resources:<br /><br /> <ol type="a"> <li><u>Principles for Determining Country Bands</u>: The Board approves the following principles for determining Country Bands to ensure focus is placed on countries with the highest disease burden and least ability to pay:<br /><br /> <ol type="i"> <li>Sufficient Critical Mass: Each Country Band should have a large enough number of countries and sufficient resources to enable flexibility within it;<br /><br /></li> <li>Logical Coherence within Each band: As the incentive funding introduces a need for comparison between applications, countries in each Country Band should be roughly comparable;<br /><br /></li> <li>Bands Should Not Be Disease-Specific: Each country should only be part of one Country Band; and<br /><br /></li> <li>Simplicity: The system of Country Bands should be easy to communicate and implement.<br /><br /></li> </ol> </li> <li><u>Composition Criteria for Country Bands</u>: Countries will be allotted to Country Bands based on a composite score generated based on a combination of a country's (i) Gross National Income (GNI) per capita and (ii) disease burden. The principles for these criteria are as follows:<br /><br /> <ol type="i"> <li>Transparency: The factors for "ability to pay" and disease burden should be objective and use widely accepted and available data;<br /><br /></li> <li>Proportionality: To adjust funding to population size, the disease-burden measure should take into account the scale of affected persons (in terms of absolute numbers, not percentages) by the three diseases in each country; and<br /><br /></li> <li>Comprehensiveness: To avoid putting a country in more than one Country Band, the burden metrics for each of the three diseases in a country should be aggregated into a composite disease-burden measure.<br /><br /></li> </ol> </li> <li><u>Number of Country Bands:</u> Based on these composition criteria, eligible countries<a id="_ftnref3" name="_ftnref3" href="#_ftn3"><sup>2</sup></a> will be placed in one of four Country Bands based on a combination of: (i) higher or lower disease burden; and (ii) higher or lower income (GNI per capita). One of these Country Bands, corresponding to higher income (GNI per capita) and lower disease burden, will include countries that should finance strategies, projects or plans targeted at most-at-risk populations (MARPs); however, countries in this band with generalized epidemics will not be restricted to MARPs related funding.<a id="_ftnref3" name="_ftnref3" href="#_ftn3" target="_self"><sup>3</sup></a>.<br /><br /></li> <li><u>Revising the Bands:</u> Prior to each allocation period, the Board may revisit the composition of the Bands, based on recommendations from the SIIC.<br /><br /></li> </ol> </li> <li>Allocation of Available Funding to Each Country Band: As outlined in GF/B27/DP7, the Board will undertake, on a regular basis, a strategic allocation of resources to Country Bands, and this will serve as the primary pool for funding grants. Such allocation will be based on a forecast of available resources approved by the Finance and Operational Performance Committee (FOPC). The Board approves the following approach to the allocation methodology and formula:<br /><br /> <ol type="a"> <li><u>Principles for Allocating Funding to Country Bands</u>: The Board agrees on the following principles for allocating funding to Country Bands:<br /><br /> <ol type="i"> <li>Strategic Focus: Focus funding on countries with the highest needs and least ability to pay;<br /><br /></li> <li>Simplicity: The methodology should be easy to communicate to implementers and other stakeholders;<br /><br /></li> <li>Transparency: The allocation methodology should use objective and widely accepted and available data;<br /><br /></li> <li>Global Reach:  The funding distribution should remain global;<br /><br /></li> <li>Comprehensive Scope:  Taking committed and uncommitted assets into account; and<br /><br /></li> <li>Flexibility: The output of the allocation formula is a guiding number, to be adjusted by pre-determined qualitative criteria.<br /><br /></li> </ol> </li> <li><u>Allocation Formula</u>: The formula for apportioning funding to Country Bands will be based on each country's "ability to pay" (measured by GNI per capita) and disease burden. The SIIC will assess the indicators used in the formula prior to each allocation period, and approve changes deemed appropriate. The specific construction of the formula shall follow the principles below:<br /><br /> <ol type="i"> <li>Proportionality:  The disease split implied by the allocation formula at the country should be based on each country's share of global disease burden and its ability to pay, applied to each of the three diseases;<br /><br /></li> <li>Flexibility: The system should feature flexibility in how to apportion funding between the three diseases and health and community systems strengthening (HCSS) at the country level;<br /><br /></li> <li>Sensitivity: Qualitative factors will adjust the initial figures derived from the allocation formula to account for the specific circumstances in each country the allocation formula might not capture; and<br /><br /></li> <li>Calibrated Eligibility: Not all countries are eligible for all three diseases, as reflected in current Global Fund policy.<br /><br /></li> </ol> </li> <li><u>Disease Split</u>: As previously agreed by the Board (GF/B27/DP7), to apportion resources to the Country Bands at the start of each allocation period, the Board will first split the total projected resources for a given allocation period between the three diseases. As the Board previously agreed (GF/B27/DP7), the Secretariat will under the oversight of the SIIC develop a measure that can be used to estimate disease burden and financial demand across all three diseases for approval by the Board no later than September 2013.<br /><br /></li> <li><u>Apportionment to Country Bands</u>: After making the global disease split described in GF/B27/DP7, the Board will then apportion to each Band a share of the total funding available for the chosen period. These shares will be calculated by adding up the shares produced by the allocation formula for all of the countries in each Band, adjusted for major sources of external financing and, if necessary, a transitional provision to ensure the Global Fund's financial commitments in some countries do not fall below a minimum required level<a id="_ftnref4" name="_ftnref4" href="#_ftn4"><sup>4</sup></a> over the allocation period. For countries in the band with lower disease burden and higher income, this aggregation of shares will be based on a separate methodology that is currently under development by the Secretariat which recognizes the particular needs of countries in this band including multi-country grants, regional grants, small island states and MARPs. The Secretariat will present this methodology to the SIIC for approval. Although countries' initial funding ranges will be dependent on the outcome of the Global Fund replenishment, countries will be encouraged to apply to the Global Fund for their full quality demand.<br /><br /></li> <li><u>New Resources:</u> Any resources that become available during an allocation period in addition to the initially allocated funding can be used by the Secretariat to (i) increase the amount of funding available in the Country Bands, (ii) fund "unfunded quality demand" (see paragraph 6), or (iii) propose to the SIIC to use some of these resources to fund special initiatives as described in GF/B27/DP7.<br /><br /></li> </ol> </li> <li>Indicative and Incentive Funding: As part of its allocation, the Board will divide the total amount of resources allocated to each Country Band into indicative and incentive funding: <br /><br /> <ol type="a"> <li><u>Purpose of</u><u>Indicative</u><u> Funding</u>: Indicative funding should ensure predictability for applicants, and should defend the Global Fund's aggregate investments in ways that go beyond the Continuity of Essential Services.<br /><br /></li> <li><u>Purpose of Incentive Funding</u>: As the Board previously agreed (GF/B27/DP7), a portion of funds will be used to establish a funding stream to incentivize high impact, well-performing programs and the submission of robust, ambitious requests based on national strategic plans or investment cases. The apportionment of funding to this stream will be substantial so as to ensure sufficient funds are available to motivate full expressions of quality demand<br /><br /></li> <li><u>Determining the Division Between Indicative and Incentive Funding</u>: The Board will decide the required resource levels to meet the applicants' prioritized needs through the indicative funding ranges for the allocation period, and apportion to the incentive funding the difference between prioritized needs and the amount of available assets identified at the time of the allocation. In this way, additional resources mobilized during the given replenishment period may be apportioned to incentive funding. Additional principles to guide the division between indicative and incentive funding, including a final definition of prioritized needs, will be approved by the Board at its Twenty-Ninth Meeting, based on recommendations of the SIIC.<br /><br /></li> <li><u>Access to Funding</u>: The access to funding process will be based on country dialogue and reviews where the Global Fund is part of joint country-led processes, including within the CCMs and with other relevant partners, and will result in the development of a Concept Note.<br /><br /> <ol type="i"> <li><u>Access to Indicative Funding</u>: The determination of indicative funding ranges will be supplemented by qualitative factors including, but not limited to, the following:<br /><br /> <ol> <li>Major sources of external financing;</li> <li>Minimum funding levels;</li> <li>Willingness to pay;</li> <li>Past program performance and absorptive capacity;</li> <li>Risk; and</li> <li>Increasing rates of new infections in lower prevalence countries.<br /><br /></li> </ol> </li> <li><u>Access to Incentive Funding</u>: The Secretariat will develop the process and methodology for awarding incentive funding. Prior to the full implementation of the new funding model, the Secretariat will present to the SIIC for approval this methodology, which shall conform to the following principles: <br /><br /> <ol> <li>Ambition: Additional funding should foster quality expressions of full demand to address the totality of the response to a disease;</li> <li>Strategic Focus:  Additional funding should reward robust National Strategies and investment cases, and well-performing programs with a potential for increased, quantifiable impact;</li> <li>Alignment: The processes for awarding additional funding should ensure that applicants can access funding aligned to national planning cycles, by avoiding unintended incentives to apply either early or late in an allocation period</li> <li>Sustainability:  Additional funding should leverage contributions from other sources, including domestic budgets</li> <li>Simplicity:  The processes for awarding additional funding must minimize complexity and transaction costs for implementers, and avoid disruptions to grant-making; and</li> <li>Co-investment or Willingness to Pay:  Additional funding should also leverage financing from Governments in implementing countries.<br /><br /></li> </ol> </li> </ol> </li> </ol> </li> <li>Managing Unfunded Quality Demand: Since quality demand by countries could exceed the level of resources available, the Secretariat will maintain a register of unfunded quality demand. The Global Fund will prioritize this demand for future funding should additional resources become available, as well as invite other donors to finance this demand directly:<br /><br /> <ol type="a"> <li><u>Prioritizing and Awarding Financing to Unfunded Quality Demand</u>: The Secretariat will determine how to prioritize and award financing to unfunded quality demand and will present this methodology to the SIIC, as appropriate, for approval prior to the full implementation of the new funding model. This methodology for prioritizing and awarding financing to unfunded quality demand shall conform to the same set of principles as set forth in paragraph 5.d.ii above.</li> </ol> </li> </ol> <div>***</div> <p><u>Notes:</u></p> <div> <div id="ftn1"> <p><u><a id="_ftn1" name="_ftn1" href="#_ftnref1"></a></u></p> <p>1) Justifications for variations from the three-year standard will be provided to the Board as part of the Secretariat's grant approval requests.</p> </div> <div id="ftn2"> <p><a id="_ftn2" name="_ftn2" href="#_ftnref2"></a>2) Country eligibility will follow existing criteria approved by the Board in the Policy and Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund (Twenty-Third Board Meeting Documents, attachment to GF/B23/14), GF/B25/DP16 and B25/ER/05.</p> </div> <div id="ftn3"> <p><a id="_ftn3" name="_ftn3" href="#_ftnref3"></a>3) It is anticipated that some countries will have MARPs-related epidemics for one disease, and not for others.</p> </div> <div id="ftn4"> <p><a id="_ftn4" name="_ftn4" href="#_ftnref4"></a>4) Based on a recommendation from the Secretariat, the FOPC and SIIC, as appropriate, will define this "minimum required level" before the first full allocation period under the new funding model.</p> </div> </div>
2012-11-15 28 GF/B28/DP03 Approval of Report of the Twenty-Seventh Board Meeting
The report of the Twenty-Seventh Board Meeting (GF/B28/11) is approved.
2012-11-15 28 GF/B28/DP02 Approval of Agenda
The agenda for the Twenty-Eighth Board Meeting (GF/B28/1) is approved.
2012-11-15 28 GF/B28/DP01 Appointment of Rapporteur
Jan Paehler from the European Commission constituency (Belgium, Finland, Portugal, Italy and Spain) is designated as Rapporteur for the Twenty-Eighth Board Meeting.
2012-10-31 27 GF/B27/EDP04 Approval of Board Processes for Executive Director selection
Based on consultations over September and October 2012, the Board approves the framework for candidate engagement and decision-making as proposed by the Board Chair to Board Members on 29 October 2012 as specified in GF/B27/ER3 Revision 1.
2012-10-22 27 GF/B27/EDP03 October 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 636,344,148 for the following grants: BEN-304-G04-M ; BEN-T-PNTUB ; BIH-T-UNDP ; BOL-910-G09-H ; BOL-910- G10-T ; MOL-H-PCIMU ; MOL-809-G06-H ; NIC-910-G07-M ; SLE-H-NAS ; TKM-910-G01-T ; TNZ-809-G13-H ; AZE-910-G05-H ; AZE-910-G06-T ; BAN-T-BRAC ; BAN-T-NTP ; GMB-S10-G07-M (GMB-M-MOH) ; GMB-M-CRS ; GYA-810-G06-T ; IDA-910-G23-M ; IDA-910-G22-M ; SSD-910-G13-S</p>
2012-09-24 27 GF/B27/EDP02 Additional funding for Continuity of Services for the South Sudan Round 5 TB program (SSD-506-G06-T)
<p>The Board approves additional funding for up to twenty (20) months for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s Continuity of Services form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the Secretariat’s recommendations.</p><p>See attached tabledetailing total recommended funding amount of USD 1,537,483 for the following grant: SSD-506-G06-T</p>
2012-09-24 27 GF/B27/EDP01 September 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 478,957,450 for the following grants: SNG-S10-G09-H (SNG-H-CNLS) ; SNG-H-ANCS ; SNG-S10-G11-H (SNG-H-DLSI) ; IDA-202-G19-H ; IDA-202-G02-H ; CIV-S10-G10-T ; CIV-S10-G11-T ; ZAN-809-G07-M ; CAM-M-CNM ; NGA-H-NACA ; NGA-H-SFHNG ; NGA-H-ARFH ; NGA-H-CiSHAN ; NGA-H-PPFN ; NGA-T-ARFH ; NGA-T-IHVN ; BUR-810-G10-T ; BUR-810-G11-T ; KGZ-S10-G08-T ; KGZ-910-G07-T ; MOL-T-PCIMU ; MOL-S10-G09-T ; IRQ-T-UNDP ; GMB-T-MRC ; GMB-T-MOH ; LAO-H-GFMOH ; PRY-T-AV</p>
2012-09-14 27 GF/B27/DP07 Evolving the Funding Model
<p>The Board:</p><ol><li>Adopts in principle the elements of the new funding model detailed in Annex 1.</li><li>Requests the SIIC to recommend to the Board at its Twenty-Eighth Meeting the additional elements of the new funding model so as to allow for its implementation beginning in 2013, based on funds available.</li><li>Requests regular evaluation of the new funding model.</li><li>Requests the SIIC to continue the work of evolving the business model of the Global Fund beyond the new funding model, enabling the full implementation of the new strategy.</li></ol>
2012-09-14 27 GF/B27/DP06 Amendments to the Charters of Audit and Ethics Committee and the Finance and Operational Performance Committee
<ol><li>The Board decides to amend the Charters of the Audit and Ethics Committee (the "AEC") and the Finance and Operational Performance Committee (the "FOPC") to reallocate the advisory and oversight responsibilities related to the external audit of the Global Fund's annual financial statements between the AEC and FOPC, as set forth in Annexes 3 and 4 to GF/B27/07.</li><li>The AEC and FOPC Charters, as amended and set forth in Annexes 3 and 4 of GF/B27/07, shall be effective as of the date of this decision.</li></ol>
2012-09-14 27 GF/B27/DP05 Revision to the Policy on Ethics and Conflict of Interest for Global Fund Institutions
The Board approves the revised Policy on Ethics and Conflict of Interest for Global Fund Institutions attached as Annex 1 of GF/B27/07 and the revised Declaration of Interest Form attached as Annex 2 of GF/B27/07 as updated to reflect the new Board Committee structure established with the Board's adoption of the Governance Reform at its Twenty-Fifth Meeting.
2012-09-14 27 GF/B27/DP04 Transitional Arrangements for the Affordable Medicines Facility - malaria
<p>The Board refers to its earlier decision regarding the duration of Phase 1 of the Affordable Medicines Facility - malaria ("AMFm") (GF/B22/DP13) and notes that Phase 1 will end on 31 December 2012.</p><p>The Board recognizes the importance of an orderly transition for those countries that are part of the Phase 1 pilot following its decision expected in November 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line. In order to support an orderly transition towards implementing the outcome of the November decision, the Global Fund will continue to host AMFm during a twelve-month transition period, and the Board will approve the details of the transition in November.</p><p>In order to support the transition period, the capacity of the Global Fund Secretariat to manage the activities of the AMFm shall be extended by twelve months (until 31 December 2013). The Board requests that the Secretariat include the appropriate budgetary implications of the extended mandate of the AMFm in the 2013 Operating Expenses Budget.</p>
2012-09-14 27 GF/B27/DP03 Approval of Report of the Twenty-Sixth Board Meeting
The report of the Twenty-Sixth Board Meeting (GF/B27/12 Revision 1) is approved.
2012-09-14 27 GF/B27/DP02 Approval of Agenda
The agenda for the Twenty-Seventh Board Meeting (GF/B27/1) is approved.
2012-09-14 27 GF/B27/DP01 Appointment of Rapporteur
Dr Palitha Mahipala from the South East Asia constituency is designated as rapporteur for the Twenty-Seventh Board Meeting.
2012-08-13 26 GF/B26/EDP13 Increase in Incremental Funding of the Colombia Malaria Grant (COL-809-G02-M)
The Board approves additional incremental funding up to EUR 1,075,944 for the Phase 2 period of the Colombia malaria grant (COL-809-G02-M) with conditions stipulated in its B26/EDP/04 decision of 20 June 2012.
2012-08-13 26 GF/B26/EDP12 August 2012 Phase 2 Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 99,032,607 for the following grants: BAN-202-G11-H-00 ; BAN-202-G12-H-00 ; BAN-202-G13-H-00 ; LBR-810-GO7-H ; SUD-T-UNDP</p>
2012-08-24 26 GF/B26/EDP11 Approval of Transitional Funding Mechanism Proposals
<ol><li><p>The Board endorses the Technical Review Panel (TRP) Recommendation Categories for the Transitional Funding Mechanism (TFM) as set forth in the GF/B26/ER 07.</p></li><li><p>The Board approves all TFM proposals recommended for funding by the TRP as Categories 1, 2, and 3 as indicated in Annex 1 of GF/B26/ER 07, subject to all applicable clarifications or conditions outlined in TRP review forms. The aggregate total of the maximum upper ceilings of funding for Category 1, 2 and 3 TFM proposals is US$ 419.8 million.</p></li><li><p>Applicants whose proposals are recommended for funding as "Category 3" shall: </p><ol type="a"><li><p>provide an initial detailed written response to the requested TRP clarifications no later than four (4) weeks after the applicant's receipt of notification in writing by the Secretariat of this Board decision; and</p></li><li><p>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than eight (8) weeks after the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p></li></ol></li><li><p>The Board conditionally approves all TFM proposals which are recommended for funding by the TRP as "Category 4" as indicated in Annex 1 of GF/B26/ER 07 subject to review and approval by the TRP of the revised TFM proposals. The Board notes that applicants whose proposals are recommended for funding as "Category 4" submitted proposals in need of substantial revision despite risks of disruption of essential prevention, treatment and/or care services during the TFM eligibility period of 1 January 2012 and 31 March 2014. The aggregate total of the maximum upper ceilings of funding for Category 4 TFM proposals is US$ 91.2 million.</p></li><li><p>Applicants whose proposals are recommended for funding as "Category 4" shall: </p><ol type="a"><li><p>submit a revised proposal, based on the parameters set out in the applicants' TRP review form; and</p></li><li><p>complete the revised proposal review process, including anyclarification which the TRP may require, within the timeframe stipulated in the TRP review form resulting from such a review.</p></li></ol></li><li><p>The Secretariat will notify the Board of the outcomes of all Category 4 proposals.</p></li><li><p>The Board declines to approve for funding those proposals recommended by the TRP as "Category 5." These proposals are eligible to appeal this decision subject to the grounds and process for appeals as stipulated in the 'Rules Governing the Global Fund's Appeal Mechanism for Applications not Approved for Funding'. </p></li><li><p>The Board notes that many applicants will face disruption during the second half of 2013 or in 2014, the latter stages of the TFM eligibility period. There may be circumstances where there are advantages to signing a TFM grant closer to the date of disruption, including circumstances created by the Board's decision to accelerate the implementation of the Global Fund Strategy (GF/B26/DP6). As such, the Board decides that TFM grants may be signed beyond the currently required 12-month period after Board approval of a proposal (GF/B8 Timeframes for Grant Agreements, Decision Point 2) and may have start dates that are beyond 15 or 18 months after Board approval, as applicable, in accordance with their respective disruption dates.</p></li><li><p>The Board's approval of proposals is made with the clear understanding that the proposal amounts recommended for funding by the TRP, as set forth in Annex 1 - GF/B26/ER 07, are maximum upper ceilings rather than final approved grant amounts and are subject to reduction upon successful completion of TRP clarifications, TRP reviews of revised proposals, and grant negotiations.</p></li></ol>
2012-08-20 26 GF/B26/EDP10 Additional Funding for the Ghana Round 8 HIV Grants (GHN-809-G09-H; GHN-809-G10-H; GHN-809-G11-H; and GHN-809-G12-H)
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period of the Ghana Round 8 HIV grants (GHN-809-G09-H; GHN-809-G10-H; GHN-809-G11-H; and GHN-809-G12-H) as a ‘Conditional Go’ in the amount of US$ 43,524,540 subject to Technical Review Panel (‘TRP’) clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of these grants shall be the amount approved by this decision and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grants.</li></ol>
2012-07-30 26 GF/B26/EDP09 July 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 130,325,572 for the following grants: BLR-304-G01-H ; BRN-910-G09-M ; BRN-910-G10-M ; CPV-810-G01-H ; CPV-810-G02-H ; PRK-810-G02-T ; SLV-910-G08 ; SLV-910-G07-T ; ERT-910-G07-M ; FJI-T-MOH ; LSO-809-G07-H ; MDG-810-G13-T ; MDG-810-G14-T ; MNT-910-G03-H ; NIC-202-G05-T-00 ; PRY-910-G06-S ; SER-910-G06-T ; SER-910-G07-T ; SLB-810-G01-T ; SWZ-809-G08-S ; TAJ-304-G02-T</p>
2012-07-06 26 GF/B26/EDP08 Approval of Revised Terms of Reference of the Executive Director
The Board approves revised Terms of Reference for the Executive Director as set out in Annex 1 to Electronic Report B26/ER/05, which shall be used as the basis for the recruitment of a new Executive Director.
2012-06-27 26 GF/B26/EDP07 Authorization for Chief Financial Officer Salary
In accordance with the Board-adopted Global Fund Human Resources Policy Framework (GF/EDP/08/16 – Annex 1), any staff salary above CHF 245,000 requires Board approval. The Board authorizes the Secretariat to enter into a contract of employment with a new Chief Financial Officer within the Grade 09 level with an annual salary above CHF 245,000 and below the ceiling for Grade 09 salaries of CHF 349,800.
2012-06-24 26 GF/B26/EDP06 Approval for the Re-launch of the Mozambique Round 8 Health Systems Strengthening (HSS) Grant (MOZ-809-G08-S)
<ol><li>The Board refers to the Mozambique Round 8 Health Systems Strengthening grant (MOZ-809-G08-S) which has not begun implementation more than 24 months from the original Board approval of the proposal.</li><li>Noting that the Country Coordinating Mechanism has requested a material re-programming of the program, the Board approves the grant to be re-launched with additional funding of up to USD 5,653,933 and with one additional year of implementation, subject to the approval of the Technical Review Panel (‘TRP’) to the re-programming and any clarifications which the TRP may require, so that the program will be implemented for a total of three years from the date of the re-launch.</li></ol>
2012-06-20 26 GF/B26/EDP05 June 2012 Bridge Funding Recommendations
<p>The Board:</p><ol><li>Approves bridge funding for the grants listed in Table 2 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts and are approved for the continuation of essential programs up to the period of the Transitional Funding Mechanism (GF/B25/DP16 Annex 2).</li></ol><p>See attached tabledetailing total recommended funding amount of USD 1,745,524 for the following grants: RUS-304-G01-H ; RUS-506-G05-H</p>
2012-06-20 26 GF/B26/EDP04 June 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 81,836,373 for the following grants: COL-809-G02-M ; COL-809-G03-M ; ARM-809-G04-S ; ARM-202-G05-H-00 ; ARM-202-G06-H00 ; DMR-309-G07-T ; TUN-810-G02-T ; TUN-810-G03-T ; BUL-809-G03-T ; RUS-304-G02-T ; IRN-810-G04-H ; TCD-810-G07-T ; CIV-809-G08-M ; CIV-809-G09-M ; AFG-809-G08-M</p>
2012-05-31 26 GF/B26/EDP03 Additional Funding for the Ethiopia Round 8 Malaria Grant (ETH-809-G10-M)
The Board approves additional funding for the Phase 2 period of the Ethiopia Round 8 Malaria grant (ETH-809-G10-M) as a ‘Conditional Go’ in the amount of up to US$ 114,264,421 subject to Technical Review Panel clarifications and conditions within a limited timeframe, and any additional conditions to be cleared by the Secretariat. Approval is also subject to the provision that continued funding for the grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).
2012-05-31 26 GF/B26/EDP02 May 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li> Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 420,336,975 for the following grants: COM-810-G03-M ; ETH-202-G03-H-00 ; HTI-102-G09-H ; NGA-809-G11-M ; NGA-809-G13-M ; NGA-809-G14-M ; UZB-809-G04-M ; ZAM-809-G21-H ; ZAM-809-G22-H ; ZAM-809-G23-H</p>
2012-05-31 26 GF/B26/EDP01 Approval of the 2011 Consolidated Financial Statements and Annual Report
The Board approves the Global Fund’s 2011 Annual Report and 2011 Consolidated Financial Statements, which have been audited by Ernst &amp; Young Ltd.
2012-05-11 26 GF/B26/DP08 Launch of the Selection Process for the next Executive Director
<p>The Board:</p><blockquote><p>1. Establishes an ad hoc nominations committee (‘AHNC’) to assist the Board with its selection of the next Executive Director.</p></blockquote><blockquote><p>2. Notes the constituency nominations for members of the AHNC, and appoints the following individuals as members, each serving in his or her personal capacity:</p></blockquote><blockquote><blockquote><p>Don Baxter<br/>Agnes Binagwaho<br/>Karlo Boras<br/>Nils Daulaire<br/>Mireille Guigaz<br/>Masaki Noke</p></blockquote></blockquote><blockquote><p>3. Requests the AHNC to initiate the selection process in accordance with its Terms of Reference, including the timely appointment of three non-constituency affiliated members to facilitate the work of the AHNC.</p></blockquote>
2012-05-11 26 GF/B26/DP07 Modification of Rules Governing Grant Renewals
<p>The Board:</p><blockquote><p>1. Refers to its decision on the Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16) which, among other adopted measures, required that the total funding approved for grant renewals for Low Income Countries be no less than 55% of any annual funding window (the “55% Rule”);</p></blockquote><blockquote><p>2. Acknowledges that the 55% Rule is intended to drive resources toward the places with the greatest need and least ability to address the three epidemics, and that existing policies, including the Policy on Eligibility, Counterpart Financing and Prioritization, already shape the Global Fund portfolio by directing resources and requiring middle-income implementing countries to contribute financial resources to the response;</p></blockquote><blockquote><p>3. Notes unintended consequences of the 55% Rule and some negative impact on achievement of the targets of the Global Fund Strategy and on vital programs targeted for the poorest people in lower middle-income countries; and</p></blockquote><blockquote><p>4. Directs the Secretariat to develop further analysis of the 55% Rule in consultation with the Strategy, Investment, and Impact Committee at its next meeting, with a recommendation to the Board before its November meeting. Until that time, the Board decides to freeze the implementation of the 75% ceiling on grant renewals funding for Lower-Middle Income Countries and above (including on the four approved grant renewals affected by its implementation).</p></blockquote>
2012-05-11 26 GF/B26/DP06 Accelerating Implementation of the Global Fund Strategy
<p>1. Given the new and encouraging financial forecasts presented to the Global Fund’s Board at its Twenty-Sixth Meeting in Geneva in May 2012, the Board decides to accelerate the implementation of the new Global Fund Strategy ‘Investing for Impact’ by opening new funding opportunities starting in late September 2012 to allow for Board funding decisions to be made no later than the end of April 2013.</p><p>2. The Secretariat, under the guidance of the Strategy, Investment and Impact Committee (‘SIIC’), will design in consultation with countries, partners and other stakeholders, the elements of the new funding models, including the structure and parameters of the new ‘iterative process’, options for distribution of funds available, and other elements, and the SIIC will bring its recommendation to a special Board meeting in September 2012.</p><p>3. The Finance and Operational Performance Committee will work with the Secretariat to test the resource forecasting model on a monthly basis and confirm the resource forecast in September 2012.</p><p>4. As soon as possible, and under the oversight of the SIIC, the Secretariat will work with countries and partners to develop estimates of demand for programs for the three diseases and related health systems and civil society strengthening investments that are consistent with the new strategic approach and take into account existing resources available in country, by September to inform the Board and other stakeholders and to aid replenishment.</p><p>5. The new funding models will be developed in line with the new Strategy and the principles articulated in the Framework Document that the ‘Fund will base its work on programs that reflect national ownership and respect country-led formulation and implementation processes’.</p><p>6. It is envisaged that this will :</p><blockquote><p>a. create a specific opportunity for countries to assess the gap between national coverage levels for the 3 diseases and actual need;</p></blockquote><blockquote><p>b. permit the establishment of multiple funding opportunities per year and have a mechanism that allows for high quality, grant ready proposals to be financed as funding becomes available ;<br/>Accelerating Implementation of the Global Fund Strategy</p></blockquote><blockquote><p>c. ensure a comprehensive and specific analysis of complementarity among funders; and</p></blockquote><blockquote><p>d. increase the sustainability of Global Fund supported programs.</p></blockquote>
2012-05-11 26 GF/B26/DP05 Delegation of Authority to Secretariat for Grant Operations
<ol><li>The Board notes that: <ol type="a"><li> it has previously made decisions restricting the timeframe for signing grant agreements, placing parameters around the flexibility to set grant start dates, limiting the ability to extend the total length of a grant, and detailing the process for Phase 2 and Periodic Reviews;</li><li> the principles surrounding these decisions remain valid and support the Global Fund’s mandate to efficiently and effectively provide funding to programs while ensuring that only strategic, cost-effective investments are made; and</li><li>while the general principles remain valid, there is a need to allow for additional flexibilities, where necessary, to ensure the Secretariat is able to independently respond to grant specific needs while managing day-to-day grant management operations.</li></ol></li><li>In order to address certain operational constraints and increase the efficiency and effectiveness of the Secretariat in grant management operations, the Board <ol type="a"><li> further delegates to the Secretariat, in line with the authorities provided under GF/B24/EDP/4, the authority to approve extensions of up to three months to the signing timeframe for future approved proposals on an exceptional case-by-case basis and only in situations in which there is a strong justification for granting an extension;</li><li> extends the authorities provided under GF/B24/EDP/7 by delegating to the Secretariat the authority to make exceptions, due to operational needs, to the general principle that grant start dates should not be set beyond 15 months, or 18 months, as applicable, after Board approval of a proposal; so long as no exception results in a grant start date being set beyond 22 months after Board approval of a proposal;</li><li> delegates to the Secretariat the authority to make exceptions, due to compelling circumstances, to the existing policy which only allows for a maximum extension period of six months to the total length of a grant’s implementation period, at the end of a program; so long as any extension does not lengthen the total implementation period by more than twelve additional months; and</li><li> delegates to the Secretariat the authority to, on an exceptional case-by-case basis:<ol type="i"><li> provide additional no-cost extensions to the current grant implementation period during the renewals process, based on specific grant related circumstances, to allow for continued grant implementation; and Delegation of Authority to Secretariat for Grant Operations</li><li> amend conditions upon which the Board has conditioned the approval of incremental funding where necessary to account for changes in circumstances; so long as measures are available to effectively mitigate the risk addressed in the condition.</li></ol></li></ol></li><li> In order to ensure proper oversight, the Secretariat must limit the ability to approve the use of the delegations of authority granted above to the appropriate panel or committee of senior managers within the Secretariat</li><li> The Board requests that the Secretariat prepare a report twice a year detailing any exceptions or extensions approved in connection with this decision point and submit such report to the Strategy, Investment and Impact Committee (the “SIIC”) for review. The first such report will be submitted to the SIIC prior to its first meeting in 2013.</li></ol>
2012-05-11 26 GF/B26/DP04 Decision-Making Authority on Adjustments within the Operating Expenses Budget
<p>1. The Board affirms the Finance and Operational Performance Committee (the “FOPC”) is authorized to approve operating expenditures that do not result in an increase in the amount of the Board-approved operating expenses budget for any financial year.</p><p>2. The FOPC is authorized to establish a framework to determine when decision-making authority on adjustments, reallocations or additions to the operating expenses budget may be taken by the Secretariat or FOPC provided that:</p><blockquote><p>a. such decision does not result in an increase in the operating expenses budget approved by the Board for the relevant financial year;</p></blockquote><blockquote><p>b. the FOPC shall consult with the Secretariat to develop appropriate criteria and thresholds within such criteria to establish this decision-making framework; and</p></blockquote><blockquote><p>c. decisions taken by the Secretariat shall be reported to the FOPC and decisions taken by the FOPC shall be reported to the full Board.</p></blockquote>
2012-05-11 26 GF/B26/DP03 Approval of Report of the Twenty-Fifth Board Meeting
The report of the Twenty-Fifth Board Meeting (GF/B25/08 Revision 1) is approved.
2012-05-11 26 GF/B26/DP02 Approval of Agenda
The agenda for the Twenty-Sixth Board Meeting (GF/B26/01) is approved.
2012-05-11 26 GF/B26/DP01 Appointment of Rapporteur
Dr. Reinhard Tittel-Gronefeld from the Germany (Canada, Switzerland) constituency is designated as rapporteur for the Twenty-Sixth Board Meeting.
2012-01-26 25 GF/B25/EDP22 Implementation of the 55% floor for funding for Low Income Countries
<p>Consistent with the Board’s November 2011 decision titled ‘Modification of Grant Renewals and Transition to New Funding’ (GF/B25/DP16) as it applies to grant renewals:</p><ol><li>While the Secretariat works on scenarios to model the impact of the 55% rule, and the most effective measures for implementation, grant renewal invitation letters issued to Country Coordinating Mechanisms will have ceilings of 90% for Low Income Countries and Low-Lower Middle Income Countries, and 75% for all other country income level categories; </li><li>New ceilings will apply to all grant renewal invitation letters issued on or after 1 January 2012; and </li><li>The letters will explain the reasons for these (in some cases) new ceilings, and will also mention that the ceilings may be adjusted later.</li></ol>
2012-01-26 25 GF/B25/EDP21 Application of NGO Rule to the Transitional Funding Mechanism
Notwithstanding the effect of Decision 1 (GF/B25/EDP20 applied post factum) above, paragraph 11 of the Global Fund's 'Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals' (GF/B23/14), which allows NGOs from Upper Middle Income Countries not listed on the OECD's DAC list of ODA recipients to apply for HIV/AIDS funding, shall remain applicable to the Transitional Funding Mechanism.
2012-01-26 25 GF/B25/EDP20 Application of G-20 rule to the Transitional Funding Mechanism
Consistent with the Board's November 2011 decision titled 'Modification of Grant Renewals and Transition to New Funding' (GF/B25/DP16) as it applies to grant renewals, Group of 20 Upper Middle Income Countries with less than an extreme disease burden will not be eligible for funding under the Transitional Funding Mechanism.
2012-04-26 25 GF/B25/EDP19 Exception to the Quality Assurance Policy for Pharmaceutical Products for the Procurement of Ritonavir 100mg in Cuba
<p>The Board refers to the Quality Assurance Policy for Pharmaceutical Products (the “QA Policy”) (as last approved and amended in GF/B22/DP9), and the requirement set forth therein that Global Fund grant funds may only be used to purchase Finished Pharmaceutical Products which comply with the QA Policy.</p><p>The Board grants an exception to the quality standards set forth in the QA Policy such that sufficient quantities of ritonavir 100mg may be procured under existing Global Fund grants in Cuba to avoid a treatment disruption.</p><p>This exception is valid until a source of ritonavir 100mg that is compliant with the quality standards of the QA Policy is available for the Global Fund Cuba programs, and if such a source becomes available and a procurement of ritonavir 100mg can be made from that source in time to avoid a treatment disruption in Cuba, that procurement should be made and this exception should not be applied.</p><p>The Secretariat shall take appropriate measures to minimize and address any quality risks associated with the procurement authorized by this decision, including:</p><ol><li>Requiring that, at a minimum, the manufacturing site of the ritonavir 100mg procured must, at the time of the procurement, be in compliance with Good Manufacturing Practices as verified by the WHO Prequalification Programme, a Stringent Drug Regulatory Authority, or a regulatory authority participating in the Pharmaceutical Inspection Cooperation Scheme; and</li><li>Applying the notification/confirmation and systematic quality control testing as described in paragraphs 9 and 31 of the QA Policy to such procurement.</li></ol>
2012-04-16 25 GF/B25/EDP18 Appointment of Independent Members of the Audit and Ethics Committee
<p>The Board notes that:</p><ol><li>In September 2011, the Board decided (GF/B24/DP3, entitled “High Level Independent Review Panel”) to form an Audit and Ethics Committee (“AEC”) comprised of seven members, four of whom would be independent of any constituency of the Board.<br/><br/></li><li>In November 2011, the Board mandated the Coordinating Group (GF/B25/DP14, entitled “Appointment of Committee Leadership”) to provide nominations to the Board to fill the four independent member seats on the AEC, with one of those seats being for the Chair of the AEC.<br/><br/></li><li>The Coordinating Group’s 27 March 2012 “Electronic Report” to the Board on the nominations process (GF/B25/ER11) recommended that the Board increase the number of independent AEC members from four persons to five in order to ensure that the AEC will have an appropriate level of expertise in its financial audit function, in addition to the three other necessary disciplines of forensic investigation, ethics, and legal and dispute resolution.</li></ol><p>The Board:</p><ol><li value="4">Approves the increase in independent members of the AEC from four persons to five, to bring the full membership of the committee to eight.<br/><br/></li><li>Amends the Charter of the Audit and Ethics Committee and the Board and Committee Operating Procedures in the manner set forth below with immediate effect:<br/><br/><ol><li type="a">Amendments to the Charter of the Audit and Ethics Committee:<br/><br/><ol><li>the word “<i>four</i>” is deleted in each of paragraphs 3.i, 6 and 7, and is replaced with “<i>five</i>”; and<br/><br/></li><li>a new paragraph is inserted immediately following paragraph 4, containing the following text: “<i>In instances in which the Committee is unable to take a decision, the AEC Chair shall, in consultation with the AEC Vice-Chair, exercise an additional vote in order to resolve such impasse</i>.”<br/><br/></li></ol></li><li type="a">Amendments to the Board and Committee Operating Procedures:<br/><br/><ol><li>Table 3.b of Annex 1 (“Expected Minimum Key Competencies and Responsibilities of Members of each of the Standing Committees of the Board”), is amended by striking out the whole of the text in bulleted item 1 in column three of that table (“Key Competencies of Audit and Ethics Committee Members”); and<br/><br/></li><li>replacing it with the following text: “<i>At least two voting members with financial audit experience, with professional accreditation in financial accounting (Committee Chair should be selected from amongst the independent members who hold professional accreditation in financial accounting</i>)”.<br/><br/></li><li>The word “four” is deleted in paragraph 44.1.3 and is replaced with “five.”<br/><br/></li></ol></li></ol></li><li>Approves the appointment of the following individuals as independent members of the AEC to serve for two-year terms from the date of effect of this decision, or until the appointment of their respective successors:<br/><br/><ol><li type="a">Graham Joscelyne (Financial audit competency) as member and Chair of the AEC</li><li type="a">Gabor Amon (Forensic investigation competency) as member of the AEC</li><li type="a">Veronica Charlesworth (Financial audit competency) as member of the AEC</li><li type="a">Wendy Harrison (Ethics competency) as member of the AEC</li><li type="a">Barry Metzger (Legal/dispute resolution competency) as member of the AEC<br/><br/></li></ol></li><li>Acknowledges that the Finance and Operational Performance Committee will bring to the November 2012 Board meeting a comprehensive remuneration and honorarium strategy across the Global Fund’s governance and advisory entities, which will include a recommendation on the appropriate honorarium for independent members of the AEC having regard to their role and fiduciary obligations.<br/><br/></li><li>Approves an honorarium for the period April to December 2012 of US$ 14,000 for the independent Chair of the AEC, and US$ 9,000 for other independent members of the AEC. The Board notes that the FOPC’s recommendations in November 2012 may include a recommendation to retroactively increase the honorarium of independent members of the AEC.<br/><br/></li><li>Requests the Audit and Ethics Committee to provide recommendations into the Phase 2 Governance Reform process on revised “Criteria for Independent Members of the Audit and Ethics Committee” that takes into account lessons learned during the process of constituting the committee.</li></ol>
2012-04-13 25 GF/B25/EDP17 Decision on additional funding for the Continuity of Services to the Albania Round 5 HIV program (ALB-506-G01-H).
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s COS form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the Secretariat’s recommendations.</p><p>See attached tabledetailing total recommended funding amount of US$419,941 for the following grant: ALB-506-G01-H</p>
2012-04-13 25 GF/B25/EDP16 Decision on April 2012 Grant Renewals Funding Recommendations
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period<sup>[1]</sup> for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by <span style="font-size: 12px; line-height: 1.5;">recipients under the grant.</span></li></ol><p>See attached tabledetailing total recommended funding amount of US$ 313,697,746 for the following grants: AFG-809-G09-M ; AFG-809-G10-M ; PRK-810-G01-M ; ZAR-810-G09-M ; MAL-809-G08-H ; ZIM-809-G11-H ; ZIM-809-G12-T </p>
2012-03-14 25 GF/B25/EDP15 Extension of Grant Signing Deadline for Niger Round 10 - Tuberculosis Proposal
The Board decides to extend the deadline for the signing of the Niger Round 10 Tuberculosis Proposal until such time as the Secretariat has established appropriate safeguards and implementation arrangements for the related grants. The Secretariat will report back to the Board or its relevant Committee when the grant is signed.
2012-03-11 25 GF/B25/EDP14 Discontinuation of Funding for the Guyana HSS grant (GYA-809-G05-S)
<p>The Board declines approval of additional funding for the next implementation period for them Round 8 Guyana HSS (GYA-809-G05-S) grant.</p><p>See attached table.</p>
2012-03-11 25 GF/B25/EDP13 March 2012 Grant Renewals Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the next implementation period<sup>[1]</sup> for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li><li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 157,073, 590 for the following grants: BAN-M-NMCP ; BAN-M-BRAC ; TCD-810-G04-H ; TCD-810-G05-H ; TCD-810-G06-H ; ZAR-809-G10-H ; ZAR-810-G11-H ; ZAR-810-G12-H</p>
2012-03-08 25 GF/B25/EDP12 Transitional Funding Mechanism Arrangements for RUS-506-G05
<ol><li>The Board approves, on an exceptional basis, the following specific arrangements for the RUS-506-G05-H grant (“Grant”): <ol type="a"><li>An application may be submitted for funding under the Bridge Funding Mechanism in the context of the Transitional Funding Mechanism (“BFM”), as well as to the Transitional Funding Mechanism (“TFM”); </li><li>In assessing the TFM application, the relevant period for considering whether there has been a disruption of essential prevention, treatment and/or care programs financed by the Global Fund shall be 31 August 2011 to 31 March 2014 (inclusive); and </li><li>In accordance with Decision Point GF/B25/DP16, the Secretariat shall provide appropriate BFM arrangements for the Grant up to 31 December 2012, when TFM funding is expected to come into effect.</li></ol></li></ol>
2012-02-12 25 GF/B25/EDP11 Discontinuation of Funding for the Gabon Round 8 HIV (GAB-809-G05-H) and the Multi-Country Africa RCC Malaria (MAF-202-G01-M-00)
<p>The Board declines approval of additional funding for the Phase 2 period for the Round 8 Gabon HIV (GAB-809-G05-H) and the Multi-Country Africa RCC Malaria (MAF-202-G01-M-00) <span style="font-size: 12px; line-height: 1.5;">proposals.</span></p><p>See attached table.</p>
2012-02-12 25 GF/B25/EDP10 Additional funding for the Continuity of Services to the South Sudan Round 4 grant ( SSD-405-G05-H)
<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s COS form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements <span style="font-size: 12px; line-height: 1.5;">for such proposal consistent with the recommendations set forth in the Secretariat’s COS form.</span></p><p>See attached tabledetailing total recommended funding amount of US$8,317,359 for the following grant: SSD-405-G05-H</p>
2012-02-12 25 GF/B25/EDP09 February 2012 Phase 2 Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the <span style="font-size: 12px; line-height: 1.5;">amounts indicated for each proposal, with the clear understanding that the amounts </span><span style="font-size: 12px; line-height: 1.5;">approved are upper ceilings rather than final funding amounts, and based on an </span><span style="font-size: 12px; line-height: 1.5;">understanding that the Secretariat shall pursue on-going implementation arrangements for </span><span style="font-size: 12px; line-height: 1.5;">each proposal consistent with the recommendations set forth in its Grant Score </span><span style="font-size: 12px; line-height: 1.5;">Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification </span><span style="font-size: 12px; line-height: 1.5;">of Grant Renewals and Transition to New Funding (GF/B25/DP16).</span><sup style="font-family: inherit; font-style: inherit; font-weight: inherit;">[1]</sup></li><li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 1,654,675 for the following grant: KGZ-811-G09-M</p>
2012-02-02 25 GF/B25/EDP08 Authorization of the General Manager of the Global Fund
<p>The Board:</p><ol><li>Acknowledges the decision of Board Leadership, acting on the request of the Board and pursuant to a consultative process, to select and appoint Gabriel Jaramillo to the temporary position of General Manager of the Global Fund for a one-year term beginning 1 February 2012.</li><li>Decides that the General Manager will throughout his term exercise all of the powers and <span style="font-size: 12px; line-height: 1.5;">functions of the Executive Director, including the power to execute agreements on behalf of </span><span style="font-size: 12px; line-height: 1.5;">the Global Fund. The General Manager will report to the Board in relation to all his </span><span style="font-size: 12px; line-height: 1.5;">functions and for the management of the Secretariat.</span></li><li>Requests Board Leadership to oversee the activities of the General Manager, undertake periodic assessments of his performance, and report accordingly to the Board.</li><li>Requests the Secretariat to undertake any administrative actions necessary to facilitate the formal engagement of Gabriel Jaramillo as General Manager.</li></ol>
2012-01-20 25 GF/B25/EDP07 Funding ceilings contained in November 2011 Phase 2 Funding decision for Zimbabwe grants ZIM-809-G14-S and ZIM-809-G13-M
<p>Referring to its earlier decision on 19 December 2011 (B25/EDP/02), the Board:</p><ol><li>Notes that a transcription error was made in the reporting of the amounts requested and the Secretariat’s recommendation for incremental funding for the Phase 2 period for the Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M listed in decision point B25/EDP/02;</li><li>Decides to amend its funding decision for the two Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Table 1, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li><li>Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li></ol><p>See attached tabledetailing total recommended funding amount of US$282,752,190 for the following grants: BLR-809-G03-H ; BRN-809-G07-H ; IND-809-G13-M ; IND-809-G14-M ; KAZ-809-G04-T ; NIC-809-G06-H ; PHL-202-G09-M ; PHL-202-G11-T ; SOM-809-G06-H ; ZIM-809-G14-S ; ZIM-809-G13-M</p>
2012-01-20 25 GF/B25/EDP06 January 2012 Phase 2 Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li><li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li></ol><p><span style="font-size: 12px; line-height: 1.5;">See attached tabledetailing total recommended funding amount of US$ 146,478,569 for the following grants: BRN-809-G08-H ; ZAR-809-G07-M ; ZAR-810-G08-M ; ECU-809-G04-M ; ECU-809-G05-M ; PER-809-G06-T ; PER-809-G07-T</span></p>
2012-01-06 25 GF/B25/EDP05 Committee Membership
<p>The Board:</p><ol><li>Expresses its gratitude to the out-going Committee Chairs and Vice-Chairs for their leadership and service to the Global Fund.<br/><br/></li><li>Notes the nominations presented by the Board Chair and Vice-Chair for membership of the Finance and Operational Performance Committee and the Strategy, Investment and Impact Committee, each identified through reference to the key competencies and responsibilities required for membership in such Committees.<br/><br/></li><li>Approves the appointment of the following individuals as representatives of their respective constituencies to the Finance and Operational Performance Committee to serve as Committee Members for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>Pasqualino Procacci, Italy and Spain</li><li>Ann Lion, Private Sector</li><li>Tom Hunstad, Point Seven</li><li>Carlton Evans, United Kingdom and Australia</li><li>Jan Paehler, European Commission</li><li>Allan Ragi, Developing Country NGOs </li><li>Juliette Bynoe-Sutherland, Latin America and the Caribbean</li><li>Joseph Niangue, West and Central Africa</li><li>Bal Suvedi, South East Asia<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as non-voting, ex-officio members of the Finance and Operational Performance Committee to serve for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>Denis Broun, Partners</li><li>Veronique Bishop, World Bank<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as representatives of their respective constituencies to the Strategy, Investment, and Impact Committee to serve as Committee Members for two-year terms, or until the appointment of their respective successors:<br/><br/><ul><li>David Stevenson, Germany (Canada, Switzerland)</li><li>Mireille Guigaz, France</li><li>Masaki Noke, Japan</li><li>Julia Martin, USA</li><li>Kieran Daly, Private Foundations</li><li>Joanne Carter, Developed Country NGOs</li><li>Lucy Cheshire, Communities</li><li>Narciso Matos, East and Southern Africa</li><li>Ren Minghui, Western Pacific Region</li><li>Maksut Kulzhanov, Eastern Europe and Central Asia<br/><br/></li></ul></li><li>Approves the appointment of the following individuals as non-voting, ex-officio members of the Strategy, Investment, and Impact Committee to serve for two-year terms, or until the appointment of their respective successors: <br/><br/><ul><li>Bernard Schwartlander, UNAIDS</li><li>Winnie Mpanju-Shumbusho, WHO<br/><br/></li></ul></li><li>Delegates to the Board Chair and Vice-Chair the authority to fill, in consultation with the Chair and Vice-Chair of the Finance and Operational Performance Committee, the current vacancy on that committee through appointment of a suitably qualified representative of the Eastern Mediterranean constituency, to serve as a Committee Member for the remaining period of the two year term for the currently vacant seat. </li></ol>
2011-12-19 25 GF/B25/EDP04 Extension of timeline for a completion of condition for the Malawi Round 7 Malaria (MLW-708-G05-M) grant.
<p>The Board decides to extend the timeline for the completion of the condition requiring the Principal Recipient to deliver a detailed and costed Action Plan to address and improve the diagnosis of suspected malaria cases and reduce the current trends in over prescription of ACTs <span style="font-size: 12px; line-height: 1.5;">at health facility level from 21 October 2011 to 21 January 2012.</span></p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses <span style="font-size: 12px; line-height: 1.5;">Budget.</span></p>
2011-12-19 25 GF/B25/EDP03 Approval of an exception to the standard methodology under the Continuity of Services Policy for quantification of eligible patients for the Mauritania Round 5 HIV Grant (MRT-506-G03-H) grant.
<p>The Board notes the decision of the Phase 2 Panel to provisionally approve funding of a ceiling amount of USD 3,547,057 for two years for Continuity of Services for the Mauritania Round 5 HIV (MRT-506-G03-H) grant. The Board further notes that while incremental funding is not required due to sufficient funds within the expired grant, the Phase 2 Panel has approved Continuity of Services subject to approval by the Board of an exception to the standard methodology under the Continuity of Services Policy for quantification of eligible patients. Based upon the information presented by the Secretariat, the Board approves the proposed exception so as to permit financing for continuation of life-saving treatment for the <span style="font-size: 12px; line-height: 1.5;">1,631 patients receiving treatment as of the Ending Date of the Grant.</span></p><p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>
2011-12-19 25 GF/B25/EDP02 December 2011 Phase 2 Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li><li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li></ol><p>See attached tabledetailing total recommended funding amount of US$282,752,190 for the following grants: BLR-809-G03-H ; BRN-809-G07-H ; IND-809-G13-M ; IND-809-G14-M ; KAZ-809-G04-T ; NIC-809-G06-H ; PHL-202-G09-M ; PHL-202-G11-T ; SOM-809-G06-H ; ZIM-809-G14-S ; ZIM-809-G13-M</p>
2011-12-06 25 GF/B25/EDP01 November 2011 Phase 2 Funding Decision
<p>The Board:</p><ol><li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).<sup>[1]</sup></li><li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li></ol><p>See attached tabledetailing total recommended funding amount of US$ 475,214,596 for the following grants: CAF-708-G05-H ; DMR-202-G01-H ; MR-202-G04-H ; GMB-809-G05-H ; GMB-809-G06-H ; LSO-809-G06-H ; MLW-102-G01-H ; PNG-809-G04-M ; PNG-809-G05-M ; PNG-809-G06-M ; TP-809-G04-T ; TNZ-809-G11-M ; TNZ-809-G12-H ; TGO-809-G08-H ; TGO-809-G09-H ; UGD-708-G08-M ; UZB-809-G05-T ; PSE-809-G02-T</p>
2011-11-22 25 GF/B25/DP16 Modification of Grant Renewals and Transition to New Funding
<p><b>The Board:</b> </p><ol><li> In light of current resource constraints, adopts the measures identified in Annex 1 in order to make available resources to provide for continuation of essential prevention, treatment and/or care services by current grantees.</li><li> Agrees to establish a Transitional Funding Mechanism as described in Annex 2 in order to provide this continuation funding.</li><li> Decides to convert Round 11 into a new funding opportunity consistent with the new Global Fund 2012-2016 Strategy, with a view towards funding proposals under the new model beginning in early 2014. Round 11 proposals that are updated as appropriate may form the basis for an application for the next funding opportunity.</li><li> Directs the Secretariat to work with countries and partners to develop full expressions of demand for programs for the three diseases and related health systems and civil society strengthening investments that are consistent with the new strategic approach envisioned in the new Strategy with such information to be available for the Mid-Term Replenishment.</li><li> Urgently requests donors to consider measures to increase and accelerate funding, and implementing country governments, especially those from middle-income countries, to increase funding for the three diseases and related health investments.</li><li>Delegates to the Board Chair, in consultation with the Vice-Chair, authority to make or delegate any additional decisions necessary to implement the above. The Board Chair shall report to the Board on any such decisions taken.</li></ol><p><b>Annex 1: Financial Measures</b> </p><ol><li> Effective 1 January 2012, a revised application and approval process for renewals will be employed to ensure strategic investments, as described in “Options for Modification of the Application, Renewal and Approval Processes for New and Existing Investments,” (GF/B25/8).</li><li> Effective 1 January 2012, the following eligibility criteria for renewals applications will become effective: <ol type="a"><li> Group of 20 (G-20) upper middle income countries with less than an extreme disease burden will no longer be eligible for renewals of grants; and</li><li> The counterpart financing and focus of proposal requirements under the Policy on Eligibility, Counterpart Financing and Prioritization will apply.</li></ol></li><li> Transitional measures as described in GF/B25/8 will be made available to countries impacted by the above changes to eligibility.</li><li> The one-year Grace Period provision for changes in country income classification will be rescinded for both new proposals and grant renewals.</li><li> The TRP will support the renewals process by providing independent technical expertise to the Secretariat panel making recommendations on grant renewals.</li><li> The total funding approved for grant renewals for Low Income Countries will be no less than 55% of any annual funding window.</li><li> Additional Commitments (as defined in the Comprehensive Funding Policy) longer than one year shall be committed in annual tranches for renewals of existing grants.</li></ol><p><b>Annex 2: Transitional Funding Mechanism</b> </p><p> Scope:</p><ol&